POLYPEPTIDE COMPOUND AND USE THEREOF IN TREATMENT OF ENTERITIS

Abstract

Provided is a new polypeptide. The new polypeptide shows a significant effect of relieving intestinal lumen distension in pharmacodynamic tests of a Brachydanio Rerio inflammatory bowel disease model and a rat inflammatory bowel disease model, and can be used for preparing a drug for treating enteritis, especially ulcerative colitis.

Description

FIELD OF THE INVENTION

The present invention relates to a novel polypeptide and use thereof. The polypeptide of the present invention has a significant therapeutic effect on inflammatory bowel disease, especially has a therapeutic effect on ulcerative colitis.

BACKGROUND OF THE INVENTION

Enteritis is an inflammatory response of the intestine caused by various reasons, such as infection by intestinal bacteria, viruses and other pathogenic microorganisms, or immune damage, radiation damage, dietary stimulation, drug stimulation and other factors. Its main clinical manifestations include fever, nausea, vomiting, abdominal pain, diarrhea, watery stools or mucus, pus and blood in the stools, and some patients may also have a feeling of tenesmus.

Enteritis can be divided into specific enteritis and nonspecific enteritis according to the manifestations of inflammation. Specific enteritis includes inflammatory bowel disease, necrotizing enteropathy and dysbacteriosis enteritis. Among them, inflammatory bowel disease, as a more common one, is an idiopathic, non-infectious, intestinal, chronic, persistent, recurrent, and inflammatory disease that involves the intestines. Its clinical manifestations are abdominal pain and diarrhea, pus and blood stool, and even fever, abdominal mass, emaciation and malnutrition. Inflammatory bowel disease is a chronic, long-term disease that requires long-term active treatment.

Generally, specific enteritis has a clear cause, such as bacterial enteritis, pseudomembranous enteritis, viral enteritis, radiation enteritis and the like, which are all enteritis with clear causes, while non-specific enteritis has no clear cause and is considered to be caused by immune system diseases, such as ulcerative colitis, Crohn's disease and the like. Inflammatory bowel disease includes ulcerative colitis and Crohn's disease. Ulcerative colitis is a chronic nonspecific intestinal inflammatory disease with an unclear etiology, which most often occurs in young and middle-aged people. Its clinical manifestations are persistent or recurrent diarrhea, mucus, pus and blood in the stool with abdominal pain, tenesmus and varying degrees of systemic symptoms. There may be manifestations outside the intestines, such as in skin, mucous membranes, joints, eyes, liver, gallbladder and the like. Complications include toxic megacolon, intestinal perforation, massive lower gastrointestinal bleeding, intraepithelial neoplasia, and carcinoma. There is a lack of accurate data on the morbidity of UC in China. Regional epidemiological surveys suggest that the morbidity of UC in China is 0.42-2.22/100,000. Although the morbidity is still low compared with Western countries, it has shown a clear upward trend compared with the last two decades. The lesions mainly affect the colon mucosa and submucosa, starting from the colon distal to the rectum, developing retrogradely to the proximal end, and even affecting the entire colon. In 5% of cases, the lesions may affect the terminal ileum, showing a continuous distribution. The main clinical manifestations of ulcerative colitis are diarrhea, abdominal pain, and mucus, pus and blood in the stool. The cause of the disease is not yet fully understood, but it is currently believed to be related to infection, immune abnormalities, genetics and mental factors. In addition, patients with enteritis usually have symptoms such as intestinal lumen dilatation (also known as intestinal dilatation or intestinal canal dilatation), the cause of which may be that inflammation destroys the nerve and muscle regulation mechanism that controls the normal intestine, and the pressure in the intestinal lumen causes the intestinal wall to expand beyond its normal range of motion. Alternatively, it may be caused by excessive growth of microorganisms and the toxins they produce, mucus exudation, etc. Relieving or inhibiting intestinal lumen dilatation is helpful in the treatment of enteritis.

Although the drugs currently commonly used to treat ulcerative colitis have certain preventive and therapeutic effects, they still have disadvantages such as slow absorption, long treatment cycle, and unclear treatment effect.

SUMMARY OF THE INVENTION

In order to overcome the deficiencies and defects of the prior art, an objective of the present invention is to provide a new polypeptide compound and use thereof. The inventors of the present invention have found that the polypeptide compound of the present invention can effectively or significantly alleviate or inhibit intestinal lumen dilatation, thereby playing a role in treating enteritis.

In a first aspect, the present invention relates to a compound of formula (I) or a physiologically compatible salt thereof, wherein the compound of formula (I) is as follows:

H—X_a—Z₁-Z₂—Z₃—Z₄—X_b—OH  (I)

• • wherein
  • Z₁ is Pro, Ala, Gly, D-Pro or is absent;
  • Z₂ is Val, Ala, D-Val, Ile or is absent;
  • Z₃ is Pro, Ala, Gly, D-Pro or is absent; and
  • Z₄ is Gln, Ala, Glu, Ile, D-Gln or is absent;
  • provided that at most 2 of Z₁, Z₂, Z₃ and Z₄ are absent.
  • X_a is a sequence containing 0-10 amino acid residues; and
  • X_b is a sequence containing 0-9 amino acid residues.

In one embodiment, 2 of Z₁, Z₂, Z₃ and Z₄ are absent. In one embodiment, Z₁ and Z₂ are absent. In one embodiment, Z₃ and Z₄ are absent. In one embodiment, 1 of Z₁, Z₂, Z₃ and Z₄ is absent. In one embodiment, Z₁ is absent. In one embodiment, Z₄ is absent. In one embodiment, 0 of Z₁, Z₂, Z₃ and Z₄ is absent.

In one embodiment, Z₁ is Pro; Z₂ is Val; Z₃ is Pro; and Z₄ is Gln. In one embodiment, Z₁ is D-Pro; Z₂ is Val; Z₃ is Pro; and Z₄ is Gln. In one embodiment, Z₁ is Pro; Z₂ is Val; Z₃ is Ala; and Z₄ is Gln. In one embodiment, Z₁ is Pro; Z₂ is Ile; Z₃ is Pro; and Z₄ is Gln. In one embodiment, Z₁ is Pro; Z₂ is Val; Z₃ is Pro; and Z₄ is absent. In one embodiment, Z₁ is Pro; Z₂ is Ala; Z₃ is Pro; and Z₄ is Gln. In one embodiment, Z₁ is Gly; Z₂ is Val; Z₃ is Pro; and Z₄ is Gln. In one embodiment, Z₁ is Pro; Z₂ is Val; Z₃ is Gly; and Z₄ is Gln. In one embodiment, Z₁ is Ala; Z₂ is Val; Z₃ is Pro; and Z₄ is Gln. In one embodiment, Z₁ is Pro; Z₂ is Val; Z₃ is Pro; and Z₄ is Glu. In one embodiment, Z₁ is Pro; Z₂ is Val; Z₃ is D-Pro; and Z₄ is Gln. In one embodiment, Z₁ is Pro; Z₂ is Val; Z₃ is Pro; and Z₄ is D-Gln.

In one embodiment, X_a is X_a10—X_a9—X_a8—X_a7—X_a6—X_a5—X_a4—X_a3—X_a2—X_a1—*, wherein * indicates the position linked to Z₁-Z₂—Z₃—Z₄, wherein

• • X_a10 is Gly or is absent,
  • X_a9 is Gly, Pro, Ser or is absent,
  • X_a8 is Pro, Glu, Ser or is absent,
  • X_a7 is Arg, Glu, Thr, Ser or is absent,
  • X_a6 is Lys, Thr, Ala, Asp, Glu, Arg, Ser or is absent,
  • X_a5 is Asp, Ala, Val, Arg, Phe, Ile, Pro, Lys, Glu or is absent,
  • X_a4 is Val, Phe, Pro, Pyro-Glu, Lys, Leu, Ile, Ala, Asp or is absent,
  • X_a3 is Tyr, Leu, Pro, Asp, Arg, Glu, Lys, Tys, Val, Ile or is absent,
  • X_a2 is D-Lys, Lys, Ala, Arg, Val, Glu, Tyr or is absent, and
  • X_a1 is Glu, Ala, D-Glu, Tyr, Gln, Asp, Asn or is absent.

In one embodiment, X_a is X_aa—X_a2—X_a1—*, wherein * indicates the position linked to Z₁-Z₂—Z₃—Z₄, X_a2—X_a1 is Lys-Glu-*, Arg-Glu-*, Val-Tyr-*, Glu-Glu-*, Lys-Gln-*, Lys-D-Glu-*or Tyr-Glu-*, and X_aa is X_a10—X_a9—X_a8—X_a7—X_a6—X_a5—X_a4—X_a3—, wherein X_a10 is Gly or is absent, X_a9 is Gly, Pro, Ser or is absent, X_a8 is Pro, Glu, Ser or is absent, X_a7 is Arg, Glu, Thr, Ser or is absent, X_a6 is Lys, Thr, Ala, Asp, Glu, Arg, Ser or is absent, X_a5 is Asp, Ala, Val, Arg, Phe, Ile, Pro, Lys, Glu or is absent, X_a4 is Val, Phe, Pro, Pyro-Glu, Lys, Leu, Ile, Ala, Asp or is absent, and X_a3 is Tyr, Leu, Pro, Asp, Arg, Glu, Lys, Tys, Val, Ile or is absent. In one embodiment, X_aa is Arg-Lys-Asp-Val-Tyr-, Gly-Pro-Glu-Thr-Ala-Phe-Leu-, Val-Pro-Pro-, Pyro-Glu-Leu-, Arg-Lys-Asp-, Gly-Pro-Glu-Thr-Ala-Phe-Leu-Arg-, Ser-Ser-Glu-Asp-Ile-Lys-Glu-, Ser-Ser-Glu-Asp-Ile-Lys-, Val-Pro-Tys-, Pro-Ala-Tys-, Arg-Lys-Asp-Val-, Ser-Ser-Glu-Asp-Ile-, or is absent, wherein the rightmost connector—indicates linkage to —X_a2—X_a1. In one embodiment, X_a is X_aa—X_a2—X_a1—*, wherein * indicates the position linked to Z₁-Z₂—Z₃—Z₄, wherein X_a2—X_a1 is Lys-Glu-*, and X_aa is as defined above.

In one embodiment, X_a is X_a1-*, wherein * indicates the position linked to Z₁-Z₂—Z₃—Z₄, wherein X_a1 is Glu, Ala, D-Glu, Asp, Asn or is absent.

In one embodiment, X_a is X_a2—X_a1-*, wherein * indicates the position linked to Z₁-Z₂—Z₃—Z₄, wherein X_a is Lys, and X_a1 is Glu, D-Glu or Gln.

In one embodiment, X_a is Glu-*, Ala-*, D-Glu-*, Asp-*, Asn-*, Lys-Glu-*, D-Lys-Glu-*, Ala-Glu-*, Lys-Gln-*, Lys-D-Glu-*, Lys-Ala-*, Arg-Lys-Asp-Val-Tyr-Lys-Glu-*, Gly-Pro-Glu-Thr-Ala-Phe-Leu-Arg-Glu-*, Val-Pro-Pro-Lys-Glu-*, Pyro-Glu-Leu-Lys-Glu-*, Arg-Lys-Asp-Val-Tyr-Lys-Glu-*, yr-*, Gly-Pro-Glu-Thr-Ala-Phe-Leu-Arg-Lys-Glu-*, Ser-Ser-Glu-Asp-Ile-Lys-Glu-Lys-Glu-*, Ser-Ser-Glu-Asp-Ile-Lys-Glu-Glu-*, Val-Pro-Tys-Lys-Glu-*, Pro-Ala-Tys-Lys-Glu-*, Arg-Lys-Asp-Val-Tyr-Glu-*, Ser-Ser-Glu-Asp-Ile-Lys-Glu-*or is absent, wherein * indicates the position linked to Z₁-Z₂—Z₃—Z₄.

In one embodiment, X_b is **—X_b1—X_b2—X_b3—X_b4—X_b5—X_b6—X_b7—X_b8—X_b9, wherein **indicates the position linked to Z₁-Z₂—Z₃—Z₄, wherein

• • X_b1 is Ala, D-Ala or is absent,
  • X_b2 is Lys, Ala, D-Lys, Arg or is absent,
  • X_b3 is Pro, Gly, D-Pro, Ser, Val, Ala or is absent,
  • X_b4 is Arg, Ala, Ser, Pro, D-Arg or is absent,
  • X_b5 is Lys, Ala, D-Lys, Glu, Tyr or is absent,
  • X_b6 is Val, Asp, D-Val, Ala or is absent,
  • X_b7 is Ala, D-Ala, Ile or is absent,
  • X_bs is Ala, D-Ala, Lys or is absent, and
  • X_b9 is Gln, Ala, Glu, Asn, D-Gln or is absent.

In one embodiment, X_b is **—X_b1—X_b2—X_b3—X_b4—X_b5—X_b6—X_b7—X_b8—X_b9, wherein ** indicates the position linked to Z₁-Z₂—Z₃—Z₄, wherein

• • X_b1 is Ala or D-Ala,
  • X_b2 is Lys, Ala or D-Lys,
  • X_b3 is Pro, Gly, or Ala,
  • X_b4 is Arg or D-Arg,
  • X_b5 is Lys or is absent, X_b6 is Val, D-Val, Ala or is absent,
  • X_b7 is Ala is absent,
  • X_b8 is Ala or is absent, and
  • X_b9 is Gln, Asn, D-Gln or is absent.

In one embodiment, X_b is **-X_bi-X_b2—X_bb, wherein ** indicates the position linked to Z₁-Z₂—Z₃—Z₄, X_b1—X_b2— is **-Ala-Lys-, **-Ala-Lys-, **-Ala-D-Lys-, **-Ala-Ala- or **-D-Ala-Lys-, X_bb is —X_b3—X_b4—X_b5—X_b6—X_b7—X_b8—X_b9, wherein X_b3 is Pro, Gly, D-Pro, Ser, Val, Ala or is absent, X_b4 is Arg, Ala, Ser, Pro, D-Arg or is absent, X_b5 is Lys, Ala, D-Lys, Glu, Tyr or is absent, X_b6 is Val, Asp, D-Val, Ala or is absent, X_b7 is Ala, D-Ala, Ile or is absent, X_b8 is Ala, D-Ala, Lys or is absent, and X_b9 is Gln, Ala, Glu, Asn, D-Gln or is absent; or X_b3 is Pro, Gly, or Ala, X_b4 is Arg or D-Arg, X_b5 is Lys or is absent, X_b6 is Val, D-Val, Ala or is absent, X_b7 is Ala or is absent, X_b8 is Ala or is absent, and X_b9 is Gln, Asn, D-Gln or is absent. In one embodiment, X_bb is -Pro-Arg-Lys-Val, -Pro-Arg-Lys, -Pro-Arg, -Ala-Gln, -Ala-Ala, -Pro, -Lys-Val, -Val-Pro-Tyr, -Arg-Lys, -Val-Ala, -Pro-Arg-Lys-Val-Ala, -Lys-Val-Ala-Ala-Gln, -Pro-Arg-Lys-Val-Ala-Ala-Gln, -Pro-A rg-Lys-Val-Ala-Ala-Gln, -Pro-Ala-Lys-Val-Ala-Ala-Gln, -Pro-Arg-Ala-Val-Ala-Ala-Gln, -Pro-Arg-Lys-Val-Ala-Ala-Ala, -Gly-Arg-Lys-Val-Ala-Ala-Gln, -D-Pro-Arg-Lys-Val-Ala-Ala-Gln, -Pro-Arg-D-Lys-Val-Ala-Ala-Gln, -Pro-Arg-Lys-Val-D-Ala-Ala-Gln, -Pro-Arg-Lys-Val-Ala-D-Ala-Gln, -Ser-Ser-Glu-Asp-Ile-Lys-Glu, -Pro-Arg-Lys-Val-Ala-Ala-Asn, -Pro-Arg-Lys-Val-Ala-Ala-Gln, -Pro-Arg-Lys-D -Val-Ala-Ala-Gln, -Ala-Arg-Lys-Val-Ala-Ala-Gln, -Pro-Arg-Lys-Ala-Ala-Ala-Gln, -Pro-Arg-Lys-Val-Ala-Ala-Gln, -Pro-D-Arg-Lys-Val-Ala-Ala-Gln, -Pro-Arg-Lys-Val-Ala-Ala-D-Gln or is absent, wherein the leftmost connector—indicates linkage to X_b1—X_b2. In one embodiment, X_b is **—X_b1—X_b2—X_bb, wherein ** represents the position linked to Z₁-Z₂—Z₃—Z₄, X_b1—X_b2— is **-Ala-Lys-, and X_bb is as defined above.

In one embodiment, X_b is **-Ala-.

In one embodiment, X_b is **-Ala-, **-Ala-Lys, **-Ala-D-Lys-, **-Ala-Ala-, **-D-Ala-Lys, **-Ala-Arg, **-Ala-Lys-Pro-Arg-Lys-Val, **-Ala-Lys-Pro-Arg-Lys, **-Ala-Lys-Pro-Arg, **-Val-Ala-Ala-Gln, **-Lys-Val-Ala-Ala, **-Ala-Lys-Pro, **-Pro-Arg-Lys-Val, **-Ala-Lys-Val-Pro-Tyr, **-Lys-Pro-Arg-Lys, **-Arg-Lys-Val-Ala, **-Ala-Lys-Pro-Arg-Lys-Val-Ala, **-Pro-Arg-Lys-Val-Ala-Ala-Gln, **-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln, **-Ala-Ala-Pro-Arg-Lys-Val-Ala-Ala-Gln, **-Ala-Lys-Pro-Ala-Lys-Val-Ala-Ala-Gln, **-Ala-Lys-Pro-Arg-Ala-Val-Ala-Ala-Gln, **-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Ala, **-Ala-Lys-Gly-Arg-Lys-Val-Ala-Ala-Gln, **-Ala-Lys-D-Pro-Arg-Lys-Val-Ala-Ala-Gln, **-Ala-Lys-Pro-Arg-D-Lys-Val-Ala-Ala-Gln, **-Ala-Lys-Pro-Arg-Lys-Val-D-Ala-Ala-Gln, **-Ala-Lys-Pro-Arg-Lys-Val-Ala-D-Ala-Gln, **-Ala-Lys-Ser-Ser-Glu-Asp-Ile-Lys-Glu, **-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Asn, **-Ala-D-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln, **-Ala-Lys-Pro-Arg-Lys-D-Val-Ala-Ala-Gln, **-Ala-Lys-Ala-Arg-Lys-Val-Ala-Ala-Gln, **-Ala-Lys-Pro-Arg-Lys-Ala-Ala-Ala-Gln, **-D-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln, **-Ala-Lys-Pro-D-Arg-Lys-Val-Ala-Ala-Gln, **-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-D-Gln, or is absent, wherein ** indicates the position linked to Z₁-Z₂—Z₃—Z₄.

In one embodiment, Z₁ is Pro; Z₂ is Val; Z₃ is Pro; and Z₄ is Gln; X_a is X_aa—X_a2—X_a1—*, wherein * indicates the position linked to Z₁-Z₂—Z₃—Z₄, wherein X_a2—X_a1 is Lys-Glu-*, and X_b is **—X_b1—X_b2—X_bb, wherein ** indicates the position linked to Z₁-Z₂—Z₃—Z₄, X_b1—X_b2— is **-Ala-Lys-, wherein X_aa and X_bb are as defined above.

In one embodiment, the compound is selected from:

• • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 1);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys (Compound 2);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg (Compound 3);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 4);
  • Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 5);
  • Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 6);
  • Lys-Glu-Pro-Val (Compound 7);
  • Val-Ala-Ala-Gln (Compound 8);
  • Glu-Pro-Val-Pro (Compound 9);
  • Lys-Pro-Arg-Lys (Compound 10);
  • Ala-Lys-Pro-Arg (Compound 11);
  • Pro-Val-Pro-Gln (Compound 12);
  • Val-Pro-Gln-Ala (Compound 13);
  • Pro-Gln-Ala-Lys (Compound 14);
  • Arg-Lys-Val-Ala (Compound 15);
  • Lys-Val-Ala-Ala (Compound 16);
  • Gln-Ala-Lys-Pro (Compound 17);
  • Pro-Arg-Lys-Val (Compound 18);
  • Ala-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 19);
  • Lys-Ala-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 20);
  • Lys-Glu-Ala-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 21);
  • Lys-Glu-Pro-Val-Ala-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 22);
  • Lys-Glu-Pro-Val-Pro-Ala-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 23);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Ala-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 24);
  • Lys-Glu-Pro-Ala-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 25);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Ala-Arg-Lys-Val-Ala-Ala-Gln (Compound 26);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Ala-Lys-Val-Ala-Ala-Gln (Compound 27);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Ala-Val-Ala-Ala-Gln (Compound 28);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Ala-Ala-Ala-Gln (Compound 29);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Ala (Compound 30);
  • Lys-Glu-Gly-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 31);
  • Lys-Glu-Pro-Val-Gly-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 32);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Gly-Arg-Lys-Val-Ala-Ala-Gln (Compound 33);
  • Lys-Glu-Pro-Val-Gly-Gln-Ala-Lys-Gly-Arg-Lys-Val-Ala-Ala-Gln (Compound 34);
  • Lys-Glu-Gly-Val-Gly-Gln-Ala-Lys-Gly-Arg-Lys-Val-Ala-Ala-Gln (Compound 35);
  • Lys-Glu-Gly-Val-Pro-Gln-Ala-Lys-Gly-Arg-Lys-Val-Ala-Ala-Gln (Compound 36);
  • Lys-Glu-Gly-Val-Gly-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 37);
  • Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys (Compound 38);
  • Pro-Val-Pro-Gln-Ala (Compound 39);
  • Pro-Val-Pro-Glu-Ala (Compound 40);
  • Pro-Val-Pro-Ile-Ala (Compound 41);
  • Pro-Val-Pro-Ala (Compound 42);
  • Glu-Pro-Val-Pro-Gln-Ala (Compound 43);
  • Pro-Val-Pro-Gln-Ala-Lys (Compound 44);
  • Glu-Pro-Val-Pro-Gln-Ala-Arg (Compound 45);
  • Ala-Pro-Val-Pro-Gln-Ala-Lys (Compound 46);
  • Glu-Pro-Val-Pro-Ala-Ala-Lys (Compound 47);
  • Glu-Pro-Val-Pro-Gln-Ala-Ala (Compound 48);
  • Asp-Pro-Val-Pro-Gln-Ala-Lys (Compound 49);
  • Asn-Pro-Val-Pro-Gln-Ala-Lys (Compound 50);
  • Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala (Compound 51);
  • Glu-Pro-Ala-Pro-Gln-Ala-Lys (Compound 52);
  • Glu-Ala-Val-Pro-Gln-Ala-Lys (Compound 53);
  • Glu-Pro-Val-Ala-Gln-Ala-Lys (Compound 54);
  • Glu-Pro-Val-Pro-Glu-Ala-Lys (Compound 55);
  • Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val (Compound 56);
  • Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg (Compound 57);
  • Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro (Compound 58);
  • Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg (Compound 59);
  • Pro-Val-Pro-Gln-Ala-Lys-Pro (Compound 60);
  • D-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 61);
  • Lys-D-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 62);
  • Lys-Glu-D-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 63);
  • Lys-Glu-Pro-D-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 64);
  • Lys-Glu-Pro-Val-D-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 65);
  • Lys-Glu-Pro-Val-Pro-D-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 66);
  • Lys-Glu-Pro-Val-Pro-Gln-D-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 67);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-D-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 68);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-D-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 69);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-D-Arg-Lys-Val-Ala-Ala-Gln (Compound 70);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-D-Lys-Val-Ala-Ala-Gln (Compound 71);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-D-Val-Ala-Ala-Gln (Compound 72);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-D-Ala-Ala-Gln (Compound 73);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-D-Ala-Gln (Compound 74);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-D-Gln (Compound 75);
  • Glu-Gly-Val-Pro-Gln-Ala-Lys (Compound 76);
  • Glu-Pro-Val-Gly-Gln-Ala-Lys (Compound 77);
  • D-Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 78);
  • Glu-D-Pro-Val-Pro-Gln-Ala-Lys (Compound 79);
  • Glu-Pro-D-Val-Pro-Gln-Ala-Lys (Compound 80);
  • Glu-Pro-Val-D-Pro-Gln-Ala-Lys (Compound 81);
  • Glu-Pro-Val-Pro-D-Gln-Ala-Lys (Compound 82);
  • Glu-Pro-Val-Pro-Gln-D-Ala-Lys (Compound 83);
  • Glu-Pro-Val-Pro-Gln-Ala-D-Lys (Compound 84);
  • Lys-Glu-Pro-Val-Pro (Compound 85);
  • Glu-Pro-Val-Pro-Gln (Compound 86);
  • Lys-Glu-Pro-Val-Pro-Gln (Compound 87);
  • Val-Pro-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 88);
  • Pyro-Glu-Leu-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 89);
  • Pro-Ala-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 90);
  • Arg-Lys-Asp-Val-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 91);
  • Arg-Lys-Asp-Val-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 92);
  • Arg-Lys-Asp-Val-Tyr-Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 93);
  • Arg-Lys-Asp-Val-Tyr-Pro-Val-Pro-Gln (Compound 94);
  • Gly-Pro-Glu-Thr-Ala-Phe-Leu-Arg-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 95);
  • Gly-Pro-Glu-Thr-Ala-Phe-Leu-Arg-Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 96); Ser-Ser-Glu-Asp-Ile-Lys-Glu-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 97);
  • Ser-Ser-Glu-Asp-Ile-Lys-Glu-Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 98);
  • Ser-Ser-Glu-Asp-Ile-Lys-Glu-Pro-Val-Pro-Gln (Compound 99);
  • Val-Pro-Pro-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 100);
  • Glu-Pro-Val-Pro-Gln-Ala-Lys-Ser-Ser-Glu-Asp-Ile-Lys-Glu (Compound 101);
  • Glu-Pro-Val-Pro-Gln-Ala-Lys-Val-Pro-Tyr (Compound 102);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Glu (Compound 103);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Asn (Compound 104);
  • Lys-Gln-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 105);
  • Lys-Glu-Pro-Ile-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 106);
  • Val-Pro-Gln-Ala (Compound 107); or
  • Val-Pro-Gln-Ala-Lys (Compound 108).

In one embodiment, the compound is selected from:

• • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 1);
  • Lys-Glu-D-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 63);
  • Gly-Pro-Glu-Thr-Ala-Phe-Leu-Arg-Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 96);
  • Val-Pro-Pro-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 100);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Asn (Compound 104);
  • Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 6);
  • Pro-Val-Pro-Gln (Compound 12);
  • Glu-Pro-Val-Ala-Gln-Ala-Lys (Compound 54);
  • Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg (Compound 57);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-D-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 68);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-D-Val-Ala-Ala-Gln (Compound 72);
  • Pyro-Glu-Leu-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 89);
  • Arg-Lys-Asp-Val-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 92);
  • Arg-Lys-Asp-Val-Tyr-Pro-Val-Pro-Gln (Compound 94);
  • Gly-Pro-Glu-Thr-Ala-Phe-Leu-Arg-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 95);
  • Ser-Ser-Glu-Asp-Ile-Lys-Glu-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 97);
  • Ser-Ser-Glu-Asp-Ile-Lys-Glu-Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 98);
  • Lys-Gln-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 105);
  • Lys-Glu-Pro-Ile-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 106);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 4);
  • Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 5);
  • Glu-Pro-Val-Pro (Compound 9);
  • Lys-Pro-Arg-Lys (Compound 10);
  • Arg-Lys-Val-Ala (Compound 15);
  • Lys-Glu-Pro-Ala-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 25);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Ala-Arg-Lys-Val-Ala-Ala-Gln (Compound 26);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Ala-Ala-Ala-Gln (Compound 29);
  • Lys-Glu-Gly-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 31);
  • Lys-Glu-Pro-Val-Gly-Gln-Ala-Lys-Gly-Arg-Lys-Val-Ala-Ala-Gln (Compound 34);
  • Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys (Compound 38);
  • Glu-Pro-Val-Pro-Gln-Ala-Ala (Compound 48);
  • Asp-Pro-Val-Pro-Gln-Ala-Lys (Compound 49);
  • Asn-Pro-Val-Pro-Gln-Ala-Lys (Compound 50);
  • Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala (Compound 51);
  • Glu-Ala-Val-Pro-Gln-Ala-Lys (Compound 53);
  • Glu-Pro-Val-Pro-Glu-Ala-Lys (Compound 55);
  • Lys-D-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 62);
  • Lys-Glu-Pro-Val-D-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 65);
  • Lys-Glu-Pro-Val-Pro-D-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 66);
  • Lys-Glu-Pro-Val-Pro-Gln-D-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 67);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-D-Arg-Lys-Val-Ala-Ala-Gln (Compound 70);
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-D-Gln (Compound 75);
  • Glu-Pro-Val-Pro-Gln-D-Ala-Lys (Compound 83);
  • Lys-Glu-Pro-Val-Pro (Compound 85);
  • Glu-Pro-Val-Pro-Gln (Compound 86);
  • Val-Pro-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 88);
  • Pro-Ala-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 90);
  • Arg-Lys-Asp-Val-Tyr-Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 93);
  • Ser-Ser-Glu-Asp-Ile-Lys-Glu-Pro-Val-Pro-Gln (Compound 99); or
  • Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Glu (Compound 103).

In a second aspect, the present invention provides the use of the polypeptide compound or a physiologically compatible salt thereof in the preparation of a drug for treating enteritis; or a method for treating enteritis, the method comprising administering a therapeutically effective amount of the polypeptide compound or a physiologically compatible salt thereof to a subject; or the polypeptide compound or a physiologically compatible salt thereof for treating enteritis.

Furthermore, enteritis includes specific enteritis and nonspecific enteritis. Furthermore, specific enteritis includes inflammatory bowel disease, necrotizing enteropathy and flora imbalance enteritis.

Furthermore, inflammatory bowel disease includes ulcerative colitis.

Furthermore, the present invention provides a pharmaceutical composition comprising the polypeptide compound of the present invention or a physiologically compatible salt thereof, and a pharmaceutically acceptable excipient.

Furthermore, the dosage forms of the drug include tablets, capsules, solutions, powders and pills.

The beneficial effects of the novel polypeptide provided by the present invention and use thereof:

The polypeptide of the present invention has a short peptide chain, so it is absorbed faster and better. The experimental results show that the polypeptide provided in the present application showed a significant effect of alleviating intestinal lumen dilatation in the test of a rat model of acute inflammatory bowel disease; and had a significant therapeutic effect in the test of the rat model of acute inflammatory bowel disease. The polypeptide of the present invention has a significant effect of alleviating colitis and can be used to prepare drugs for treating enteritis, especially drugs for ulcerative colitis.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a schematic diagram of the steps of solid phase synthesis of polypeptides; and

FIG. 2 shows the mass spectrum of the polypeptide.

DETAILED DESCRIPTION OF THE INVENTION

The following is an explanation of the present invention in combination with specific experiments, which is not intended to limit the scope of protection of the present invention.

As used in the present application (including the attached claims), unless the context otherwise clearly indicates, singular forms of words such as “one/a, an” and “the” include their corresponding plural referents.

Unless otherwise clearly indicated by the context, the term “or” is used to refer to the term “and/or” and may be used interchangeably with the term “and/or”.

The term “effective amount” or “therapeutically effective amount” refers to the amount of an active ingredient (such as a compound) which when administered to a subject to treat a disease, or at least one clinical symptom of a disease or disorder, is sufficient to influence the treatment of the disease, disorder or symptom. The “therapeutically effective amount” may vary depending on the compound, the disease, disorder and/or symptoms of the disease or disorder, the severity of the disease, disorder and/or symptoms of the disease or disorder, the age of the subject to be treated and/or the weight of the subject to be treated. In any given case, the appropriate amount will be apparent to those skilled in the art, or can be determined by routine experimentation. In some embodiments, a “therapeutically effective amount” is an amount of at least one compound and/or at least one stereoisomer thereof, and/or at least one pharmaceutically acceptable salt thereof, disclosed in the present application, that is effective for the “treatment” (as defined above) of a disease or disorder in a subject. In the case of a combination therapy, “therapeutically effective amount” is the total amount of the combined objects used to effectively treat a disease, disorder or condition.

The term “physiologically compatible salt” refers to a salt form which is physiologically compatible (i.e., pharmacologically acceptable), and is substantially non-toxic to the individual to which the compounds of the invention will be administered. Physiologically compatible salts of the compounds of this invention include conventional and stoichiometric acid addition salts or base addition salts formed from suitable non-toxic organic or inorganic acids or inorganic bases.

The term “intestinal lumen dilatation” refers to intestinal dilatation or intestinal canal dilatation. In patients with enteritis, due to various factors such as intestinal damage, mucus exudation, intestinal gas or fluid accumulation, microbial overgrowth and the like, the intestinal lumen is dilated and the intestinal canal is thicker than normal. Recurrent enteritis such as inflammatory bowel disease leading to intestinal canal dilatation, or tumors causing intestinal canal dilatation and intestinal obstruction are common in clinic.

The abbreviations for amino acid used in the present application are as follows.

TABLE 1
English names and abbreviations
of solvents and reagents, and their
corresponding Chinese names
	Chinese	English
	name	name	Abbreviation
		Alanine	Ala
		Arginine	Arg
		Asparagine	Asn
		Aspartic acid	Asp
		Cysteine	Cys
		Glutamine	Gln
		Glutamic acid	Glu
		Glycine	Gly
		Histidine	His
		Isoleucine	Ile
		Leucine	Leu
		Lysine	Lys
		Methionine	Met
		Phenylalanine	Phe
		Proline	Pro
		Serine	Ser
		Threonine	Thr
		Tryptophan	Trp
		Tyrosine	Tyr
		Valine	Val

English name and
abbreviation            Chinese name
2-Chlorotrityl Chloride 2-chlorotrityl chloride Resin
Resin
DMF                     N, N-dimethyl formamide
DCM                     Dichloromethane
PIP                     Piperidine
HOBt                    1-hydroxybenzotriazole
DIPEA                   N,N-diisopropylethylamine
Methanol                Methyl alcohol
tert-Butyl methyl ether Methyl tertiary butyl ether
TFA                     Trifluoroacetic acid
TIPS                    Triisopropylsilane
DIC                     N,N′-diisopropyl carbodiimide
Ethanol                 Ethyl alcohol
Aa                      Amino acid

Example 1: Chemical Synthesis of Polypeptides

The synthesis of polypeptide compounds adopts the conventional solid phase synthesis method using a fully automatic polypeptide synthesizer, and the chemical synthesis of the polypeptide is carried out through the processes of resin swelling, deprotection, washing, amino acid activation and condensation.

Taking Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 1) as an example, the schematic diagram of the solid phase synthesis steps of the polypeptide is shown in FIG. 1.

Step 1: Preparation of Fully Protected Peptide Resin for Polypeptide

(1) Resin swelling: 7.71 g (SD=0.73 mmol/g) of 2-Chlorotrityl Chloride Resin was weighed, added into a synthesis tube with a sieve plate, and swollen with 100 ml of dichloromethane (DCM).

(2) Preparation of Fmoc-Gln (Trt)-resin: Fmoc-Gln(Trt)-OH and DIPEA were weighed in a molar ratio of 1:1.78:4.31 of resin, Fmoc-Gln(Trt)-OH and DIPEA respectively and added into the synthesis tube. Nitrogen (N₂) bubbling and shaking were performed at room temperature for 1-3 h, and then the mixture was pumped dry; then the mixture was washed with dimethylformamide (DMF) 5 times, 100 ml each time, and the resin was pumped dry.

(3) Removal of Fmoc protecting group: 100 ml of a 20% piperidine-DMF (v/v) solution was added into the reactor, nitrogen was bubbled, and the system was allowed to react for 20 min, pumped dry, then washed with DMF 5 times, at 100 ml/time, 3 min/time, pumped dry, and detected for the Fmoc removal result by the ninhydrin method.

(4) Amino acid pre-activation: 15 mmol of Fmoc-protected amino acid, 15 mmol of HOBt, and 15 mmol of DIC was added into a 250 ml beaker, dissolved in 100 ml of DMF, and stirred at room temperature for later use.

(5) Amino acid linkage: The activated protected amino acid solution was poured into the reactor, and an appropriate amount of DCM was additionally added to clean the apparatus. Nitrogen was bubbled at room temperature and the system was allowed to react for 1-3 h, and whether the amino acid linkage is complete was detected using the ninhydrin method. If so, the system was pumped dry. The resin was washed with DMF 5 times, at 100 ml/time, 3 min/time, and then pumped dry. The amount of each of the amino acids and condensing agents used is shown in Table 2.

(6) After the condensation of the first amino acid was completed, steps (4) and (5) were repeated to extend the peptide chain in the order of amino acids until the coupling of last amino acid was completed.

(7) The resin peptide was washed with DMF 4 times, at 150 ml/time, 3 min/time; then washed with DCM 5 times, at 150 ml/time, 3 min/time, and pumped dry.

TABLE 2
Usages of amino acids and condensing agents
Amino acid name	Aa/eq	Amino acid usage/g	HOBt/g	DIPEA/g	DIC/g
Fmoc-L-Gln(Trt)-OH	10	6.107	1	3.128	/
Fmoc-L-Ala-OH•H2O	15	4.941	2.027	/	2.379
Fmoc-L-Ala-OH•H2O	15	4.941	2.027	/	2.379
Fmoc-L-Val-OH	15	5.091	2.027	/	2.379
Fmoc-L-Lys(Boc)-OH	15	7.029	2.027	/	2.379
Fmoc-L-Arg(Pbf)-OH	15	9.732	2.027	/	2.379
Fmoc-L-Pro-OH•H2O	15	5.061	2.027	/	2.379
Fmoc-L-Lys(Boc)-OH	15	7.029	2.027	/	2.379
Fmoc-L-Ala-OH•H2O	15	4.941	2.027	/	2.379
Fmoc-L-Gln(Trt)-OH	15	9.161	2.027	/	2.379
Fmoc-L-Pro-OH•H2O	15	5.061	2.027	/	2.379
Fmoc-L-Val-OH	15	5.091	2.027	/	2.379
Fmoc-L-Pro-OH•H2O	15	5.061	2.027	/	2.379
Fmoc-L-Glu(OtBu)-OH•H2O	15	6.653	2.027	/	2.379
Fmoc-L-Lys(Boc)-OH	15	7.029	2.027	/	2.379

Step 2: Cleaving

(1) 100 ml of a cleavage agent (TFA:TIPS:H₂O=95:2.5:2.5, v/v) was added into the synthesis tube, nitrogen was bubbled, the system was allowed to react for 1.5-3 h.

(2) After the cleavage reaction was completed, the cleavage agent was suction-filtered into a 250 ml round-bottom flask. After vacuum concentration to one-fourth of the original volume of the cleavage agent, 10 times the existing volume of methyl tert-butyl ether was added to precipitate a white solid. The obtained mixture was filtered and washed three times with 50 ml of methyl tert-butyl ether, and then the obtained crude peptide product was placed in a sand core funnel and blowed dry with nitrogen in a fume hood to evaporate the solvent until the crude peptide was in powder form. 9.04 g of crude peptide was obtained with a crude yield of 74.7%.

Step 3: Purification, Salt Exchange and Freeze-Drying

Polypeptide HPLC direct salt exchange (Acetate Salt)

A. Chromatographic Parameters

Chromatographic column: dynamic axial compression column 80*250 mm, filler: Daisogel C18 (SP-100-8-ODS-P)

• • Eluent A1: 0.1 M acetic acid
  • Eluent A2: 0.025 M acetic acid-0.1 M ammonium acetate
  • Eluent B: acetonitrile
  • Flow rate: 180 ml/min
  • UV detection wavelength: 220 nm

B. Operating Steps

• • a) Dissolving the crude peptide in water and/or acetonitrile and filtering through a 0.45 μm filter membrane
  • b) Equilibrating the chromatographic column with 95% Al+5% B
  • c) Sample injection
  • d) Equilibrating the chromatographic column with 95% A2+5% B
  • e) Gradient elution with Al and B
  • f) Collecting the target peptide eluate
  • g) Rotary evaporation for concentration
  • h) Freeze drying

8.26 g of crude peptide was purified to obtain 4.92 g of pure peptide, with a purification yield of 59.5%.

In a similar manner to the synthesis of compound 1, other compounds were synthesized. The results are shown in Table 3 and other parts of the specification.

TABLE 3
Synthesized polypeptide compounds
Serial	Compound	Crude	Purification	Acetate
No.	sequence	product (g)	yield	purity	MS
1	Lys-Glu-Pro-Val-	9.04	59.5%	99.44%	412.70 (quadruply
	Pro-Gln-Ala-Lys-				charged)
	Pro-Arg-Lys-Val-				549.9 (triply
	Ala-Ala-Gln				charged)
2	Lys-Glu-Pro-Val-	2.04	14.7%	97.05%	426.60 (triply
	Pro-Gln-Ala-Lys-				charged)
	Pro-Arg-Lys				639.30 (doubly
					charged)
3	Lys-Glu-Pro-Val-	2.11	25.7%	97.47%	383.90 (triply
	Pro-Gln-Ala-Lys-				charged)
	Pro-Arg				575.20 (doubly
					charged)
4	Lys-Glu-Pro-Val-	1.55	26.1%	98.22%	448.70 (doubly
	Pro-Gln-Ala-Lys				charged)
					896.20 [M + H]+
5	Pro-Arg-Lys-Val-	1.06	30.6%	96.82%	385.60 (doubly
	Ala-Ala-Gln				charged)
					769.20 [M + H]+
6	Glu-Pro-Val-Pro-	1.64	20.8%	98.32%	384.70 (doubly
	Gln-Ala-Lys				charged)
					768.20 [M + H]+
7	Lys-Glu-Pro-Val	4.30	52.0%	97.22%	472.20 [M + H]+
8	Val-Ala-Ala-Gln	3.60	53.0%	100%	388.10 [M + H]+
9	Glu-Pro-Val-Pro	N/A	57.0%	99.01%	441.30 [M + H]+
10	Lys-Pro-Arg-Lys	0.50	13.5%	98.39%	264.70 doubly
					charged
					528.20 [M + H]+
11	Ala-Lys-Pro-Arg	3.79	17.3%	98.79%	471.20 [M + H]+
12	Pro-Val-Pro-Gln	0.20	48.7%	100%	440.30 [M + H]+
13	Val-Pro-Gln-Ala	0.35	57.5%	99.42%	414.30 [M + H]+
14	Pro-Gln-Ala-Lys	3.81	22.0%	98.20%	443.10 [M + H]+
15	Arg-Lys-Val-Ala	4.23	32.5%	97.48%	237.10 (doubly
					charged)
					473.20 [M + H]+
16	Lys-Val-Ala-Ala	3.81	27.0%	98.17%	388.10 [M + H]+
17	Gln-Ala-Lys-Pro	N/A	22.9%	96.01%	443.20 [M + H]+
18	Pro-Arg-Lys-Val	N/A	17.7%	97.47%	250.20 (doubly
					charged)
					499.30 [M + H]+
19	Ala-Glu-Pro-Val-	1.73	43.7%	100%	795.60 (doubly
	Pro-Gln-Ala-Lys-				charged)
	Pro-Arg-Lys-Val-				530.80 (triply
	Ala-Ala-Gln				charged)
20	Lys-Ala-Pro-Val-	1.96	45.8%	99.36%	795.10 (doubly
	Pro-Gln-Ala-Lys-				charged)
	Pro-Arg-Lys-Val-				530.50 (triply
	Ala-Ala-Gln				charged)
21	Lys-Glu-Ala-Val-	1.24	54.9%	99.59%	811.10 (doubly
	Pro-Gln-Ala-Lys-				charged)
	Pro-Arg-Lys-Val-				541.20 (triply
	Ala-Ala-Gln				charged)
22	Lys-Glu-Pro-Val-	1.5	46.5%	99.54%	811.10 (doubly
	Ala-Gln-Ala-Lys-				charged)
	Pro-Arg-Lys-Val-				541.20 (triply
	Ala-Ala-Gln				charged)
23	Lys-Glu-Pro-Val-	1.67	51.3%	99.42%	795.50 (doubly
	Pro-Ala-Ala-Lys-				charged)
	Pro-Arg-Lys-Val-				530.70 (triply
	Ala-Ala-Gln				charged)
24	Lys-Glu-Pro-Val-	2.65	52.6%	99.72%	795.50 (doubly
	Pro-Gln-Ala-Ala-				charged)
	Pro-Arg-Lys-Val-				530.70 (triply
	Ala-Ala-Gln				charged)
25	Lys-Glu-Pro-Ala-	3.21	51.8%	99.90%	810.20 (doubly
	Pro-Gln-Ala-Lys-				charged)
	Pro-Arg-Lys-Val-				540.50 (triply
	Ala-Ala-Gln				charged)
26	Lys-Glu-Pro-Val-	3.09	53.6%	99.82%	811.00 (doubly
	Pro-Gln-Ala-Lys-				charged)
	Ala-Arg-Lys-Val-				541.00 (triply
	Ala-Ala-Gln				charged)
27	Lys-Glu-Pro-Val-	3.07	42.0%	98.06%	781.50 (doubly
	Pro-Gln-Ala-Lys-				charged)
	Pro-Ala-Lys-Val-				521.40 (triply
	Ala-Ala-Gln				charged)
28	Lys-Glu-Pro-Val-	2.74	42.3%	99.73%	795.50 (doubly
	Pro-Gln-Ala-Lys-				charged)
	Pro-Arg-Ala-Val-				530.70 (triply
	Ala-Ala-Gln				charged)
29	Lys-Glu-Pro-Val-	2.61	39.2%	99.10%	810.00 (doubly
	Pro-Gln-Ala-Lys-				charged)
	Pro-Arg-Lys-Ala-				540.40 (triply
	Ala-Ala-Gln				charged)
30	Lys-Glu-Pro-Val-	1.82	53.5%	99.68%	795.60 (doubly
	Pro-Gln-Ala-Lys-				charged)
	Pro-Arg-Lys-Val-				530.80 (triply
	Ala-Ala-Ala				charged)
31	Lys-Glu-Gly-Val-	2.38	50.3%	100%	804.10 (doubly
	Pro-Gln-Ala-Lys-				charged)
	Pro-Arg-Lys-Val-				536.50 (triply
	Ala-Ala-Gln				charged)
32	Lys-Glu-Pro-Val-	1.93	38.5%	99.12%	804.10 (doubly
	Gly-Gln-Ala-Lys-				charged)
	Pro-Arg-Lys-Val-				536.40 (triply
	Ala-Ala-Gln				charged)
33	Lys-Glu-Pro-Val-	2.95	55.5%	100%	536.50 (triply
	Pro-Gln-Ala-Lys-				charged)
	Gly-Arg-Lys-Val-				804.00 (doubly
	Ala-Ala-Gln				charged)
34	Lys-Glu-Pro-Val-	3.37	53.2%	100%	523.10 (triply
	Gly-Gln-Ala-Lys-				charged)
	Gly-Arg-Lys-Val-				784.10 (doubly
	Ala-Ala-Gln				charged)
35	Lys-Glu-Gly-Val-	2.51	59.1%	100%	509.7 (triply
	Gly-Gln-Ala-Lys-				charged)
	Gly-Arg-Lys-Val-				764.10 (doubly
	Ala-Ala-Gln				charged)
36	Lys-Glu-Gly-Val-	2.93	53.4%	100%	523.10 (triply
	Pro-Gln-Ala-Lys-				charged)
	Gly-Arg-Lys-Val-				784.10 (doubly
	Ala-Ala-Gln				charged)
37	Lys-Glu-Gly-Val-	2.65	59.4%	100%	523.10 (triply
	Gly-Gln-Ala-Lys-				charged)
	Pro-Arg-Lys-Val-				784.10 (doubly
	Ala-Ala-Gln				charged)
38	Glu-Pro-Val-Pro-	1.85	51.1%	99.00%	575.50 (doubly
	Gln-Ala-Lys-Pro-				charged)
	Arg-Lys				384.00 (triply
					charged)
39	Pro-Val-Pro-Gln-		N/A	99.93%	511.20 [M + H]+
	Ala
40	Pro-Val-Pro-Glu-	4.50	47.9%	100%	512.40 [M + H]+
	Ala
41	Pro-Val-Pro-Ile-	4.77	60.8%	99.87%	496.50 [M + H]+
	Ala
42	Pro-Val-Pro-Ala	3.48	60.7%	100%	383.30 [M + H]+
43	Glu-Pro-Val-Pro-	0.66	60.1%	97.77%	640.20 [M + H]+
	Gln-Ala
44	Pro-Val-Pro-Gln-	0.61	45.2%	99.87%	639.30 [M + H]+
	Ala-Lys
45	Glu-Pro-Val-Pro-	0.73	42.3%	98.98%	796.30 [M + H]+
	Gln-Ala-Arg
46	Ala-Pro-Val-Pro-	0.70	52.8%	99.78%	710.30 [M + H]+
	Gln-Ala-Lys
47	Glu-Pro-Val-Pro-	1.02	39.7%	98.55%	711.40 [M + H]+
	Ala-Ala-Lys
48	Glu-Pro-Val-Pro-	1.03	63.3%	97.75%	711.40 [M + H]+
	Gln-Ala-Ala
49	Asp-Pro-Val-Pro-	N/A	N/A	99.69%	754.30 [M + H]+
	Gln-Ala-Lys
50	Asn-Pro-Val-Pro-	1.03	58.3%	99.53%	753.30 [M + H]+
	Gln-Ala-Lys
51	Glu-Pro-Val-Pro-	N/A	N/A	97.89%	660.50 (doubly
	Gln-Ala-Lys-Pro-				charged)
	Arg-Lys-Val-Ala
52	Glu-Pro-Ala-Pro-	1.04	56.9%	99.14%	740.30 [M + H]+
	Gln-Ala-Lys
53	Glu-Ala-Val-Pro-	N/A	N/A	98.45%	371.80 doubly
	Gln-Ala-Lys				charged
					742.40 [M + H]+
54	Glu-Pro-Val-Ala-	0.66	63.2%	98.35%	742.40 [M + H]+
	Gln-Ala-Lys
55	Glu-Pro-Val-Pro-	N/A	N/A	97.91%	385.30 (doubly
	Glu-Ala-Lys				charged) 769.30
					[M + H]+
56	Glu-Pro-Val-Pro-	N/A	N/A	98.46%	417.10 (triply
	Gln-Ala-Lys-Pro-				charged)
	Arg-Lys-Val				625.10 [M + H]+
57	Glu-Pro-Val-Pro-	N/A	N/A	98.76%	511.40 (doubly
	Gln-Ala-Lys-Pro-				charged)
	Arg
58	Glu-Pro-Val-Pro-	N/A	N/A	98.17%	433.30 (doubly
	Gln-Ala-Lys-Pro				charged)
					865.50 [M + H]+
59	Pro-Val-Pro-Gln-	N/A	N/A	99.47%	298.20 (triply
	Ala-Lys-Pro-Arg				charged)
					446.90 (doubly
					charged)
					892.50 [M + H]+
60	Pro-Val-Pro-Gln-	N/A	N/A	99.42%	368.90 (doubly
	Ala-Lys-Pro				charged)
					736.40 [M + H]+
61	D-Lys-Glu-Pro-	2.35	52.4%	100%	824.2 doubly
	Val-Pro-Gln-Ala-				charged
	Lys-Pro-Arg-Lys-				549.8 triply
	Val-Ala-Ala-Gln				charged
62	Lys-D-Glu-Pro-	2.21	53.8%	100%	824.2 doubly
	Val-Pro-Gln-Ala-				charged
	Lys-Pro-Arg-Lys-				549.8 triply
	Val-Ala-Ala-Gln				charged
63	Lys-Glu-D-Pro-	2.1	54.3%	100%	824.2 doubly
	Val-Pro-Gln-Ala-				charged
	Lys-Pro-Arg-Lys-				549.9 triply
	Val-Ala-Ala-Gln				charged
64	Lys-Glu-Pro-D-	2.1	54.8%	99.74%	824.2 doubly
	Val-Pro-Gln-Ala-				charged
	Lys-Pro-Arg-Lys-				549.7 triply
	Val-Ala-Ala-Gln				charged
65	Lys-Glu-Pro-Val-	1.97	48.6%	100%	824.1 doubly
	D-Pro-Gln-Ala-				charged
	Lys-Pro-Arg-Lys-				549.8 triply
	Val-Ala-Ala-Gln				charged
66	Lys-Glu-Pro-Val-	1.99	59.8%	100%	824.1 doubly
	Pro-D-Gln-Ala-				charged
	Lys-Pro-Arg-Lys-				549.8 triply
	Val-Ala-Ala-Gln				charged
67	Lys-Glu-Pro-Val-	1.71	86.5%	100%	824.2 doubly
	Pro-Gln-D-Ala-				charged
	Lys-Pro-Arg-Lys-				549.8 triply
	Val-Ala-Ala-Gln				charged
68	Lys-Glu-Pro-Val-	2.21	71.5%	100%	824.2 doubly
	Pro-Gln-Ala-D-				charged
	Lys-Pro-Arg-Lys-				549.9 triply
	Val-Ala-Ala-Gln				charged
69	Lys-Glu-Pro-Val-	1.87	74.3%	99.59%	824.3 doubly
	Pro-Gln-Ala-Lys-				charged
	D-Pro-Arg-Lys-				549.8 triply
	Val-Ala-Ala-Gln				charged
70	Lys-Glu-Pro-Val-	1.99	63.4%	100%	824.3 doubly
	Pro-Gln-Ala-Lys-				charged
	Pro-D-Arg-Lys-				549.9 triply
	Val-Ala-Ala-Gln				charged
71	Lys-Glu-Pro-Val-	2.15	67.1%	100%	824.2 doubly
	Pro-Gln-Ala-Lys-				charged
	Pro-Arg-D-Lys-				549.9 triply
	Val-Ala-Ala-Gln				charged
72	Lys-Glu-Pro-Val-	1.95	73.3%	100%	824.2 doubly
	Pro-Gln-Ala-Lys-				charged
	Pro-Arg-Lys-D-				550.0 triply
	Val-Ala-Ala-Gln				charged
73	Lys-Glu-Pro-Val-	2.94	46.3%	97.94%	824.0 doubly
	Pro-Gln-Ala-Lys-				charged
	Pro-Arg-Lys-Val-				549.7 triply
	D-Ala-Ala-Gln				charged
74	Lys-Glu-Pro-Val-	3.32	37.3%	99.12%	824.1 doubly
	Pro-Gln-Ala-Lys-				charged
	Pro-Arg-Lys-Val-				549.8 triply
	Ala-D-Ala-Gln				charged
75	Lys-Glu-Pro-Val-	3.73	44.2%	99.03%	824.1 doubly
	Pro-Gln-Ala-Lys-				charged
	Pro-Arg-Lys-Val-				549.7 triply
	Ala-Ala-D-Gln				charged
76	Glu-Gly-Val-Pro-	N/A	N/A	97.45%	364.80 doubly
	Gln-Ala-Lys				charged
					728.50 [M + H]+
77	Glu-Pro-Val-Gly-	N/A	N/A	97.89%	364.80 doubly
	Gln-Ala-Lys				charged
					728.50 [M + H]+
78	D-Glu-Pro-Val-	N/A	N/A	96.92%	768.50 [M + H]+
	Pro-Gln-Ala-Lys				384.90 doubly
					charged
79	Glu-D-Pro-Val-	N/A	N/A	96.65%	768.60 [M + H]+
	Pro-Gln-Ala-Lys				384.70 doubly
					charged
80	Glu-Pro-D-Val-	3.86	48.5%	98.51%	768.5 [M + H]+
	Pro-Gln-Ala-Lys				384.9 doubly
					charged
81	Glu-Pro-Val-D-	3.39	45.6%	98.06%	768.6 [M + H]+
	Pro-Gln-Ala-Lys				384.8 doubly
					charged
82	Glu-Pro-Val-Pro-	3.76	41.2%	98.34%	768.6 [M + H]+
	D-Gln-Ala-Lys				384.9 doubly
					charged
83	Glu-Pro-Val-Pro-	3.83	45.2%	97.85%	768.3 [M + H]+
	Gln-D-Ala-Lys				384.7 doubly
					charged
84	Glu-Pro-Val-Pro-	N/A	55.0%	97.06%	768.2 [M + H]+
	Gln-Ala-D-Lys
85	Lys-Glu-Pro-Val-	3.38	42.8%	99.94%	569.1 [M + H]+
	Pro
86	Glu-Pro-Val-Pro-	330 m	38.4%	97.14%	569.2 [M + H]+
	Gln
87	Lys-Glu-Pro-Val-	560 m	91.8%	98.83%	697.3 [M + H]+
	Pro-Gln				349.1 doubly
					charged
88	Val-Pro-Tyr-Lys-	3.57	39.7%	99.40%	669.6 triply
	Glu-Pro-Val-Pro-				charged
	Gln-Ala-Lys-Pro-				1003.7 doubly
	Arg-Lys-Val-Ala-				charged
	Ala-Gln
89	Pyro-Glu-Leu-Lys-	2.66	48.6%	99.86%	624.5 triply
	Glu-Pro-Val-Pro-				charged
	Gln-Ala-Lys-Pro-				936.1 doubly
	Arg-Lys-Val-Ala-				charged
	Ala-Gln
90	Pro-Ala-Tyr-Lys-	3.15	49.3%	98.66%	660.2 triply
	Glu-Pro-Val-Pro-				charged
	Gln-Ala-Lys-Pro-				990.2 doubly
	Arg-Lys-Val-Ala-				charged
	Ala-Gln
91	Arg-Lys-Asp-Val-	3.37	27.4%	100%	770.2 triply
	Tyr-Lys-Glu-Pro-				charged
	Val-Pro-Gln-Ala-				1154.8 doubly
	Lys-Pro-Arg-Lys-				charged
	Val-Ala-Ala-Gln
92	Arg-Lys-Asp-Val-	1.82	44.1%	98.42%	779.4 doubly
	Tyr-Lys-Glu-Pro-				charged
	Val-Pro-Gln-Ala-				520.0 triply
	Lys				charged
93	Arg-Lys-Asp-Val-	1.3	48.5%	98.83%	715.3 doubly
	Tyr-Glu-Pro-Val-				charged
	Pro-Gln-Ala-Lys				477.3 triply
					charged
94	Arg-Lys-Asp-Val-	0.77	57.1%	98.08%	551.3 doubly
	Tyr-Pro-Val-Pro-				charged
	Gln				1101.5 [M + H]+
95	Gly-Pro-Glu-Thr-	1.58	52.7%	94.96%	840.2 triply
	Ala-Phe-Leu-Arg-				charged
	Lys-Glu-Pro-Val-				1260.2 doubly
	Pro-Gln-Ala-Lys-				charged
	Pro-Arg-Lys-Val-
	Ala-Ala-Gln
96	Gly-Pro-Glu-Thr-	0.98	55.1%	96.59%	820.4 doubly
	Ala-Phe-Leu-Arg-				charged
	Glu-Pro-Val-Pro-				547.2 triply
	Gln-Ala-Lys				charged
97	Ser-Ser-Glu-Asp-	4.04	39.1%	94.51%	812.7 triply
	Ile-Lys-Glu-Lys-				charged
	Glu-Pro-Val-Pro-				1218.4 doubly
	Gln-Ala-Lys-Pro-				charged
	Arg-Lys-Val-Ala-
	Ala-Gln
98	Ser-Ser-Glu-Asp-	2.42	43.6%	99.27%	779.0 doubly
	Ile-Lys-Glu-Glu-				charged
	Pro-Val-Pro-Gln-				519.7 triply
	Ala-Lys				charged
99	Ser-Ser-Glu-Asp-	1.58	49.9%	98.08%	614.9 doubly
	Ile-Lys-Glu-Pro-				charged
	Val-Pro-Gln				1228.6 [M + H]+
100	Val-Pro-Pro-Lys-	2.81	37.9%	100%	647.5 triply
	Glu-Pro-Val-Pro-				charged
	Gln-Ala-Lys-Pro-				970.8 doubly
	Arg-Lys-Val-Ala-				charged
	Ala-Gln
101	Glu-Pro-Val-Pro-	4.65	11.0%	98.63%	778.9 doubly
	Gln-Ala-Lys-Ser-				charged
	Ser-Glu-Asp-Ile-				519.6 triply
	Lys-Glu				charged
102	Glu-Pro-Val-Pro-	4.3	49.8%	97.73%	564.1 doubly
	Gln-Ala-Lys-Val-				charged
	Pro-Tyr				1127.5 [M + H]+
103	Lys-Glu-Pro-Val-	5.9	26.3%	99.84%	824.4 doubly
	Pro-Gln-Ala-Lys-				charged
	Pro-Arg-Lys-Val-				550.0 triply
	Ala-Ala-Glu				charged
104	Lys-Glu-Pro-Val-	6.04	42.8%	98.79%	817.0 doubly
	Pro-Gln-Ala-Lys-				charged
	Pro-Arg-Lys-Val-				545.1 triply
	Ala-Ala-Asn				charged
105	Lys-Gln-Pro-Val-	6.4	39.3%	98.66%	823.6 doubly
	Pro-Gln-Ala-Lys-				charged
	Pro-Arg-Lys-Val-				549.5 triply
	Ala-Ala-Gln				charged
106	Lys-Glu-Pro-Ile-	5.98	39.7%	99.54%	831.1 doubly
	Pro-Gln-Ala-Lys-				charged
	Pro-Arg-Lys-Val-				554.5 triply
	Ala-Ala-Gln				charged
107	Val-Pro-Gln-Ala	0.47	47.2%	100%	414.2 [M + H]+
108	Val-Pro-Gln-Ala-	0.50	51.3%	99.63%	542.3 [M + H]+
	Lys
Note:
A doubly charged peak indicates that the target molecule is bound to 2 protons, and a triply charged peak indicates that the target molecule is bound to 3 protons; and N/A means that the weighing is difficult and the actual weight is not considered.

Compound 1: Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate salt)

High resolution mass spectrometry (TOF-HRMS), molecular formula: C₇₃H₁₂₇N₂₃O₂₀; m/z:m/z: 549.65904 ([M+3H]³⁺), 823.98493 ([M+2H]²⁺), 1646.96346 ([M+H]⁺).

¹H NMR (600 MHz, D₂O+CD₃CN) δ 4.48 (dd, J=9.5, 4.1 Hz, 1H), 4.42 (dd, J=9.2, 4.5 Hz, 1H), 4.32-4.27 (m, 1H), 4.27-4.21 (m, 3H), 4.20-4.07 (m, 6H), 4.00 (dd, J=8.3, 4.8 Hz, 1H), 3.95 (d, J=7.5 Hz, 1H), 3.86 (t, J=6.7 Hz, 1H), 3.77-3.62 (m, 3H), 3.59-3.43 (m, 3H), 3.04 (t, J-6.7 Hz, 2H), 2.87-2.78 (m, 6H), 2.28-2.08 (m, 9H), 2.00-1.80 (m, 31H, AcOH), 1.80-1.41 (m, 23H), 1.40-1.24 (m, 6H), 1.24-1.18 (m, 9H), 0.87-0.73 (m, 12H).

Compound 2: Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys (Acetate Salt)

High resolution mass spectrometry (TOF-HRMS), molecular formula: C₅₇H₁₀₀N₁₈O₁₅; m/z: 426.59680 ([M+3H]³⁺), 639.39021 ([M+2H]²⁺), 1277.77023 ([M+H]⁺).

1H NMR (600 MHz, DMSO-d6) δ 4.57 (dd, J=8.7, 4.9 Hz, 1H), 4.41-4.11 (m, 10H), 3.83 (s, 1H), 3.78 (t, J=6.5 Hz, 1H), 3.54 (d, J=73.5 Hz, 7H), 3.08 (d, J=7.0 Hz, 2H), 2.74-2.68 (m, 7H), 2.32 (d, J=9.1 Hz, 2H), 2.23-2.17 (m, 2H), 2.05-1.46 (m, AcOH, 56H), 1.43-1.22 (m, 7H), 1.17 (d, J=7.0 Hz, 3H), 0.82 (dd, J=19.6, 6.7 Hz, 6H).

Compound 3: Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg (Acetate Salt)

High resolution mass spectrometry (TOF-HRMS), molecular formula: C₅₁H₈₈N₁₆O₁₄; m/z: 383.89927 ([M+3H]³⁺), 575.34276 ([M+2H]²⁺), 1149.67551 ([M+H]⁺).

¹H NMR (600 MHz, DMSO-d₆) δ 4.58-4.55 (m, 1H), 4.44-4.37 (m, 2H), 4.33 (dd, J=8.4, 4.2 Hz, 1H), 4.30-4.22 (m, 3H), 4.16-4.12 (m, 2H), 3.79 (d, J=6.1 Hz, 1H), 3.64-3.48 (m, 6H), 3.08 (t, J=7.0 Hz, 2H), 2.71 (d, J=8.2 Hz, 5H), 2.36-2.30 (m, 2H), 2.15 (t, J=7.6 Hz, 2H), 2.09-1.41 (m, AcOH, 46H), 1.37-1.29 (m, 4H), 1.16 (d, J=7.1 Hz, 3H), 0.85 (dd, J=20.7, 6.7 Hz, 6H).

Compound 4: Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (TOF-HRMS), molecular formula: C₄₀H₆₉N₁₁O₁₂; m/z: 448.76653 ([M+2H]²⁺), 896.52058 ([M+H]⁺).

¹H NMR (600 MHz, DMSO-d₆) δ 4.56 (dd, J=9.0, 4.9 Hz, 1H), 4.39 (dd, J=8.3, 4.4 Hz, 1H), 4.31-4.24 (m, 3H), 4.13 (dd, J=9.1, 5.1 Hz, 2H), 3.78 (dd, J=7.9, 4.3 Hz, 1H), 3.67-3.51 (m, 4H), 2.75-2.70 (m, 4H), 2.38-2.29 (m, 2H), 2.14 (t, J=7.8 Hz, 2H), 2.04-1.47 (m, AcOH, 33H), 1.35-1.28 (m, 4H), 1.19 (d, J=7.2 Hz, 3H), 0.85 (dd, J=22.1, 6.8 Hz, 6H).

Compound 5: Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (TOF-HRMS), molecular formula: C₃₃H₆₀N₁₂O₉; m/z: 385.24021 ([M+2H]²⁺), 769.46971 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.23-4.17 (m, 1H), 4.15-4.07 (m, 4H), 3.95 (dd, J=8.5, 4.8 Hz, 1H), 3.89 (d, J=7.7 Hz, 1H), 3.25-3.15 (m, 2H), 3.00 (t, J=7.0 Hz, 2H), 2.78 (t, J=7.7 Hz, 2H), 2.30-2.22 (m, 1H), 2.12-2.05 (m, 2H), 1.93-1.80 (m, 5H), 1.75 (s, AcOH, 10H), 1.62-1.40 (m, 8H), 1.19 (d, J=7.2 Hz, 8H), 0.73 (dd, J=6.7, 4.0 Hz, 6H).

Compound 6: Glu-Pro-Val-Pro-Gln-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (TOF-HRMS), molecular formula: C₃₄H₅₇N₉O₁₁; m/z: 768.42641 ([M+H]⁺).

¹H NMR (600 MHz, D₂O) δ 4.46 (dd, J=8.4, 6.4 Hz, 1H), 4.35-4.27 (m, 3H), 4.26-4.18 (m, 2H), 4.09 (dd, J=8.2, 5.1 Hz, 1H), 3.84-3.77 (m, 1H), 3.68-3.52 (m, 3H), 2.91 (t, J=7.5 Hz, 2H), 2.39 (t, J=7.2 Hz, 2H), 2.33 (t, J=7.6 Hz, 2H), 2.27-2.17 (m, 2H), 2.12-1.87 (m, AcOH, 13H), 1.83-1.72 (m, 3H), 1.66-1.57 (m, 3H), 1.32 (dd, J=11.8, 7.5 Hz, 5H), 0.92 (dd, J=12.6, 6.7 Hz, 6H).

Compound 7: Lys-Glu-Pro-Val (Acetate Salt)

High resolution mass spectrometry (TOF-HRMS), molecular formula: C₂₁H₃₇N₅O₇; m/z: 472.27768 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.43 (dd, J=10.2, 4.0 Hz, 1H), 4.27 (dd, J=8.3, 5.3 Hz, 1H), 3.85-3.80 (m, 2H), 3.68-3.60 (m, 1H), 3.59-3.46 (m, 1H), 2.80 (t, J=7.6 Hz, 2H), 2.22-2.14 (m, 2H), 2.10-2.06 (m, 1H), 1.96-1.64 (m, AcOH, 11H), 1.52-1.47 (m, 2H), 1.29-1.22 (m, 2H), 0.71 (dd, J=15.3, 6.9 Hz, 6H).

Compound 8: Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₁₆H₂₉N₅O₆; m/z: 388.2187 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.25 (q, J=7.2 Hz, 1H), 4.17 (q, J=7.2 Hz, 1H), 4.05 (dd, J=8.5, 4.8 Hz, 1H), 3.67 (d, J=6.0 Hz, 1H), 2.23-2.14 (m, 2H), 2.13-2.05 (m, 1H), 2.04-1.95 (m, 1H), 1.85-1.76 (m, 1H), 1.28 (dd, J=7.2, 5.0 Hz, 6H), 0.90 (dd, J=10.3, 6.9 Hz, 6H).

Compound 9: Glu-Pro-Val-Pro (Acetate Salt)

High resolution mass spectrometry (TOF-HRMS), molecular formula: C₂₀H₃₂N₄O₇; 441.23562 ([M+H]⁺).

¹H NMR (600 MHz, DMSO-d₆) δ 4.42 (dd, J=8.4, 4.6 Hz, 1H), 4.28 (t, J=8.3 Hz, 1H), 4.17 (dd, J=8.5, 4.7 Hz, 1H), 3.78 (dd, J=8.3, 4.2 Hz, 1H), 3.64-3.45 (m, 4H), 2.37-2.27 (m, 2H), 2.08-1.58 (m, AcOH, 16H), 0.87 (dd, J=25.7, 6.7 Hz, 6H).

Compound 10: Lys-Pro-Arg-Lys(acetate salt)

High resolution mass spectrometry (TOF-HRMS), molecular formula: C₂₃H₄₅N₉O₅; 264.68527 ([M+2H]²⁺), 528.36210 ([M+H]⁺).

¹H NMR (600 MHz, DMSO-d₆) δ 4.42 (dd, J=8.2, 5.2 Hz, 1H), 4.23 (t, J=6.7 Hz, 1H), 4.14 (dd, J=8.9, 5.2 Hz, 1H), 4.09 (d, J=7.9 Hz, 1H), 3.64 (dd, J=9.9, 6.6 Hz, 1H), 3.45-3.40 (m, 1H), 3.07 (s, 2H), 2.72 (t, J=6.3 Hz, 4H), 2.11-2.04 (m, 1H), 1.92-1.66 (m, AcOH, 18H), 1.56-1.48 (m, 8H), 1.45-1.38 (m, 2H), 1.33-1.29 (m, 2H).

Compound 11: Ala-Lys-Pro-Arg (Acetate Salt)

High resolution mass spectrometry (TOF-HRMS), molecular formula: C₂₀H₃₈N₈O₅; 236.15638 ([M+2H]²⁺), 471.30462 ([M+H]⁺).

¹H NMR (600 MHz, D₂O )) δ 4.55 (dd, J=8.3, 5.6 Hz, 1H), 4.34 (dd, J=8.4, 5.9 Hz, 1H), 4.09-3.96 (m, 2H), 3.82-3.74 (m, 1H), 3.64-3.55 (m, 1H), 3.12 (t, J=6.9 Hz, 2H), 2.93 (t, J=7.6 Hz, 2H), 2.28-2.20 (m, 1H), 2.04-1.83 (m, 3H), 1.82 (s, AcOH, 6H), 1.79-1.60 (m, 6H), 1.58-1.51 (m, 2H), 1.42 (d, J=7.1 Hz, 5H).

Compound 12: Pro-Val-Pro-Gln (Acetate Salt)

High resolution mass spectrometry (TOF-HRMS), molecular formula: C₂₀H₃₃N₅O₆; m/z: 440.25122 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.33-4.18 (m, 3H), 3.97 (dd, J=8.9, 4.8 Hz, 1H), 3.74-3.65 (m, 1H), 3.53-3.46 (m, 1H), 3.25-3.16 (m, 2H), 2.29-2.22 (m, 1H), 2.17-2.10 (m, 3H), 1.99-1.66 (m, AcOH, 12H), 0.82 (d, J=6.8 Hz, 3H), 0.76 (d, J=6.7 Hz, 3H).

Compound 13: Val-Pro-Gln-Ala (Acetate Salt)

High resolution mass spectrometry (TOF-HRMS), molecular formula: C₁₈H₃₁N₅O₆; m/z: 414.23575 ([M+H]⁺).

¹H NMR (600 MHz, D₂O) δ 4.37 (t, J=7.5 Hz, 1H), 4.15 (dd, J=8.6, 6.0 Hz, 1H), 4.07 (d, J=5.5 Hz, 1H), 4.03 (t, J=7.2 Hz, 1H), 3.68-3.61 (m, 1H), 3.55-3.48 (m, 1H), 2.35-2.26 (m, 2H), 2.26-2.15 (m, 2H), 2.04-1.74 (m, AcOH, 7H), 1.22 (d, J=7.2 Hz, 3H), 0.98 (d, J=7.0 Hz, 3H), 0.87 (d, J=6.8 Hz, 3H).

Compound 14: Pro-Gln-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (TOF-HRMS), molecular formula: C₁₉H₃₄N₆O₆; m/z: 222.13480([M+2H]²⁺), 443.26183([M+H]⁺).

¹H NMR (600 MHz, D₂O) δ 4.28 (dd, J=8.7, 6.1 Hz, 1H), 4.25-4.15 (m, 2H), 4.01 (dd, J=8.1, 5.2 Hz, 1H), 3.34-3.22 (m, 2H), 2.86 (t, J=7.5 Hz, 2H), 2.37-2.29 (m, 1H), 2.26 (t, J=7.6 Hz, 2H), 2.00-1.84 (m, 5H), 1.73-1.64 (m, 1H), 1.62-1.50 (m, 3H), 1.30-1.24 (m, 5H).

Compound 15: Arg-Lys-Val-Ala (Acetate Salt)

High resolution mass spectrometry (TOF-HRMS), molecular formula: C₂₀H₄₀N₈O₅; m/z: 237.16465 ([M+2H]²⁺), 473.32087 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.28 (t, J=7.3 Hz, 1H), 4.00-3.94 (m, 2H), 3.90 (t, J=6.4 Hz, 1H), 3.07 (t, J=7.0 Hz, 2H), 2.85 (t, J=7.6 Hz, 2H), 2.01-1.92 (m, 1H), 1.80-1.75 (m, AcOH, 8H), 1.73-1.59 (m, 2H), 1.59-1.40 (m, 4H), 1.35-1.22 (m, 2H), 1.19 (d, J=7.2 Hz, 3H), 0.81 (t, J=6.9 Hz, 6H).

Compound 16: Lys-Val-Ala-Ala (Acetate Salt)

High resolution mass spectrometry (TOF-HRMS), molecular formula: C₁₇H₃₃N₅O₅; m/z: 388.25660 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.18 (q, J=7.1 Hz, 1H), 4.03-3.91 (m, 3H), 2.87 (t, J=7.7 Hz, 2H), 1.98-1.89 (m, 1H), 1.83-1.74 (m, AcOH, 6H), 1.60-1.53 (m, 2H), 1.36-1.27 (m, 2H), 1.26 (d, J=7.2 Hz, 3H), 1.19 (d, J=7.2 Hz, 3H), 0.83 (d, J=6.8 Hz, 6H).

Compound 17: Gln-Ala-Lys-Pro (Acetate Salt)

High resolution mass spectrometry (TOF-HRMS), molecular formula: C₁₉H₃₄N₆O₆; m/z: 443.26161([M+H]⁺).

¹H NMR (600 MHz, D₂O) δ 4.48 (dd, J=8.2, 5.6 Hz, 1H), 4.26-4.20 (m, 1H), 4.10 (dd, J=8.5, 5.4 Hz, 1H), 3.91 (t, J=6.6 Hz, 1H), 3.68-3.61 (m, 1H), 3.55-3.43 (m, 1H), 2.88 (t, J=7.5 Hz, 2H), 2.39-2.27 (m, 2H), 2.15-1.96 (m, 3H), 1.92-1.69 (m, 8H), 1.66-1.49 (m, 3H), 1.43-1.29 (m, 2H), 1.28-1.22 (m, 3H).

Compound 18: Pro-Arg-Lys-Val (Acetate Salt)

High resolution mass spectrometry (TOF-HRMS), molecular formula: C₂₂H₄₂N₈O₅; m/z: 250.17158 ([M+2H]²⁺), 499.33464 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.27 (dd, J=8.7, 6.0 Hz, 1H), 4.24-4.17 (m, 2H), 3.88 (d, J=6.2 Hz, 1H), 3.33-3.20 (m, 2H), 3.09-3.02 (m, 2H), 2.85 (t, J=7.5 Hz, 2H), 2.37-2.28 (m, 1H), 1.98-1.86 (m, 4H), 1.78 (s, AcOH, 6H), 1.72-1.42 (m, 8H), 1.38-1.23 (m, 2H), 0.75 (dd, J=11.2, 6.8 Hz, 6H).

Compound 19: Ala-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (TOF-HRMS), molecular formula: C₇₀H₁₂₀N₂₂O₂₀; m/z: 530.64499 ([M+3H]³⁺), 795.46224 ([M+2H]²⁺), 1589.91350 ([M+H]⁺).

¹H NMR (600 MHz, D₂O) δ 4.53-4.43 (m, 2H), 4.33 (dd, J=8.3, 6.0 Hz, 1H), 4.27 (t, J=7.7 Hz, 3H), 4.24-4.12 (m, 6H), 4.06-3.94 (m, 3H), 3.77 (q, J=7.6 Hz, 1H), 3.73-3.67 (m, 2H), 3.63-3.53 (m, 2H), 3.51 (q, J=7.6 Hz, 1H), 3.08 (t, J=6.9 Hz, 2H), 2.91-2.83 (m, 4H), 2.29 (t, J=7.6 Hz, 2H), 2.26-2.12 (m, 7H), 2.03-1.46 (m, AcOH,38H), 1.39 (d, J=7.1 Hz, 4H), 1.36-1.30 (m, 2H), 1.30-1.22 (m, 10H), 0.92-0.77 (m, 12H).

Compound 20: Lys-Ala-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (TOF-HRMS), molecular formula: C₇₁H₁₂₅N₂₃O₁₈; m/z: 530.32804 ([M+3H]³⁺), 794.98683 ([M+2H]²⁺), 1588.96546 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.51 (q, J=7.1 Hz, 1H), 4.48-4.43 (m, 1H), 4.31-4.25 (m, 3H), 4.24-4.11 (m, 6H), 4.03 (dd, J=8.4, 4.9 Hz, 1H), 3.98 (d, J=7.6 Hz, 1H), 3.87 (t, J=6.7 Hz, 1H), 3.79-3.67 (m, 3H), 3.60-3.47 (m, 3H), 3.08 (t, J=6.9 Hz, 2H), 2.91-2.83 (m, 6H), 2.28 (t, J=7.6 Hz, 2H), 2.21-2.13 (m, 5H), 2.03-1.64 (m, AcOH, 33H), 1.64-1.47 (m, 11H), 1.44-1.28 (m, 6H), 1.28-1.21 (m, 12H), 0.89-0.76 (m, 12H).

Compound 21: Lys-Glu-Ala-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (TOF-HRMS), molecular formula: C₇₁H₁₂₅N₂₃O₂₀; m/z: 540.99125 ([M+3H]³⁺), 810.98235 ([M+2H]²⁺), 1620.94722 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.45 (dd, J=9.4, 4.9 Hz, 1H), 4.30-4.24 (m, 3H), 4.24-4.11 (m, 8H), 4.02 (dd, J=8.4, 4.9 Hz, 1H), 3.97 (d, J=7.6 Hz, 1H), 3.89 (t, J=6.7 Hz, 1H), 3.79-3.66 (m, 2H), 3.60-3.47 (m, 2H), 3.08 (t, J=6.9 Hz, 2H), 2.91-2.83 (m, 6H), 2.28 (t, J=7.6 Hz, 2H), 2.22-2.12 (m, 6H), 2.02-1.46 (m, AcOH, 41H), 1.43-1.28 (m, 6H), 1.28-1.20 (m, 12H), 0.88-0.75 (m, 12H).

Compound 22: Lys-Glu-Pro-Val-Ala-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (TOF-HRMS), molecular formula: C₇₁H₁₂₅N₂₃O₂₀; m/z: 540.99088([M+3H]³⁺), 810.98168([M+2H]²⁺), 1620.95237([M+H]⁺).

¹H NMR (600 MHz, D₂O) δ 4.51 (dd, J=9.6, 4.4 Hz, 1H), 4.46 (dd, J=9.4, 4.8 Hz, 1H), 4.35 (dd, J=8.4, 5.8 Hz, 1H), 4.28 (dd, J=8.3, 6.1 Hz, 1H), 4.25-4.13 (m, 7H), 4.03 (dd, J=8.3, 4.9 Hz, 1H), 3.98 (d, J=7.6 Hz, 1H), 3.94-3.88 (m, 2H), 3.75-3.67 (m, 2H), 3.63-3.56 (m, 1H), 3.51 (q, J=7.3 Hz, 1H), 3.09 (t, J=6.9 Hz, 2H), 2.91-2.83 (m, 6H), 2.29-2.21 (m, 4H), 2.21-2.13 (m, 4H), 2.03-1.65 (m, AcOH, 31H), 1.64-1.46 (m, 11H), 1.45-1.28 (m, 6H), 1.28-1.22 (m, 12H), 0.89-0.78 (m, 12H).

Compound 23: Lys-Glu-Pro-Val-Pro-Ala-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₁H₁₂₄N₂₂O₁₉; m/z: 398.24191 ([M+4H]⁴⁺), 530.65344 ([M+3H]³⁺), 795.97791 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O) δ 4.51 (dd, J=9.6, 4.4 Hz, 1H), 4.44 (dd, J=9.4, 4.9 Hz, 1H), 4.33 (dd, J=8.4, 5.8 Hz, 1H), 4.31-4.08 (m, 9H), 4.03 (dd, J=8.4, 4.9 Hz, 1H), 3.97 (d, J=7.6 Hz, 1H), 3.92-3.87 (m, 1H), 3.79-3.73 (m, 1H), 3.73-3.66 (m, 2H), 3.62-3.52 (m, 2H), 3.51-3.46 (m, 1H), 3.07 (t, J=6.9 Hz, 2H), 2.90-2.81 (m, 6H), 2.29-2.21 (m, 2H), 2.21-2.10 (m, 5H), 2.02-1.64 (m, AcOH, 37H), 1.64-1.45 (m, 11H), 1.44-1.27 (m, 6H), 1.27-1.20 (m, 12H), 0.91-0.74 (m, 12H).

Compound 24: Lys-Glu-Pro-Val-Pro-Gln-Ala-Ala-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₀H₁₂₀N₂₂O₂₀; m/z: 398.23245([M+4H]⁴⁺), 530.64075([M+3H]³⁺), 795.45752([M+2H]²⁺).

¹H NMR (600 MHz, D₂O) δ 4.51 (dd, J=9.7, 4.4 Hz, 1H), 4.45 (q, J=7.1 Hz, 1H), 4.33 (dd, J=8.4, 5.8 Hz, 1H), 4.31-4.24 (m, 3H), 4.23-4.12 (m, 6H), 4.03 (dd, J=8.4, 4.8 Hz, 1H), 3.97 (d, J=7.6 Hz, 1H), 3.92-3.87 (m, 1H), 3.79-3.73 (m, 1H), 3.73-3.64 (m, 2H), 3.62-3.48 (m, 3H), 3.08 (t, J=6.9 Hz, 2H), 2.91-2.83 (m, 4H), 2.32-2.21 (m, 4H), 2.20-2.11 (m, 5H), 2.03-1.71 (m, AcOH, 32H), 1.71-1.45 (m, 10H), 1.37-1.27 (m, 4H), 1.27-1.17 (m, 12H), 0.90-0.76 (m, 12H).

Compound 25: Lys-Glu-Pro-Ala-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₁H₁₂₃N₂₃O₂₀; m/z: 405.48935 ([M+4H]⁴⁺), 540.31677 ([M+3H]³⁺), 809.97144 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.51 (dd, J=9.5, 4.4 Hz, 1H), 4.48-4.41 (m, 2H), 4.32-4.25 (m, 3H), 4.21 (dd, J=8.1, 6.7 Hz, 1H), 4.19-4.12 (m, 5H), 4.02 (dd, J=8.4, 4.9 Hz, 1H), 3.97 (d, J=7.6 Hz, 1H), 3.92-3.85 (m, 1H), 3.74-3.64 (m, 3H), 3.60-3.46 (m, 3H), 3.07 (t, J=6.9 Hz, 2H), 2.90-2.83 (m, 6H), 2.30-2.20 (m, 4H), 2.20-2.12 (m, 5H), 2.02-1.45 (m, AcOH, 48H), 1.43-1.27 (m, 6H), 1.27-1.21 (m, 12H), 0.80 (dd, J=6.8, 4.4 Hz, 6H).

Compound 26: Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Ala-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₁H₁₂₅N₂₃O₂₀; m/z: 405.99350 ([M+4H]⁴⁺), 540.98883 ([M+3H]³⁺), 810.97961 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O) δ 4.51 (dd, J=9.6, 4.4 Hz, 1H), 4.33 (dd, J=8.4, 5.8 Hz, 1H), 4.31-4.23 (m, 2H), 4.23-4.09 (m, 8H), 4.03 (dd, J=8.4, 4.9 Hz, 1H), 3.97 (d, J=7.6 Hz, 1H), 3.93-3.86 (m, 1H), 3.81-3.66 (m, 2H), 3.62-3.52 (m, 2H), 3.07 (t, J=6.9 Hz, 2H), 2.86 (m, 6H), 2.31-2.11 (m, 8H), 2.03-1.41 (m, AcOH, 48H), 1.40-1.27 (m, 6H), 1.25 (dd, J=13.7, 7.3 Hz, 12H), 0.90-0.76 (m, 12H).

Compound 27: Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Ala-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₀H₁₂₀N₂₀O₂₀; m/z: 391.23177 ([M+4H]⁴⁺), 781.45496 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.52-4.43 (m, 2H), 4.33 (dd, J=8.4, 5.8 Hz, 1H), 4.31-4.22 (m, 3H), 4.21-4.10 (m, 6H), 4.02 (dd, J=8.5, 4.8 Hz, 1H), 3.96 (d, J=7.7 Hz, 1H), 3.92-3.84 (m, 1H), 3.81-3.73 (m, 1H), 3.73-3.65 (m, 2H), 3.61-3.52 (m, 2H), 3.52-3.45 (m, 1H), 2.91-2.81 (m, 6H), 2.30-2.10 (m, 9H), 2.02-1.62 (m, AcOH, 31H), 1.62-1.51 (m, 8H), 1.41-1.27 (m, 6H), 1.27-1.20 (m, 12H), 0.90-0.75 (m, 12H).

Compound 28: Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Ala-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₀H₁₂₀N₂₂O₂₀; m/z: 398.23303([M+4H]⁴⁺), 530.64142([M+3H]³⁺), 795.45850([M+2H]²⁺).

¹H NMR (600 MHz, D₂O) δ 4.52-4.42 (m, 2H), 4.33 (dd, J=8.4, 5.8 Hz, 1H), 4.30-4.24 (m, 3H), 4.23-4.09 (m, 6H), 4.02 (dd, J=8.5, 4.8 Hz, 1H), 3.95 (d, J=7.5 Hz, 1H), 3.92-3.85 (m, 1H), 3.79-3.73 (m, 1H), 3.72-3.67 (m, 2H), 3.62-3.42 (m, 3H), 3.08 (t, J=6.9 Hz, 2H), 2.87 (t, J=7.6 Hz, 4H), 2.30-2.25 (m, 2H), 2.24-2.10 (m, 7H), 2.02-1.65 (m, AcOH, 29H), 1.64-1.48 (m, 8H), 1.42-1.29 (m, 4H), 1.28-1.19 (m, 12H), 0.90-0.75 (m, 12H).

Compound 29: Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Ala-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₁H₁₂₃N₂₃O₂₀; m/z: 405.48969([M+4H]⁴⁺), 540.31714([M+3H]³⁺), 809.97205([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.49 (dd, J=9.6, 4.3 Hz, 1H), 4.45 (dd, J=9.3, 4.9 Hz, 1H), 4.33 (dd, J=8.4, 5.8 Hz, 1H), 4.29-4.24 (m, 3H), 4.19-4.13 (m, 7H), 4.02 (dd, J=8.4, 4.8 Hz, 1H), 3.89 (t, J=6.8 Hz, 1H), 3.79-3.66 (m, 3H), 3.61-3.47 (m, 3H), 3.08 (t, J=6.9 Hz, 2H), 2.86 (q, J=8.0 Hz, 6H), 2.28 (t, J=7.6 Hz, 2H), 2.23-2.13 (m, 7H), 2.02-1.46 (m, AcOH, 47H), 1.42-1.18 (m, 20H), 0.85 (dd, J=14.2, 6.7 Hz, 6H).

Compound 30: Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Ala (Acetate Salt)

High resolution mass spectrometry (TOF-HRMS), molecular formula: C₇₁H₁₂₄N₂₂O₁₉; m/z: 398.24493 ([M+4H]⁴⁺), 530.65551 ([M+3H]³⁺), 795.47815 ([M+2H]²⁺), 1589.94194 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.51 (dd, J=9.6, 4.4 Hz, 1H), 4.46 (dd, J=9.4, 4.9 Hz, 1H), 4.34 (dd, J=8.4, 5.8 Hz, 1H), 4.31-4.24 (m, 3H), 4.24-4.20 (m, 1H), 4.20-4.09 (m, 5H), 4.02-3.96 (m, 2H), 3.93-3.86 (m, 1H), 3.80-3.74 (m, 1H), 3.74-3.67 (m, 2H), 3.63-3.43 (m, 3H), 3.08 (t, J=6.9 Hz, 2H), 2.91-2.82 (m, 6H), 2.31-2.12 (m, 7H), 2.01-1.65 (m, AcOH, 34H), 1.64-1.46 (m, 11H), 1.35 (dd, J=16.0, 8.1 Hz, 6H), 1.27-1.20 (m, 12H), 0.92-0.77 (m, 12H).

Compound 31: Lys-Glu-Gly-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (TOF-HRMS), molecular formula: C₇₀H₁₂₃N₂₃O₂₀; m/z: 402.49240 ([M+4H]⁴⁺), 536.31955 ([M+3H]³⁺), 803.97442 ([M+2H]²⁺), 1606.91471 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.45 (dd, J=9.4, 4.9 Hz, 1H), 4.32 (d, J=8.1 Hz, 1H), 4.30-4.25 (m, 2H), 4.24-4.19 (m, 2H), 4.19-4.11 (m, 5H), 4.02 (dd, J=8.4, 4.9 Hz, 1H), 3.97 (d, J=7.6 Hz, 1H), 3.91-3.84 (m, 2H), 3.82-3.73 (m, 2H), 3.69 (q, J=7.7, 7.0 Hz, 1H), 3.59-3.52 (m, 1H), 3.52-3.46 (m, 1H), 3.07 (t, J=6.9 Hz, 2H), 2.90-2.82 (m, 6H), 2.28 (t, J=7.6 Hz, 2H), 2.23-2.12 (m, 6H), 2.02-1.64 (m, AcOH, 35H), 1.63-1.45 (m, 11H), 1.44-1.27 (m, 6H), 1.27-1.21 (m, 9H), 0.88-0.73 (m, 12H).

Compound 32: Lys-Glu-Pro-Val-Gly-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (TOF-HRMS), molecular formula: C₇₀H₁₂₃N₂₃O₂₀; m/z: 402.49278([M+4H]⁴⁺), 536.31975([M+3H]³⁺), 803.97422([M+2H]²⁺), 1606.92969([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.51 (dd, J=9.7, 4.4 Hz, 1H), 4.46 (dd, J=9.4, 4.9 Hz, 1H), 4.36 (dd, J=8.3, 5.9 Hz, 1H), 4.28 (dd, J=8.3, 6.1 Hz, 1H), 4.24-4.14 (m, 6H), 4.03 (dd, J=8.3, 4.9 Hz, 1H), 3.97 (dd, J=10.0, 7.5 Hz, 2H), 3.90 (t, J=6.8 Hz, 1H), 3.87-3.78 (m, 2H), 3.76-3.67 (m, 2H), 3.61-3.54 (m, 1H), 3.54-3.47 (m, 1H), 3.08 (t, J=6.9 Hz, 2H), 2.91-2.83 (m, 6H), 2.26-2.13 (m, 8H), 2.03-1.87 (m, 9H), 1.87-1.45 (m, AcOH, 33H), 1.44-1.28 (m, 6H), 1.26 (dd, J=18.4, 7.2 Hz, 9H), 0.89-0.79 (m, 12H).

Compound 33: Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Gly-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₀H₁₂₃N₂₃O₂₀; m/z: 402.48917 ([M+4H]⁴⁺), 536.31647 ([M+3H]³⁺), 803.97101 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O) δ 4.51 (dd, J=9.6, 4.4 Hz, 1H), 4.34 (dd, J=8.4, 5.8 Hz, 1H), 4.31-4.11 (m, 9H), 4.03 (dd, J=8.4, 4.9 Hz, 1H), 3.97 (d, J=7.6 Hz, 1H), 3.92-3.86 (m, 1H), 3.85-3.74 (m, 3H), 3.74-3.66 (m, 1H), 3.62-3.52 (m, 2H), 3.06 (t, J=7.0 Hz, 2H), 2.91-2.83 (m, 6H), 2.31-2.11 (m, 8H), 2.03-1.43 (m, AcOH, 45H ), 1.40-1.27 (m, 6H), 1.27-1.23 (m, 9H), 0.91-0.77 (m, 12H).

Compound 34: Lys-Glu-Pro-Val-Gly-Gln-Ala-Lys-Gly-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₆₇H₁₁₉N₂₃O₂₀; m/z: 392.48178 ([M+4H]⁴⁺), 522.97314 ([M+3H]³⁺), 784.45752 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.51 (dd, J=9.6, 4.4 Hz, 1H), 4.35 (dd, J=8.3, 5.9 Hz, 1H), 4.25-4.12 (m, 7H), 4.03 (dd, J=8.4, 4.8 Hz, 1H), 3.96 (dd, J=10.6, 7.5 Hz, 2H), 3.92-3.86 (m, 1H), 3.85-3.77 (m, 4H), 3.75-3.68 (m, 1H), 3.60-3.53 (m, 1H), 3.06 (t, J=7.0 Hz, 2H), 2.92-2.83 (m, 6H), 2.28-2.12 (m, 7H), 2.05-1.41 (m, AcOH, 42H), 1.40-1.27 (m, 6H), 1.27-1.24 (m, 9H), 0.85 (dd, J=11.0, 6.7 Hz, 6H), 0.80 (dd, J=6.8, 5.1 Hz, 6H).

Compound 35: Lys-Glu-Gly-Val-Gly-Gln-Ala-Lys-Gly-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₆₄H₁₁₅N₂₃O₂₀; m/z: 382.47363 ([M+4H]⁴⁺), 509.62903 ([M+3H]³⁺), 763.93982 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.27-4.13 (m, 8H), 4.05-4.00 (m, 2H), 3.97 (d, J=7.6 Hz, 1H), 3.93-3.87 (m, 2H), 3.85-3.76 (m, 5H), 3.06 (t, J=7.0 Hz, 2H), 2.90-2.83 (m, 6H), 2.24-2.12 (m, 6H), 2.02-1.41 (m, AcOH, 40H), 1.39-1.27 (m, 6H), 1.27-1.22 (m, 9H), 0.85-0.76 (m, 12H).

Compound 36: Lys-Glu-Gly-Val-Pro-Gln-Ala-Lys-Gly-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₆₇H₁₁₉N₂₃O₂₀; m/z: 392.48172([M+4H]⁴⁺), 522.97314([M+3H]³⁺), 783.95605([M+2H]²⁺).

¹H NMR (600 MHz, D₂O) δ 4.32 (d, J=8.0 Hz, 1H), 4.28 (dd, J=8.2, 6.7 Hz, 1H), 4.25-4.12 (m, 8H), 4.03 (dd, J=8.4, 4.8 Hz, 1H), 3.97 (d, J=7.6 Hz, 1H), 3.92-3.83 (m, 2H), 3.83-3.73 (m, 4H), 3.60-3.53 (m, 1H), 3.06 (t, J=7.0 Hz, 2H), 2.91-2.83 (m, 6H), 2.28 (t, J=7.5 Hz, 2H), 2.24-2.12 (m, 5H), 2.02-1.42 (m, AcOH, 43H), 1.41-1.27 (m, 6H), 1.27-1.22 (m, 9H), 0.91-0.72 (m, 12H).

Compound 37: Lys-Glu-Gly-Val-Gly-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₆₇H₁₁₉N₂₃O₂₀; m/z: 392.48172([M+4H]⁴⁺), 522.97314([M+3H]³⁺), 783.95605([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.44 (dd, J=9.4, 4.9 Hz, 1H), 4.29-4.12 (m, 8H), 4.04-3.99 (m, 2H), 3.96 (d, J=7.6 Hz, 1H), 3.91-3.82 (m, 3H), 3.81 (s, 2H), 3.72-3.65 (m, 1H), 3.52-3.44 (m, 1H), 3.06 (t, J=6.9 Hz, 2H), 2.89-2.81 (m, 6H), 2.23-2.12 (m, 7H), 2.01-1.45 (m, AcOH, 43H), 1.42-1.26 (m, 6H), 1.26-1.20 (m, 9H), 0.83-0.77 (m, 12H).

Compound 38: Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₅₁H₈₈N₁₆O₁₄; m/z: 383.89569 ([M+3H]³⁺), 575.33978 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.45 (dd, J=9.2, 5.0 Hz, 1H), 4.39 (dd, J=8.3, 6.4 Hz, 1H), 4.29-4.21 (m, 4H), 4.19-4.12 (m, 3H), 4.01 (dd, J=7.8, 5.5 Hz, 1H), 3.78-3.73 (m, 1H), 3.72-3.67 (m, 1H), 3.61-3.48 (m, 4H), 3.08 (t, J=6.8 Hz, 2H), 2.88-2.83 (m, 4H), 2.30-2.26 (m, 4H), 2.20-2.13 (m, 3H), 2.08-1.46 (m, AcOH, 38H), 1.39-1.22 (m, 7H), 0.86 (dd, J=10.3, 6.7 Hz, 6H).

Compound 39: Pro-Val-Pro-Gln-Ala (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₂₃H₃₈N₆O₇; m/z: 511.2871 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.41 (d, J=7.3 Hz, 1H), 4.38-4.32 (m, 2H), 4.20 (dd, J=8.7, 5.9 Hz, 1H), 4.11-4.04 (m, 1H), 3.85-3.77 (m, 1H), 3.62 (dt, J=10.3, 7.2 Hz, 1H), 3.39-3.29 (m, 2H), 2.39-2.31 (m, 3H), 2.28-2.20 (m, 1H), 2.08-1.90 (m, AcOH, 10H), 1.86-1.80 (m, 1H), 1.26 (d, J=7.3 Hz, 3H), 0.94 (d, J=6.8 Hz, 3H), 0.88 (d, J=6.8 Hz, 3H).

Compound 40: Pro-Val-Pro-Glu-Ala (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₂₃H₃₇N₅O₈; m/z: 512.27081 ([M+H]⁺).

¹H NMR (600 MHz, D₂O) δ 4.41 (d, J=7.3 Hz, 1H), 4.38-4.32 (m, 2H), 4.23 (dd, J=8.9, 5.6 Hz, 1H), 4.13-4.09 (m, 1H), 3.86-3.76 (m, 1H), 3.62 (dt, J=10.2, 7.2 Hz, 1H), 3.38-3.28 (m, 2H), 2.43-2.35 (m, 3H), 2.26-2.16 (m, 1H), 2.12-1.72 (m, AcOH, 12H), 1.28 (d, J=7.2 Hz, 3H), 0.94 (d, J=6.8 Hz, 3H), 0.87 (d, J=6.8 Hz, 3H).

Compound 41: Pro-Val-Pro-Ile-Ala (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₂₄H₄₁N₅O₆; m/z: 496.31158 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.36-4.27 (m, 3H), 4.03 (q, J=7.2 Hz, 1H), 3.98 (d, J=7.8 Hz, 1H), 3.79-3.72 (m, 1H), 3.60-3.53 (m, 1H), 3.34-3.21 (m, 2H), 2.36-2.25 (m, 1H), 2.21-2.12 (m, 1H), 2.03-1.96 (m, 1H), 1.96-1.81 (m, AcOH, 7H), 1.80-1.69 (m, 2H), 1.43-1.33 (m, 1H), 1.20 (d, J=7.2 Hz, 3H), 1.13-1.02 (m, 1H), 0.88 (d, J=6.8 Hz, 3H), 0.85-0.80 (m, 6H), 0.80-0.77 (m, 1H), 0.74 (t, J=7.4 Hz, 3H).

Compound 42: Pro-Val-Pro-Ala

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₁₈H₃₀N₄O₅; m/z: 383.22791 ([M+H]⁺).

¹H NMR (600 MHz, D₂O) δ 4.36 (d, J=7.2 Hz, 1H), 4.30 (dd, J=8.5, 6.3 Hz, 1H), 4.24 (dd, J=8.1, 6.5 Hz, 1H), 4.00 (q, J=7.2 Hz, 1H), 3.79-3.72 (m, 1H), 3.60-3.52 (m, 1H), 3.31-3.23 (m, 2H), 2.33-2.26 (m, 1H), 2.20-2.13 (m, 1H), 2.09-1.69 (m, AcOH, 10H), 1.21 (d, J=7.3 Hz, 3H), 0.88 (d, J=6.9 Hz, 3H), 0.81 (d, J=6.8 Hz, 3H).

Compound 43: Glu-Pro-Val-Pro-Gln-Ala (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₂₈H₄₅N₇O₁₀; m/z: 640.32892 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.34 (dd, J=8.3, 6.5 Hz, 1H), 4.25-4.15 (m, 3H), 4.08 (dd, J=8.8, 5.9 Hz, 1H), 4.04-4.00 (m, 1H), 3.73-3.65 (m, 1H), 3.57-3.41 (m, 3H), 2.35 (t, J=7.3 Hz, 2H), 2.24-2.20 (m, 2H), 2.16-2.07 (m, 2H), 2.04-1.75 (m, AcOH, 11H), 1.73-1.63 (m, 2H), 1.17 (d, J=7.2 Hz, 3H), 0.80 (dd, J=12.9, 6.8 Hz, 6H).

Compound 44: Pro-Val-Pro-Gln-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₂₉H₅₀N₈O₈; m/z: 320.19421 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.29-4.19 (m, 3H), 4.13-4.06 (m, 2H), 3.95 (dd, J=8.2, 5.1 Hz, 1H), 3.73-3.68 (m, 1H), 3.52-3.47 (m, 1H), 3.24-3.16 (m, 2H), 2.79 (t, J=7.5 Hz, 2H), 2.25-2.19 (m, 3H), 2.14-2.08 (m, 1H), 1.97-1.57 (m, AcOH, 17H), 1.53-1.45 (m, 3H), 1.21-1.17 (m, 5H), 0.82 (d, J=6.8 Hz, 3H), 0.75 (d, J=6.7 Hz, 3H).

Compound 45: Glu-Pro-Val-Pro-Gln-Ala-Arg (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₃₄H₅₇N₁₁O₁₁; m/z: 398.71835 ([M+2H]²⁺), 796.42944 ([M+H]⁺).

¹H NMR (600 MHz, D₂O) δ 4.38 (dd, J=8.3, 6.4 Hz, 1H), 4.27-4.19 (m, 3H), 4.19-4.10 (m, 2H), 4.03 (dd, J=8.3, 4.9 Hz, 1H), 3.78-3.70 (m, 1H), 3.60-3.46 (m, 3H), 3.07-3.02 (m, 2H), 2.30 (t, J=7.2 Hz, 2H), 2.25 (t, J=7.6 Hz, 2H), 2.19-2.11 (m, 2H), 2.06-1.78 (m, AcOH, 12H), 1.76-1.67 (m, 3H), 1.60-1.53 (m, 1H), 1.48-1.42 (m, 2H), 1.24 (d, J=7.1 Hz, 3H), 0.85 (dd, J=12.8, 6.7 Hz, 6H).

Compound 46: Ala-Pro-Val-Pro-Gln-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₃₂H₅₅N₉O₉; m/z: 355.71259 ([M+2H]²⁺), 710.41809 ([M+H]⁺).

¹H NMR (600 MHz, DMSO-d₆) δ 8.23 (d, J=7.7 Hz, 1H), 8.08 (d, J=8.1 Hz, 1H), 7.87 (d, J=8.4 Hz, 1H), 7.68 (s, 1H), 7.38 (d, J=6.4 Hz, 1H), 6.75 (s, 1H), 4.40-4.37 (m, 1H), 4.33-4.25 (m, 3H), 4.15 (t, J=7.2 Hz, 3H), 3.78 (d, J=6.4 Hz, 1H), 3.66 (dd, J=32.4, 8.0 Hz, 2H), 3.58-3.51 (m, 2H), 3.43 (d, J=7.0 Hz, 1H), 3.36-3.27 (m, 1H), 2.67 (t, J=7.7 Hz, 3H), 2.19-2.07 (m, 4H), 2.01-1.69 (m, AcOH, 24H), 1.63-1.60 (m, 1H), 1.55-1.41 (m, 5H), 1.26 (d, 1H), 1.18 (d, J=7.2 Hz, 6H), 1.11 (d, J=6.7 Hz, 3H), 1.04 (d, J=6.6 Hz, 1H), 0.87 (d, J=6.7 Hz, 3H), 0.83 (d, J=6.9 Hz, 3H).

Compound 47: Glu-Pro-Val-Pro-Ala-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₃₂H₅₄N₈O₁₀; m/z: 356.20514 ([M+2H]²⁺), 711.40198 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.45 (dd, J=8.4, 6.4 Hz, 1H), 4.33-4.27 (m, 3H), 4.21 (dd, J=15.1, 7.2 Hz, 2H), 4.07 (dd, J=8.1, 5.1 Hz, 1H), 3.86-3.75 (m, 1H), 3.67-3.54 (m, 3H), 2.91 (t, J=7.5 Hz, 2H), 2.37 (t, J=6.9 Hz, 2H), 2.26-2.18 (m, 2H), 2.14-1.69 (m, AcOH, 13H), 1.65-1.58 (m, 3H), 1.35-1.29 (m, 9H), 0.92 (dd, J=13.6, 6.8 Hz, 6H).

Compound 48: Glu-Pro-Val-Pro-Gln-Ala-Ala (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₃₁H₅₀N₈O₁₁; m/z: 356.18692 ([M+2H]²⁺), 711.36597 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.34 (dd, J=8.3, 6.5 Hz, 1H), 4.24-4.16 (m, 3H), 4.12-4.06 (m, 2H), 4.03-3.99 (m, 1H), 3.73-3.65 (m, 1H), 3.56-3.41 (m, 3H), 2.35 (t, J=7.3 Hz, 2H), 2.22-2.18 (m, 2H), 2.15-2.07 (m, 2H), 2.04-1.73 (m, AcOH, 11H), 1.71-1.63 (m, 2H), 1.18 (dd, J=11.2, 7.2 Hz, 6H), 0.80 (dd, J=13.0, 6.8 Hz, 6H).

Compound 49: Asp-Pro-Val-Pro-Gln-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₃₃H₅₅N₉O₁₁; m/z: 377.70767 ([M+2H]²⁺), 754.40814 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.36-4.29 (m, 2H), 4.23-4.14 (m, 2H), 4.13-4.06 (m, 2H), 3.97 (dd, J=8.3, 5.0 Hz, 1H), 3.74-3.65 (m, 1H), 3.56-3.46 (m, 2H), 3.44-3.39 (m, 1H), 2.79 (t, J=7.5 Hz, 2H), 2.65 (dd, J=17.5, 3.3 Hz, 1H), 2.38 (dd, J=17.5, 10.7 Hz, 1H), 2.21 (t, J=7.6 Hz, 2H), 2.15-2.06 (m, 2H), 1.93-1.75 (m, AcOH, 9H), 1.72-1.61 (m, 3H), 1.54-1.45 (m, 3H), 1.21 (dd, J=13.1, 7.5 Hz, 5H), 0.80 (dd, J=11.0, 6.7 Hz, 6H).

Compound 50: Asn-Pro-Val-Pro-Gln-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₃₃H₅₆N₁₀O₁₀; m/z: 377.21542 ([M+2H]²⁺), 753.42365 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.55 (dd, J=9.3, 4.0 Hz, 1H), 4.47 (dd, J=8.4, 6.1 Hz, 1H), 4.34-4.29 (m, 2H), 4.26-4.19 (m, 2H), 4.07 (dd, J=8.1, 5.1 Hz, 1H), 3.83-3.77 (m, 1H), 3.69-3.53 (m, 3H), 2.94-2.90 (m, 3H), 2.72 (dd, J=17.0, 9.3 Hz, 1H), 2.33 (t, J=7.6 Hz, 2H), 2.27-2.19 (m, 2H), 2.05-1.71 (m, AcOH, 15H), 1.65-1.57 (m, 3H), 1.34-1.30 (m, 5H), 0.91 (dd, J=13.4, 6.7 Hz, 6H).

Compound 51: Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₅₉H₁₀₂N₁₈O₁₆; m/z: 440.59735 ([M+3H]³⁺), 660.39252 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.38 (dd, J=9.3, 4.8 Hz, 1H), 4.33 (dd, J=8.3, 6.5 Hz, 1H), 4.22-4.12 (m, 5H), 4.10-4.04 (m, 3H), 3.93-3.88 (m, 2H), 3.75-3.67 (m, 1H), 3.66-3.58 (m, 1H), 3.56-3.41 (m, 4H), 3.00 (t, J=6.9 Hz, 2H), 2.82-2.76 (m, 4H), 2.24-2.19 (m, 4H), 2.14-2.06 (m, 3H), 1.97-1.41 (m, AcOH, 37H), 1.33-1.12 (m, 10H), 0.80 (dd, J=9.7, 6.7 Hz, 6H), 0.74 (dd, J=11.0, 6.8 Hz, 6H).

Compound 52: Glu-Pro-Ala-Pro-Gln-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₃₂H₅₃N₉O₁₁; m/z: 370.6998 ([M+2H]²⁺), 740.39221 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.43 (q, J=7.1 Hz, 1H), 4.33 (dd, J=8.4, 6.5 Hz, 1H), 4.26 (dd, J=8.4, 5.8 Hz, 1H), 4.22 (dd, J=7.6, 4.6 Hz, 1H), 4.18-4.11 (m, 2H), 4.01 (dd, J=8.3, 5.0 Hz, 1H), 3.67 (dt, J=10.0, 6.7 Hz, 1H), 3.61-3.54 (m, 1H), 3.53-3.44 (m, 2H), 2.84 (t, J=7.5 Hz, 2H), 2.30 (t, J=7.2 Hz, 2H), 2.25 (t, J=7.6 Hz, 2H), 2.21-2.12 (m, 2H), 2.08-1.77 (m, AcOH, 11H), 1.77-1.63 (m, 3H), 1.60-1.49 (m, 3H), 1.24 (dd, J=10.4, 7.1 Hz, 6H).

Compound 53: Glu-Ala-Val-Pro-Gln-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₃₂H₅₅N₉O₁₁; m/z: 371.7081 ([M+2H]²⁺), 742.4089([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.23-4.18 (m, 3H), 4.13-4.06 (m, 2H), 3.95 (dd, J=8.3, 5.0 Hz, 1H), 3.85-3.82 (m, 1H), 3.73-3.66 (m, 1H), 3.53-3.47 (m, 1H), 2.79 (t, J=7.5 Hz, 2H), 2.22-2.17 (m, 4H), 2.13-2.07 (m, 1H), 1.99-1.70 (m, AcOH, 9H), 1.69-1.59 (m, 2H), 1.53-1.45 (m, 3H), 1.26-1.12 (m, 9H), 0.79 (d, J=6.7 Hz, 3H), 0.76 (d, J=6.7 Hz, 3H).

Compound 54: Glu-Pro-Val-Ala-Gln-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₃₂H₅₅N₉O₁₁; m/z: 371.70767([M+2H]²⁺), 742.40802([M+H]⁺).

¹H NMR (600 MHz, DMSO-d₆+D₂O ) δ 4.34 (dd, J=8.3, 6.0 Hz, 1H), 4.15-4.05 (m, 4H), 3.97-3.87 (m, 2H), 3.51 (d, J=9.8 Hz, 1H), 3.46-3.38 (m, 1H), 2.74 (t, J=7.5 Hz, 2H), 2.23 (t, J=7.1 Hz, 2H), 2.17-2.06 (m, 3H), 1.95-1.67 (m, AcOH, 10H), 1.65-1.59 (m, 1H), 1.53-1.42 (m, 3H), 1.22-1.13 (m, 8H), 0.78 (d, J=6.8 Hz, 6H).

Compound 55: Glu-Pro-Val-Pro-Glu-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₃₄H₅₆N₈O₁₂; m/z: 385.2083 ([M+2H]²⁺), 769.4092 ([M+H]⁺).

¹H NMR (600 MHz, D₂O) δ 4.33 (dd, J=8.3, 6.5 Hz, 1H), 4.21-4.16 (m, 3H), 4.11 (t, J=7.1 Hz, 1H), 4.07 (dd, J=8.8, 5.7 Hz, 1H), 3.98 (dd, J=8.5, 4.8 Hz, 1H), 3.71-3.66 (m, 1H), 3.55-3.41 (m, 3H), 2.78 (t, J=7.5 Hz, 2H), 2.36-2.14 (m, 5H), 2.13-2.05 (m, 2H), 1.99-1.74 (m, AcOH, 11H), 1.70-1.61 (m, 3H), 1.53-1.45 (m, 3H), 1.20 (dd, J=15.4, 7.5 Hz, 5H), 0.80 (dd, J=12.5, 6.7 Hz, 6H).

Compound 56: Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₅₆H₉₇N₁₇O₁₅; m/z: 416.91827 ([M+3H]³⁺), 624.87354 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.43 (dd, J=9.3, 4.9 Hz, 1H), 4.38 (dd, J=8.4, 6.4 Hz, 1H), 4.27-4.19 (m, 5H), 4.16-4.10 (m, 3H), 3.88 (d, J=6.2 Hz, 1H), 3.74 (dt, J=10.1, 6.9 Hz, 1H), 3.71-3.63 (m, 1H), 3.60-3.46 (m, 4H), 3.07-3.02 (m, 2H), 2.87-2.82 (m, 4H), 2.29-2.24 (m, 4H), 2.19-2.11 (m, 3H), 2.04-1.43 (m, AcOH, 37H), 1.37-1.20 (m, 7H), 0.85 (dd, J=10.1, 6.8 Hz, 6H), 0.74 (dd, J=11.8, 6.9 Hz, 6H).

Compound 57: Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₄₅H₇₆N₁₄O₁₃; m/z: 511.29254 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O) δ 4.39 (dd, J=8.6, 5.5 Hz, 1H), 4.32 (dd, J=8.3, 6.5 Hz, 1H), 4.22-4.13 (m, 4H), 4.10-4.03 (m, 2H), 3.93 (dd, J=7.9, 5.2 Hz, 1H), 3.72-3.60 (m, 2H), 3.54-3.40 (m, 4H), 3.00 (t, J=6.9 Hz, 2H), 2.80 (t, J=7.5 Hz, 2H), 2.24-2.18 (m, 4H), 2.14-2.06 (m, 3H), 1.98-1.70 (m, AcOH, 19H), 1.69-1.60 (m, 4H), 1.55-1.47 (m, 4H), 1.45-1.39 (m, 2H), 1.34-1.24 (m, 2H), 1.16 (d, J=7.1 Hz, 3H), 0.80 (dd, J=10.4, 6.7 Hz, 6H).

Compound 58: Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₃₉H₆₄N₁₀O₁₂; m/z: 433.24188 ([M+2H]²⁺), 865.47662 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.41 (dd, J=8.5, 5.5 Hz, 1H), 4.33 (dd, J=8.3, 6.5 Hz, 1H), 4.22-4.14 (m, 3H), 4.11-4.02 (m, 3H), 3.75-3.67 (m, 1H), 3.59-3.41 (m, 5H), 2.81 (t, J=7.4 Hz, 2H), 2.25-2.19 (m, 4H), 2.15-1.61 (m, AcOH, 26H), 1.57-1.48 (m, 3H), 1.37-1.23 (m, 2H), 1.16 (d, J=7.0 Hz, 3H), 0.80 (dd, J=11.5, 6.7 Hz, 6H).

Compound 59: Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₄₀H₆₉N₁₃O₁₀; m/z: 298.18314 ([M+3H]³⁺), 446.77118 ([M+2H]²⁺), 892.53497 ([M+H]⁺).

¹H NMR (600 MHz, D₂O) δ 4.40 (dd, J=8.6, 5.5 Hz, 1H), 4.30-4.19 (m, 4H), 4.11-4.05 (m, 2H), 3.93 (dd, J=7.9, 5.2 Hz, 1H), 3.73-3.63 (m, 2H), 3.52-3.45 (m, 2H), 3.26-3.17 (m, 2H), 3.01 (t, J=6.9 Hz, 2H), 2.81 (t, J=7.5 Hz, 2H), 2.26-2.19 (m, 3H), 2.14-2.09 (m, 2H), 1.94-1.62 (m, AcOH, 24H), 1.57-1.40 (m, 7H), 1.34-1.26 (m, 2H), 1.16 (d, J=7.3 Hz, 3H), 0.82 (d, J=6.8 Hz, 3H), 0.76 (d, J=6.7 Hz, 3H).

Compound 60: Pro-Val-Pro-Gln-Ala-Lys-Pro (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₃₄H₅₇N₉O₉; m/z: 368.7207 ([M+2H]²⁺), 736.4343 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.46 (dd, J=8.4, 5.6 Hz, 1H), 4.34 (d, J=7.4 Hz, 1H), 4.29 (dd, J=8.5, 6.2 Hz, 1H), 4.27-4.24 (m, 1H), 4.16-4.07 (m, 3H), 3.78-3.70 (m, 1H), 3.66-3.60 (m, 1H), 3.58-3.45 (m, 2H), 3.30-3.22 (m, 2H), 2.86 (t, J=7.5 Hz, 2H), 2.32-2.24 (m, 3H), 2.19-2.13 (m, 1H), 2.12-2.03 (m, 1H), 2.02-1.69 (m, AcOH, 19H), 1.61-1.52 (m, 3H), 1.42-1.27 (m, 2H), 1.23-1.20 (m, 3H), 0.87 (d, J=6.8 Hz, 3H), 0.81 (d, J=6.7 Hz, 3H).

Compound 61: D-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₃H₁₂₇N₂₃O₂₀; m/z: 412.4978([M+4H]⁴⁺), 549.6611([M+3H]³⁺), 823.9882([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.46-4.35 (m, 2H), 4.27 (dd, J=8.3, 6.1 Hz, 1H), 4.22-4.04 (m, 9H), 3.96 (dd, J=8.4, 4.8 Hz, 1H), 3.90 (d, J=7.7 Hz, 1H), 3.84 (t, J=6.6 Hz, 1H), 3.74-3.59 (m, 3H), 3.56-3.38 (m, 3H), 3.01 (t, J=6.9 Hz, 2H), 2.83-2.76 (m, 6H), 2.23-2.06 (m, 9H), 1.96-1.39 (m, AcOH, 48H), 1.18 (dd, J=22.0, 7.2 Hz, 15H), 0.83-0.67 (m, 12H).

Compound 62: Lys-D-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₃H₁₂₇N₂₃O₂₀; m/z: 412.4976([M+4H]⁴⁺), 549.6608([M+3H]³⁺) ¹H NMR (600 MHz, D₂O ) δ 4.50 (dd, J=9.8, 4.4 Hz, 1H), 4.37 (dd, J=9.4, 4.9 Hz, 1H), 4.25-4.03 (m, 10H), 3.95 (dd, J=8.5, 4.8 Hz, 1H), 3.89 (d, J=7.7 Hz, 1H), 3.83 (t, J=6.6 Hz, 1H), 3.74-3.68 (m, 1H), 3.64-3.55 (m, 2H), 3.52-3.38 (m, 2H), 3.00 (t, J=6.9 Hz, 2H), 2.83-2.75 (m, 6H), 2.20 (t, J=7.6 Hz, 2H), 2.12-2.06 (m, 6H), 1.92-1.41 (m, AcOH, 47H), 1.32-1.13 (m, 15H), 0.78 (dd, J=9.7, 6.7 Hz, 6H), 0.73 (dd, J=6.8, 4.1 Hz, 6H).

Compound 63: Lys-Glu-D-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₃H₁₂₇N₂₃O₂₀; m/z: 412.4976([M+4H]⁴⁺), 549.6609([M+3H]³⁺), 823.9878([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.45 (dd, J=9.4, 4.4 Hz, 1H), 4.37 (dd, J=9.4, 4.9 Hz, 1H), 4.29-4.25 (m, 1H), 4.21-4.04 (m, 8H), 3.96-3.94 (m, 1H), 3.89 (d, J=7.7 Hz, 1H), 3.79 (d, J=6.9 Hz, 1H), 3.68-3.59 (m, 2H), 3.54-3.35 (m, 3H), 3.00 (t, J=6.9 Hz, 2H), 2.82-2.74 (m, 6H), 2.23-2.19 (m, 2H), 2.15-2.02 (m, 6H), 1.95-1.41 (m, AcOH, 48H), 1.17 (dd, J=21.6, 7.2 Hz, 15H), 0.83-0.64 (m, 12H).

Compound 64: Lys-Glu-Pro-D-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₃H₁₂₇N₂₃O₂₀; m/z: 412.4978([M+4H]⁴⁺), 549.6609([M+3H]³⁺), 823.9878([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.46 (dd, J=10.2, 3.9 Hz, 1H), 4.41-4.31 (m, 2H), 4.27-4.18 (m, 3H), 4.15-4.02 (m, 7H), 3.95-3.92 (m, 1H), 3.89 (d, J=7.7 Hz, 1H), 3.83 (t, J=6.6 Hz, 1H), 3.67-3.50 (m, 5H), 3.47-3.25 (m, 2H), 3.00 (t, J=6.9 Hz, 2H), 2.81-2.76 (m, 6H), 2.23-2.06 (m, 10H), 1.94-1.41 (m, AcOH, 50H), 1.17 (dd, J=19.9, 7.1 Hz, 17H), 0.76-0.68 (m, 12H).

Compound 65: Lys-Glu-Pro-Val-D-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₃H₁₂₇N₂₃O₂₀; m/z: 412.4979([M+4H]⁴⁺), 549.6612([M+3H]³⁺), 823.9883([M+2H]²⁺).

¹H NMR (600 MHz, D₂O) δ 4.42 (dd, J=9.9, 4.2 Hz, 1H), 4.34 (dd, J=9.2, 5.2 Hz, 1H), 4.31-4.23 (m, 2H), 4.22-4.18 (m, 2H), 4.15-4.05 (m, 6H), 3.94 (dd, J=8.4, 4.8 Hz, 1H), 3.89 (d, J=7.7 Hz, 1H), 3.82 (t, J=6.7 Hz, 1H), 3.65 (d, J=6.8 Hz, 3H), 3.57-3.36 (m, 3H), 3.00 (t, J=6.9 Hz, 2H), 2.82-2.75 (m, 6H), 2.18-2.03 (m, 9H), 1.95-1.40 (m, AcOH, 46H), 1.37-1.08 (m, 16H), 0.80-0.68 (m, 12H).

Compound 66: Lys-Glu-Pro-Val-Pro-D-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₃H₁₂₇N₂₃O₂₀; m/z: 412.4978([M+4H]⁴⁺), 549.6611([M+3H]³⁺), 823.9881([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.44-4.35 (m, 2H), 4.26-4.04 (m, 10H), 3.94 (dd, J=8.5, 4.8 Hz, 1H), 3.89 (d, J=7.7 Hz, 1H), 3.82 (t, J=6.8 Hz, 1H), 3.76-3.68 (m, 1H), 3.64 (d, J=8.7 Hz, 2H), 3.55-3.37 (m, 3H), 3.00 (t, J=6.9 Hz, 2H), 2.83-2.75 (m, 6H), 2.19-2.05 (m, 9H), 2.02-1.38 (m, AcOH, 47H), 1.34-1.15 (m, 15H), 0.78 (dd, J=11.2, 6.7 Hz, 6H), 0.73 (dd, J=6.7, 3.9 Hz, 6H).

Compound 67: Lys-Glu-Pro-Val-Pro-Gln-D-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₃H₁₂₇N₂₃O₂₀; m/z: 412.4961([M+4H]⁴⁺), 549.6615([M+3H]³⁺), 823.9886([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.47-4.38 (m, 2H), 4.26 (dd, J=8.4, 5.8 Hz, 1H), 4.22-4.04 (m, 9H), 3.95 (dd, J=8.5, 4.8 Hz, 1H), 3.89 (d, J=7.7 Hz, 1H), 3.82 (t, J=6.8 Hz, 1H), 3.74-3.56 (m, 3H), 3.54-3.35 (m, 3H), 3.00 (t, J=6.9 Hz, 2H), 2.86-2.74 (m, 6H), 2.23-2.05 (m, 9H), 1.94-1.38 (m, AcOH, 46H), 1.29-1.14 (m, 15H), 0.78 (dd, J=10.5, 6.7 Hz, 6H), 0.73 (dd, J=6.8, 3.9 Hz, 6H).

Compound 68: Lys-Glu-Pro-Val-Pro-Gln-Ala-D-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₃H₁₂₇N₂₃O₂₀; m/z: 412.4977([M+4H]⁴⁺), 549.6615([M+3H]³⁺), 823.9879([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.47-4.40 (m, 2H), 4.26 (dd, J=8.4, 5.9 Hz, 1H), 4.23-4.15 (m, 3H), 4.14-4.01 (m, 6H), 3.95 (dd, J=8.5, 4.8 Hz, 1H), 3.89 (d, J=7.7 Hz, 1H), 3.82 (t, J=6.8 Hz, 1H), 3.71-3.44 (m, 5H), 3.01 (t, J=6.9 Hz, 2H), 2.82-2.73 (m, 6H), 2.23-2.05 (m, 9H), 1.93-1.40 (m, AcOH, 46H), 1.30-1.14 (m, 15H), 0.79 (dd, J=12.5, 6.7 Hz, 6H), 0.73 (dd, J=6.8, 4.6 Hz, 6H).

Compound 69: Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-D-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₃H₁₂₇N₂₃O₂₀; m/z: 412.4976([M+4H]⁴⁺), 549.6608([M+3H]³⁺) ¹H NMR (600 MHz, D₂O ) δ 4.42 (dt, J=8.2, 4.3 Hz, 2H), 4.26 (dd, J=8.4, 5.9 Hz, 1H), 4.23-4.14 (m, 3H), 4.14-4.05 (m, 6H), 3.94 (dd, J=8.5, 4.8 Hz, 1H), 3.89 (d, J=7.7 Hz, 1H), 3.81 (q, J=7.7, 7.2 Hz, 1H), 3.74-3.58 (m, 3H), 3.55-3.38 (m, 3H), 2.98 (t, J=7.0 Hz, 2H), 2.82-2.75 (m, 6H), 2.23-2.05 (m, 9H), 1.93-1.13 (m, AcOH, 62H), 0.79 (dd, J=13.2, 6.7 Hz, 6H), 0.73 (dd, J=6.8, 4.7 Hz, 6H).

Compound 70: Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-D-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₃H₁₂₇N₂₃O₂₀; m/z: 412.4978([M+4H]⁴⁺), 549.6611([M+3H]³⁺), 823.9883([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.45-4.36 (m, 2H), 4.27-4.14 (m, 6H), 4.12-4.05 (m, 4H), 3.95 (dd, J=8.4, 4.8 Hz, 1H), 3.90 (d, J=7.7 Hz, 1H), 3.82 (t, J=6.8 Hz, 1H), 3.66 (dd, J=35.9, 8.3 Hz, 3H), 3.55-3.39 (m, 3H), 2.99 (t, J=7.0 Hz, 2H), 2.82-2.75 (m, 6H), 2.23-2.07 (m, 9H), 1.93-1.15 (m, AcOH, 63H), 0.79 (dd, J=13.9, 6.7 Hz, 6H), 0.74 (dd, J=6.8, 2.0 Hz, 6H).

Compound 71: Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-D-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₃H₁₂₇N₂₃O₂₀; m/z: 412.4976([M+4H]⁴⁺), 549.6609([M+3H]³⁺), 823.9878([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.45-4.36 (m, 2H), 4.26 (dd, J=8.4, 5.8 Hz, 1H), 4.22-4.16 (m, 3H), 4.12-4.05 (m, 6H), 3.96-3.91 (m, 2H), 3.82 (t, J=6.8 Hz, 1H), 3.73-3.58 (m, 3H), 3.54-3.36 (m, 3H), 3.00 (t, J=7.0 Hz, 2H), 2.82-2.75 (m, 6H), 2.22-2.06 (m, 9H), 1.93-1.41 (m, AcOH, 45H), 1.32-1.14 (m, 15H), 0.79 (dd, J=13.8, 6.7 Hz, 6H), 0.74 (d, J=6.8 Hz, 3H), 0.70 (d, J=6.8 Hz, 3H).

Compound 72: Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-D-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₃H₁₂₇N₂₃O₂₀; m/z: 412.4976([M+4H]⁴⁺), 549.6609([M+3H]³⁺), 823.9876([M+2H]²⁺).

¹H NMR (600 MHz, D₂O δ 4.45-4.35 (m, 2H), 4.26 (dd, J=8.4, 5.9 Hz, 1H), 4.21-4.05 (m, 9H), 3.94-3.88 (m, 2H), 3.82 (t, J=6.8 Hz, 1H), 3.73-3.57 (m, 3H), 3.55-3.37 (m, 3H), 2.99 (t, J=6.8 Hz, 2H), 2.82-2.75 (m, 6H), 2.23-2.06 (m, 9H), 1.96-1.36 (m, AcOH, 50H), 1.32-1.14 (m, 15H), 0.78 (dd, J=13.9, 6.7 Hz, 6H), 0.73 (d, J=6.7 Hz, 6H).

Compound 73: Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-D-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₃H₁₂₇N₂₃O₂₀; m/z: 412.4977([M+4H]⁴⁺), 549.6609([M+3H]³⁺), 823.9879([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.48 (dd, J=9.7, 4.3 Hz, 1H), 4.43 (dd, J=9.3, 4.9 Hz, 1H), 4.32 (dd, J=8.4, 5.8 Hz, 1H), 4.27-4.23 (m, 3H), 4.21-4.17 (m, 3H), 4.15-4.10 (m, 3H), 3.97 (dd, J=9.2, 4.6 Hz, 1H), 3.89-3.85 (m, 2H), 3.76-3.66 (m, 3H), 3.59-3.45 (m, 3H), 3.05 (t, J=6.9 Hz, 2H), 2.87-2.81 (m, 6H), 2.26 (t, J=7.7 Hz, 2H), 2.22-2.12 (m, 7H), 2.00-1.48 (m, AcOH, 47H), 1.37-1.20 (m, 16H), 0.86-0.77 (m, 12H).

Compound 74: Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-D-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₃H₁₂₇N₂₃O₂₀; m/z: 412.4977([M+4H]⁴⁺), 549.6610([M+3H]³⁺), 823.9879([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.48 (dd, J=9.6, 4.3 Hz, 1H), 4.44 (dd, J=9.3, 4.9 Hz, 1H), 4.32 (dd, J=8.4, 5.8 Hz, 1H), 4.28-4.17 (m, 5H), 4.17-4.09 (m, 4H), 4.05 (dd, J=9.1, 4.7 Hz, 1H), 3.95 (d, J=7.7 Hz, 1H), 3.88 (t, J=6.8 Hz, 1H), 3.78-3.63 (m, 3H), 3.60-3.37 (m, 3H), 3.06 (t, J=6.9 Hz, 2H), 2.89-2.81 (m, 6H), 2.29-2.09 (m, 9H), 2.02-1.46 (m, AcOH, 45H), 1.39-1.19 (m, 15H), 0.84 (dd, J=14.0, 6.7 Hz, 6H), 0.78 (dd, J=14.3, 6.8 Hz, 6H).

Compound 75: Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-D-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₃H₁₂₇N₂₃O₂₀; m/z: 412.4978([M+4H]⁴⁺), 549.6611([M+3H]³⁺), 823.9881([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.49-4.42 (m, 2H), 4.32 (dd, J=8.4, 5.8 Hz, 1H), 4.27-4.10 (m, 9H), 4.04 (dd, J=8.4, 4.6 Hz, 1H), 3.96 (d, J=7.4 Hz, 1H), 3.90-3.84 (m, 1H), 3.73 (d, J=7.7 Hz, 1H), 3.71-3.64 (m, 2H), 3.60-3.32 (m, 3H), 3.06 (t, J=6.9 Hz, 2H), 2.89-2.79 (m, 6H), 2.28-2.06 (m, 9H), 1.99-1.47 (m, AcOH, 44H), 1.39-1.18 (m, 15H), 0.84 (dd, J=13.9, 6.7 Hz, 6H), 0.78 (dd, J=6.8, 3.3 Hz, 6H).

Compound 76: Glu-Gly-Val-Pro-Gln-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₃₁H₅₃N₉O₁₁; m/z: 364.7022 ([M+2H]²⁺), 728.3929 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.30 (d, J=7.8 Hz, 1H), 4.26 (dd, J=8.2, 6.7 Hz, 1H), 4.19-4.11 (m, 2H), 4.02 (dd, J=8.3, 5.0 Hz, 1H), 3.95 (t, J=6.5 Hz, 1H), 3.91-3.82 (m, 2H), 3.78-3.72 (m, 1H), 3.58-3.51 (m, 1H), 2.84 (t, J=7.5 Hz, 2H), 2.29-2.24 (m, 4H), 2.20-2.11 (m, 1H), 2.01-1.82 (m, AcOH, 10H), 1.77-1.65 (m, 2H), 1.60-1.50 (m, 3H), 1.25 (dd, J=7.5, 4.7 Hz, 5H), 0.84 (d, J=6.8 Hz, 3H), 0.80 (d, J=6.7 Hz, 3H).

Compound 77: Glu-Pro-Val-Gly-Gln-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₃₁H₅₃N₉O₁₁; m/z: 364.7004([M+2H]²⁺), 728.3932([M+H]⁺).

¹H NMR (600 MHz, D₂O) δ 4.40 (dd, J=8.3, 6.5 Hz, 1H), 4.23 (dd, J=7.7, 4.4 Hz, 1H), 4.20-4.15 (m, 2H), 4.01 (dd, J=8.3, 5.1 Hz, 1H), 3.95 (d, J=7.4 Hz, 1H), 3.83-3.76 (m, 2H), 3.63-3.55 (m, 1H), 3.50-3.45 (m, 1H), 2.85 (t, J=7.5 Hz, 2H), 2.32 (t, J=7.2 Hz, 2H), 2.23-2.15 (m, 3H), 2.05-1.67 (m, AcOH, 12H), 1.59-1.50 (m, 3H), 1.26 (dd, J=9.7, 7.5 Hz, 5H), 0.84 (dd, J=14.3, 6.8 Hz, 6H).

Compound 78: D-Glu-Pro-Val-Pro-Gln-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₃₄H₅₇N₉O₁₁; m/z: 384.716 ([M+2H]²⁺), 768.4245 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.36 (dd, J=8.8, 4.3 Hz, 1H), 4.29-4.21 (m, 3H), 4.18-4.11 (m, 2H), 4.01 (dd, J=8.2, 5.1 Hz, 1H), 3.78-3.72 (m, 1H), 3.63-3.49 (m, 3H), 2.84 (t, J=7.5 Hz, 2H), 2.28-2.23 (m, 4H), 2.19-2.12 (m, 2H), 1.98-1.66 (m, AcOH, 15H), 1.59-1.50 (m, 3H), 1.25 (dd, J=11.6, 7.4 Hz, 5H), 0.85 (dd, J=15.5, 6.8 Hz, 6H).

Compound 79: Glu-D-Pro-Val-Pro-Gln-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₃₄H₅₇N₉O₁₁; m/z: 384.7159 ([M+2H]²⁺), 768.4244 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.36 (dd, J=8.8, 3.9 Hz, 1H), 4.33 (d, J=8.1 Hz, 1H), 4.28 (dd, J=8.3, 6.6 Hz, 1H), 4.23 (dd, J=7.1, 5.1 Hz, 1H), 4.19-4.13 (m, 2H), 4.02 (dd, J=8.2, 5.1 Hz, 1H), 3.76-3.68 (m, 1H), 3.61-3.51 (m, 3H), 2.84 (t, J=7.5 Hz, 2H), 2.31-2.06 (m, 7H), 2.00-1.66 (m, AcOH, 16H), 1.58-1.50 (m, 3H), 1.27-1.23 (m, 5H), 0.81 (dd, J=22.8, 6.7 Hz, 6H).

Compound 80: Glu-Pro-D-Val-Pro-Gln-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₃₄H₅₇N₉O₁₁; m/z: 384.7158 ([M+2H]²⁺), 768.4241 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.46 (d, J=7.3 Hz, 1H), 4.36 (dd, J=8.3, 6.6 Hz, 1H), 4.30-4.20 (m, 3H), 4.17 (dd, J=8.1, 6.1 Hz, 1H), 4.03-4.00 (m, 1H), 3.72-3.66 (m, 1H), 3.63-3.57 (m, 2H), 3.53-3.49 (m, 1H), 2.85 (t, J=7.5 Hz, 2H), 2.36-2.21 (m, 6H), 2.18-2.13 (m, 1H), 2.05-1.78 (m, AcOH, 17H), 1.70-1.66 (m, 1H), 1.58-1.51 (m, 3H), 1.28-1.23 (m, 6H), 0.78 (dd, J=15.0, 6.7 Hz, 6H).

Compound 81: Glu-Pro-Val-D-Pro-Gln-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₃₄H₅₇N₉O₁₁; m/z: 384.7157 ([M+2H]²⁺), 768.4240 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.43-4.30 (m, 2H), 4.28-4.21 (m, 2H), 4.21-4.13 (m, 2H), 4.03-3.98 (m, 1H), 3.72-3.53 (m, 3H), 3.50-3.44 (m, 1H), 2.85 (t, J=7.5 Hz, 2H), 2.33 (t, J=7.2 Hz, 2H), 2.23-2.11 (m, 4H), 2.07-1.74 (m, AcOH, 14H), 1.73-1.64 (m, 2H), 1.58-1.50 (m, 3H), 1.29-1.23 (m, 5H), 0.81 (dd, J=15.1, 6.7 Hz, 6H).

Compound 82: Glu-Pro-Val-Pro-D-Gln-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₃₁H₅₃N₉O₁₁; m/z: 384.7158([M+2H]²⁺), 768.4242([M+H]⁺).

¹H NMR (600 MHz, D₂O) δ 4.38 (dd, J=8.3, 6.4 Hz, 1H), 4.27-4.14 (m, 5H), 4.03 (dd, J=8.4, 5.0 Hz, 1H), 3.80-3.75 (m, 1H), 3.62-3.45 (m, 3H), 2.85 (t, J=7.5 Hz, 2H), 2.32 (t, J=7.3 Hz, 2H), 2.24-2.12 (m, 4H), 2.09-1.67 (m, AcOH, 15H), 1.60-1.50 (m, 3H), 1.28 (d, J=7.3 Hz, 5H), 0.88-0.80 (m, 6H).

Compound 83: Glu-Pro-Val-Pro-Gln-D-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₃₁H₅₃N₉O₁₁; m/z: 384.7159([M+2H]²⁺), 768.4243([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.38 (dd, J=8.3, 6.4 Hz, 1H), 4.28-4.20 (m, 3H), 4.19-4.12 (m, 2H), 4.05 (dd, J=8.6, 5.0 Hz, 1H), 3.77-3.72 (m, 1H), 3.60-3.45 (m, 3H), 2.85-2.80 (m, 2H), 2.32 (t, J=7.2 Hz, 2H), 2.26 (t, J=8.0 Hz, 2H), 2.20-2.12 (m, 2H), 2.08-1.77 (m, AcOH, 13H), 1.75-1.66 (m, 3H), 1.57-1.47 (m, 3H), 1.26-1.18 (m, 5H), 0.85 (dd, J=13.0, 6.7 Hz, 6H).

Compound 84: Glu-Pro-Val-Pro-Gln-Ala-D-Lys (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₃₁H₅₃N₉O₁₁; m/z: 384.7160([M+2H]²⁺), 768.4246([M+H]⁺).

¹H NMR (600 MHz, D₂O) δ 4.39 (dd, J=8.3, 6.4 Hz, 1H), 4.30-4.20 (m, 3H), 4.19-4.11 (m, 2H), 4.05 (dd, J=8.3, 4.8 Hz, 1H), 3.79-3.71 (m, 1H), 3.61-3.47 (m, 3H), 2.86-2.81 (m, 2H), 2.32 (t, J=7.2 Hz, 2H), 2.27 (t, J=7.5 Hz, 2H), 2.21-2.12 (m, 2H), 2.05-1.78 (m, AcOH, 12H), 1.78-1.68 (m, 3H), 1.60-1.50 (m, 3H), 1.27-1.20 (m, 5H), 0.86 (dd, J=12.5, 6.7 Hz, 6H).

Compound 85: Lys-Glu-Pro-Val-Pro (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₂₆H₄₄N₆O₈; m/z: 454.2655 ([M+2H]²⁺), 569.3287 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.50 (dd, J=9.9, 4.2 Hz, 1H), 4.36-4.22 (m, 3H), 4.09 (dd, J=8.5, 5.8 Hz, 1H), 3.89 (t, J=6.7 Hz, 1H), 3.70-3.65 (m, 2H), 3.60-3.53 (m, 2H), 3.51-3.26 (m, 1H), 2.87 (d, J=7.5 Hz, 2H), 2.28-2.09 (m, 5H), 2.00-1.68 (m, AcOH, 18H), 1.58-1.55 (m, 2H), 1.35-1.29 (m, 2H), 0.88 (d, J=6.8 Hz, 3H), 0.82 (d, J=6.7 Hz, 3H).

Compound 86: Glu-Pro-Val-Pro-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₂₅H₄₀N₆O₉; m/z: 569.2919 ([M+H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.40 (dd, J=8.3, 6.4 Hz, 1H), 4.31-4.23 (m, 3H), 4.09 (dd, J=9.0, 4.8 Hz, 1H), 3.78-3.72 (m, 1H), 3.61-3.48 (m, 3H), 2.41 (t, J=7.3 Hz, 2H), 2.25-2.14 (m, 4H), 2.09-1.70 (m, AcOH, 13H), 0.86 (dd, J=15.3, 6.7 Hz, 6H).

Compound 87: Lys-Glu-Pro-Val-Pro-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₃₁H₅₂N₈O₁₀; m/z: 349.1971 ([M+2H]²⁺), 697.3868 ([M+H]⁺).

¹H NMR (600 MHz, D₂O) δ 4.51 (dd, J=9.8, 4.3 Hz, 1H), 4.34-4.25 (m, 3H), 4.03 (dd, J=8.8, 4.7 Hz, 1H), 3.89 (t, J=6.7 Hz, 1H), 3.79-3.65 (m, 2H), 3.63-3.52 (m, 2H), 2.86 (t, J=7.5 Hz, 2H), 2.28-2.13 (m, 6H), 2.00-1.73 (m, AcOH, 17H), 1.60-1.54 (m, 2H), 1.36-1.28 (m, 2H), 0.86 (d, J=6.8 Hz, 3H), 0.83 (d, J=6.6 Hz, 3H).

Compound 88: Val-Pro-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₉₂H₁₅₂N₂₆O₂₄; m/z: 502.2934 ([M+4H]⁴⁺), 669.3699 ([M+3H]³⁺) ¹H NMR (600 MHz, D₂O ) δ 6.97-6.94 (m, 2H), 6.70-6.66 (m, 2H), 4.44 (dd, J=9.4, 4.8 Hz, 1H), 4.35-4.08 (m, 17H), 4.05-4.00 (m, 2H), 3.96 (d, J=7.6 Hz, 1H), 3.76-3.67 (m, 3H), 3.64-3.53 (m, 3H), 3.48 (dd, J=10.2, 6.3 Hz, 3H), 3.07 (t, J=6.9 Hz, 2H), 2.94 (dd, J=13.6, 6.6 Hz, 1H), 2.88-2.79 (m, 7H), 2.76 (dd, J=13.6, 9.2 Hz, 1H), 2.27 (t, J=7.6 Hz, 2H), 2.21 (t, J=7.6 Hz, 2H), 2.18-2.08 (m, 8H), 2.01-1.45 (m, AcOH, 59H), 1.30-1.10 (m, 16H), 0.95 (d, J=6.9 Hz, 3H), 0.87-0.77 (m, 18H).

Compound 89: pyro-Glu-Leu-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₈₄H₁₄₅N₂₅O₂₄; m/z: 468.7766 ([M+4H]⁴⁺), 624.6998 ([M+3H]³⁺), 936.5460 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.47-4.42 (m, 2H), 4.32-4.10 (m, 13H), 4.02 (dd, J=8.4, 4.8 Hz, 1H), 3.96 (d, J=7.6 Hz, 1H), 3.82-3.60 (m, 3H), 3.58-3.45 (m, 3H), 3.07 (t, J=6.9 Hz, 2H), 2.90-2.80 (m, 6H), 2.45-2.36 (m, 1H), 2.31-2.24 (m, 4H), 2.23-2.03 (m, 7H), 1.99-1.44 (m, AcOH, 47H), 1.39-1.19 (m, 15H), 0.85 (dd, J=12.5, 6.8 Hz, 6H), 0.81-0.77 (m, 9H), 0.75 (d, J=6.0 Hz, 3H).

Compound 90: Pro-Ala-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₉₀H₁₄₈N₂₆O₂₄; m/z: 495.2855 ([M+4H]⁴⁺), 660.0449 ([M+3H]³*), 989.5637 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 6.99-6.92 (m, 2H), 6.71-6.64 (m, 2H), 4.47-4.42 (m, 1H), 4.36 (t, J=7.8 Hz, 1H), 4.32-4.06 (m, 15H), 4.04-3.99 (m, 1H), 3.96 (d, J=7.6 Hz, 1H), 3.79-3.65 (m, 3H), 3.60-3.46 (m, 3H), 3.30-3.22 (m, 2H), 3.07 (t, J=6.9 Hz, 2H), 2.89-2.79 (m, 8H), 2.33-2.06 (m, 11H), 1.99-1.45 (m, AcOH, 51H), 1.39-1.14 (m, 19H), 0.87-0.77 (m, 12H).

Compound 91: Arg-Lys-Asp-Val-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₁₀₃H₁₇₄N₃₂O₂₈; m/z: 578.0856 ([M+4H]⁴⁺), 770.4463 ([M+3H]³⁺), 1155.1642 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O) δ 6.96 (d, J=8.5 Hz, 2H), 6.70-6.64 (m, 2H), 4.50-4.43 (m, 2H), 4.38 (t, J=8.0 Hz, 1H), 4.30-4.11 (m, 13H), 4.02 (dd, J=8.4, 4.9 Hz, 1H), 3.96 (d, J=7.6 Hz, 1H), 3.94-3.90 (m, 2H), 3.79-3.65 (m, 3H), 3.62-3.46 (m, 3H), 3.11-3.05 (m, 4H), 2.88-2.79 (m, 10H), 2.51 (dd, J=15.9, 5.3 Hz, 1H), 2.42 (dd, J=16.0, 8.5 Hz, 1H), 2.29-2.11 (m, 9H), 1.99-1.64 (m, AcOH, 45H), 1.63-1.45 (m, 19H), 1.41-1.14 (m, 18H), 0.87-0.77 (m, 12H), 0.72 (d, J=6.7 Hz, 6H).

Compound 92: Arg-Lys-Asp-Val-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₀H₁₁₆N₂₀O₂₀; m/z: 390.2233 ([M+4H]⁴⁺), 519.9619 ([M+3H]³⁺), 779.4393 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 6.96 (d, J=8.6 Hz, 2H), 6.67 (d, J=8.5 Hz, 2H), 4.49 (dd, J=8.4, 5.3 Hz, 1H), 4.38 (t, J=8.0 Hz, 1H), 4.31-4.23 (m, 5H), 4.19-4.10 (m, 3H), 4.01 (dd, J=8.2, 5.1 Hz, 1H), 3.93-3.89 (m, 2H), 3.77-3.67 (m, 2H), 3.61-3.50 (m, 2H), 3.10-3.05 (m, 2H), 2.86-2.79 (m, 8H), 2.51 (dd, J=16.0, 5.3 Hz, 1H), 2.42 (dd, J=15.9, 8.5 Hz, 1H), 2.28-2.20 (m, 4H), 2.18-2.10 (m, 2H), 1.97-1.65 (m, AcOH, 29H), 1.61-1.45 (m, 13H), 1.26 (dd, J=11.1, 7.4 Hz, 10H), 0.83 (dd, J=19.0, 6.7 Hz, 6H), 0.72 (d, J=5.6 Hz, 6H).

Compound 93: Arg-Lys-Asp-Val-Tyr-Glu-Pro-Val-Pro-Gln-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₆₄H₁₀₄N₁₈O₁₉; m/z: 715.3917 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 6.96 (d, J=8.6 Hz, 2H), 6.66 (d, J=8.5 Hz, 2H), 4.48-4.42 (m, 3H), 4.26-4.12 (m, 6H), 4.02 (dd, J=8.2, 5.0 Hz, 1H), 3.95-3.89 (m, 2H), 3.77-3.68 (m, 1H), 3.56-3.47 (m, 2H), 3.43-3.36 (m, 1H), 3.10-3.04 (m, 2H), 2.87-2.80 (m, 6H), 2.54 (dd, J=16.0, 5.1 Hz, 1H), 2.45 (dd, J=16.0, 8.4 Hz, 1H), 2.27 (t, J=7.6 Hz, 2H), 2.17-2.08 (m, 4H), 1.98-1.66 (m, AcOH, 27H), 1.65-1.45 (m, 9H), 1.26 (dd, J=11.3, 7.4 Hz, 7H), 0.84 (dd, J=13.0, 6.7 Hz, 6H), 0.70 (dd, J=6.8, 2.8 Hz, 6H).

Compound 94: Arg-Lys-Asp-Val-Tyr-Pro-Val-Pro-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₅₀H₈₀N₁₄O₁₄; m/z: 367.8727 ([M+3H]³⁺), 551.3051 ([M+2H]²⁺), 1101.6030 ([M+H]⁺).

¹H NMR (600 MHz, D₂O) δ 4.45 (dd, J=8.9, 4.8 Hz, 1H), 4.36-4.22 (m, 4H), 4.04-3.98 (m, 1H), 3.90 (dd, J=7.0, 5.8 Hz, 2H), 3.76 (dd, J=10.1, 6.4 Hz, 1H), 3.69-3.63 (m, 1H), 3.60-3.43 (m, 2H), 3.09-3.05 (m, 2H), 2.95 (dd, J=14.3, 5.2 Hz, 1H), 2.86-2.82 (m, 2H), 2.74-2.67 (m, 1H), 2.52-2.31 (m, 2H), 2.22-2.08 (m, 4H), 1.99-1.46 (m, AcOH, 29H), 1.32-1.23 (m, 2H), 0.90-0.81 (m, 6H), 0.75 (dd, J=10.3, 6.8 Hz, 2H), 0.67 (dd, J=17.1, 6.7 Hz, 4H).

Compound 95: Gly-Pro-Glu-Thr-Ala-Phe-Leu-Arg-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₁₁₃H₁₈₈N₃₄O₃₁; m/z: 504.6906 ([M+5H]⁵*), 630.6115 ([M+4H]⁴⁺), 840.4796 ([M+3H]³⁺).

¹H NMR (600 MHz, D₂O ) δ 7.22 (t, J=7.4 Hz, 2H), 7.16 (t, J=7.3 Hz, 1H), 7.12-7.07 (m, 2H), 4.47-4.41 (m, 3H), 4.35-4.03 (m, 19H), 4.02 (dd, J=8.4, 4.8 Hz, 1H), 3.95 (d, J=3.6 Hz, 1H), 3.86 (s, 1H), 3.75 (s, 1H), 3.68 (t, J=8.5 Hz, 2H), 3.58-3.42 (m, 5H), 3.06 (t, J=6.9 Hz, 4H), 2.91-2.81 (m, 7H), 2.29-2.11 (m, 12H), 2.00-1.19 (m, AcOH, 80H), 1.14 (d, J=7.1 Hz, 3H), 1.06 (d, J=6.3 Hz, 3H), 0.84 (dd, J=13.7, 6.7 Hz, 6H), 0.81-0.76 (m, 9H), 0.72 (d, J=5.6 Hz, 3H).

Compound 96: Gly-Pro-Glu-Thr-Ala-Phe-Leu-Arg-Glu-Pro-Val-Pro-Gln-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₄H₁₁₈N₂₀O₂₂; m/z: 547.2972 ([M+3H]³⁺), 820.4424 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 7.21 (dd, J=8.2, 6.6 Hz, 2H), 7.16 (t, J=7.3 Hz, 1H), 7.12-7.07 (m, 2H), 4.50-4.42 (m, 2H), 4.36-4.22 (m, 4H), 4.21-4.09 (m, 7H), 4.07-4.00 (m, 2H), 3.93 (d, J=16.5 Hz, 1H), 3.84 (d, J=16.5 Hz, 1H), 3.78-3.70 (m, 1H), 3.68-3.60 (m, 1H), 3.56-3.42 (m, 4H), 3.10-2.97 (m, 3H), 2.90-2.82 (m, 3H), 2.29-2.09 (m, 9H), 2.00-1.81 (m, AcOH, 19H), 1.77-1.66 (m, 5H), 1.61-1.37 (m, 9H), 1.26 (dd, J=11.9, 7.4 Hz, 5H), 1.14 (d, J=7.2 Hz, 3H), 1.05 (d, J=6.4 Hz, 3H), 0.84 (dd, J=15.5, 6.7 Hz, 6H), 0.77 (d, J=5.9 Hz, 3H), 0.72 (d, J=5.7 Hz, 3H).

Compound 97: Ser-Ser-Glu-Asp-Ile-Lys-Glu-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₁₀₅H₁₇₉N₃₁O₃₅; m/z: 488.0708 ([M+5H]⁵*), 609.8367 ([M+4H]⁴⁺), 812.7799 ([M+3H]³⁺).

¹H NMR (600 MHz, D₂O ) δ 4.48-4.41 (m, 3H), 4.34 (t, J=5.4 Hz, 1H), 4.31 (dd, J=8.4, 5.8 Hz, 1H), 4.28-4.22 (m, 3H), 4.22-4.09 (m, 11H), 4.04-3.88 (m, 5H), 3.81-3.72 (m, 3H), 3.71-3.62 (m, 2H), 3.59-3.43 (m, 3H), 3.07 (t, J=6.9 Hz, 2H), 2.90-2.80 (m, 8H), 2.58 (dd, J=16.0, 6.3 Hz, 1H), 2.48 (dd, J=16.0, 7.9 Hz, 1H), 2.29-2.09 (m, 13H), 2.00-1.47 (m, AcOH, 51H), 1.40-1.20 (m, 18H), 1.12-1.05 (m, 1H), 0.89-0.70 (m, 18H).

Compound 98: Ser-Ser-Glu-Asp-Ile-Lys-Glu-Glu-Pro-Val-Pro-Gln-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₆₆H₁₀₉N₁₇O₂₆; m/z: 519.5973 ([M+3H]³⁺), 778.8925 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.54-4.47 (m, 2H), 4.37-4.30 (m, 2H), 4.27-4.10 (m, 8H), 4.05-3.99 (m, 2H), 3.94-3.88 (m, 2H), 3.79-3.73 (m, 3H), 3.70-3.62 (m, 1H), 3.61-3.50 (m, 2H), 2.85 (t, J=7.6 Hz, 4H), 2.63 (dd, J=16.2, 6.2 Hz, 1H), 2.51 (dd, J=16.2, 7.9 Hz, 1H), 2.37-2.06 (m, 11H), 1.99-1.49 (m, AcOH, 30H), 1.34-1.24 (m, 8H), 1.10-1.01 (m, 1H), 0.84 (dd, J=13.8, 6.7 Hz, 6H), 0.77-0.71 (m, 6H).

Compound 99: Ser-Ser-Glu-Asp-Ile-Lys-Glu-Pro-Val-Pro-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₅₂H₈₅N₁₃O₂₁; m/z: 614.806 ([M+2H]²⁺), 1228.605 ([M+H]⁺).

¹H NMR (600 MHz, D₂O) δ 4.54-4.48 (m, 2H), 4.36 (t, J=5.5 Hz, 1H), 4.34-4.24 (m, 3H), 4.23-4.18 (m, 2H), 4.12-4.05 (m, 2H), 4.01 (d, J=7.9 Hz, 1H), 3.94-3.88 (m, 2H), 3.79-3.72 (m, 3H), 3.70-3.62 (m, 1H), 3.60-3.50 (m, 2H), 2.85 (t, J=7.6 Hz, 2H), 2.65 (dd, J=16.3, 6.0 Hz, 1H), 2.53 (dd, J=16.4, 8.0 Hz, 1H), 2.40-2.03 (m, 9H), 2.01-1.51 (m, AcOH, 21H), 1.34-1.22 (m, 3H), 1.08-1.01 (m, 1H), 0.89-0.80 (m, 6H), 0.76-0.70 (m, 6H).

Compound 100: Val-Pro-Pro-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₈₈H₁₅₀N₂₆O₂₃; m/z: 389.0348 ([M+5H]⁵*), 480.0415 ([M+4H]⁴⁺), 647.7197 ([M+3H]³⁺).

¹H NMR (600 MHz, D₂O ) δ 4.49-4.42 (m, 2H), 4.34-4.06 (m, 13H), 4.05-4.00 (m, 2H), 3.96 (d, J=7.6 Hz, 1H), 3.80-3.73 (m, 1H), 3.69 (d, J=9.8 Hz, 4H), 3.58-3.45 (m, 5H), 3.07 (t, J=6.9 Hz, 2H), 2.88-2.83 (m, 6H), 2.27 (t, J=7.7 Hz, 3H), 2.20-2.11 (m, 9H), 2.01-1.45 (m, AcOH, 55H), 1.24 (dd, J=21.5, 7.2 Hz, 16H), 0.97 (d, J=6.9 Hz, 3H), 0.88-0.78 (m, 15H).

Compound 101: Glu-Pro-Val-Pro-Gln-Ala-Lys-Ser-Ser-Glu-Asp-Ile-Lys-Glu (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₆₆H₁₀₉N₁₇O₂₆; m/z: 519.5978 ([M+3H]³⁺), 778.8933 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O) δ 4.50 (dd, J=8.0, 6.0 Hz, 1H), 4.40 (dd, J=8.4, 6.4 Hz, 1H), 4.36-4.30 (m, 2H), 4.27-4.19 (m, 6H), 4.18-4.11 (m, 2H), 4.08 (dd, J=8.8, 4.9 Hz, 1H), 4.01 (d, J=8.1 Hz, 1H), 3.82-3.71 (m, 5H), 3.62-3.47 (m, 3H), 2.86 (t, J=7.5 Hz, 4H), 2.65 (dd, J=16.4, 6.0 Hz, 1H), 2.51 (dd, J=16.3, 8.1 Hz, 1H), 2.34 (t, J=7.2 Hz, 2H), 2.31-2.10 (m, 9H), 2.06-1.52 (m, AcOH, 28H), 1.35-1.23 (m, 8H), 1.08-1.00 (m, 1H), 0.86 (dd, J=11.5, 6.7 Hz, 6H), 0.76-0.70 (m, 6H).

Compound 102: Glu-Pro-Val-Pro-Gln-Ala-Lys-Val-Pro-Tyr (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₅₃H₈₂N₁₂O₁₅; m/z: 564.3073 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 7.01-6.95 (m, 2H), 6.69 (d, J=8.5 Hz, 2H), 4.40 (dd, J=8.3, 6.4 Hz, 1H), 4.29-4.10 (m, 9H), 3.79-3.71 (m, 1H), 3.68-3.45 (m, 5H), 2.92-2.81 (m, 4H), 2.33 (t, J=7.3 Hz, 2H), 2.26 (t, J=7.7 Hz, 2H), 2.20-2.13 (m, 2H), 2.06-1.52 (m, AcOH, 25H), 1.33-1.21 (m, 5H), 0.86 (dd, J=11.3, 6.7 Hz, 6H), 0.77 (dd, J=17.6, 6.7 Hz, 6H).

Compound 103: Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Glu (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₃H₁₂₆N₂₂O₂₁; m/z: 824.4799 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.49 (dd, J=9.6, 4.4 Hz, 1H), 4.45 (dd, J=9.4, 4.9 Hz, 1H), 4.36-4.05 (m, 11H), 4.01-3.96 (m, 2H), 3.92-3.87 (m, 1H), 3.82-3.64 (m, 3H), 3.60-3.46 (m, 3H), 3.07 (t, J=7.0 Hz, 2H), 2.88-2.83 (m, 6H), 2.29-2.09 (m, 9H), 1.99-1.46 (m, AcOH, 47H), 1.39-1.20 (m, 16H), 0.85 (dd, J=14.2, 6.7 Hz, 6H), 0.80 (dd, J=6.7, 3.7 Hz, 6H).

Compound 104: Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Asn (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₂H₁₂₅N₂₃O₂₀; m/z: 408.9938 ([M+4H]⁴⁺), 544.9891 ([M+3H]³⁺), 816.9801 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.49 (dd, J=9.7, 4.4 Hz, 1H), 4.45 (dd, J=9.4, 4.8 Hz, 1H), 4.34-4.10 (m, 11H), 3.96 (d, J=7.6 Hz, 1H), 3.92-3.84 (m, 1H), 3.78-3.66 (m, 3H), 3.62-3.43 (m, 3H), 3.07 (t, J=6.9 Hz, 2H), 2.90-2.82 (m, 6H), 2.63 (dd, J=15.1, 4.9 Hz, 1H), 2.53 (dd, J=15.1, 8.1 Hz, 1H), 2.30-2.11 (m, 7H), 2.03-1.42 (m, AcOH, 44H), 1.39-1.19 (m, 15H), 0.85 (dd, J=14.0, 6.7 Hz, 6H), 0.80 (dd, J=6.8, 3.0 Hz, 6H).

Compound 105: Lys-Gln-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₃H₁₂₈N₂₄O₁₉; m/z: 412.2515 ([M+4H]⁴⁺), 549.3327 ([M+3H]³⁺), 823.4955 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O) δ 4.53 (dd, J=9.0, 5.0 Hz, 1H), 4.44 (dd, J=9.4, 4.8 Hz, 1H), 4.34 (dd, J=8.4, 6.0 Hz, 1H), 4.30-4.23 (m, 3H), 4.22-4.11 (m, 6H), 4.02 (dd, J=8.4, 4.8 Hz, 1H), 3.96 (d, J=7.6 Hz, 1H), 3.90 (t, J=6.7 Hz, 1H), 3.80-3.63 (m, 3H), 3.60-3.42 (m, 3H), 3.07 (t, J=6.9 Hz, 2H), 2.89-2.82 (m, 6H), 2.34-2.24 (m, 4H), 2.22-2.07 (m, 5H), 2.01-1.45 (m, AcOH, 50H), 1.39-1.20 (m, 15H), 0.85 (dd, J=15.5, 6.7 Hz, 6H), 0.80 (dd, J=6.8, 4.3 Hz, 6H).

Compound 106: Lys-Glu-Pro-Ile-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₇₄H₁₂₉N₂₃O₂₀; m/z: 416.0015 ([M+4H]⁴⁺), 554.3328 ([M+3H]³⁺), 830.9956 ([M+2H]²⁺).

¹H NMR (600 MHz, D₂O ) δ 4.50 (dd, J=9.6, 4.4 Hz, 1H), 4.45 (dd, J=9.3, 4.9 Hz, 1H), 4.36-4.22 (m, 4H), 4.22-4.10 (m, 6H), 4.02 (dd, J=8.4, 4.9 Hz, 1H), 3.96 (d, J=7.6 Hz, 1H), 3.92-3.84 (m, 1H), 3.82-3.74 (m, 1H), 3.73-3.63 (m, 2H), 3.61-3.41 (m, 3H), 3.07 (t, J=6.9 Hz, 2H), 2.90-2.82 (m, 6H), 2.32-2.12 (m, 9H), 2.00-1.46 (m, AcOH, 46H), 1.43-1.05 (m, 17H), 0.84 (d, J=6.8 Hz, 3H), 0.80 (dd, J=6.8, 4.3 Hz, 6H), 0.75 (t, J=7.4 Hz, 3H).

Compound 107: Val-Pro-Gln-Ala (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₁₈H₃₁N₅O₆; m/z: 414.2341 ([M+1H]⁺).

¹H NMR (600 MHz, D₂O ) δ 4.29 (t, J=7.6 Hz, 1H), 4.07 (dd, J=8.5, 6.1 Hz, 1H), 4.01-3.91 (m, 2H), 3.61-3.53 (m, 1H), 3.46-3.41 (m, 1H), 2.24-2.10 (m, 4H), 1.95-1.69 (m, AcOH, 6H), 1.14 (d, J=7.3 Hz, 3H), 0.91 (d, J=7.0 Hz, 3H), 0.80 (d, J=6.8 Hz, 3H).

Compound 108: Val-Pro-Gln-Ala-Lys (Acetate Salt)

High resolution mass spectrometry (Orbitrap-HRMS), molecular formula: C₂₄H₄₃N₇O₇; m/z: 271.6681 ([M+2H]2+), 542.3289 ([M+1H]⁺).

¹H NMR (600 MHz, D₂O) δ 4.28 (t, J=7.6 Hz, 1H), 4.13-4.06 (m, 2H), 3.99 (d, J=5.5 Hz, 1H), 3.94 (dd, J=8.2, 5.1 Hz, 1H), 3.60-3.54 (m, 1H), 3.46-3.41 (m, 1H), 2.78 (t, J=7.5 Hz, 2H), 2.21 (t, J=7.6 Hz, 2H), 2.17-2.09 (m, 2H), 1.93-1.58 (m, AcOH, 11H), 1.53-1.44 (m, 3H), 1.20 (dd, J=9.7, 7.5 Hz, 5H), 0.91 (d, J=6.9 Hz, 3H), 0.80 (d, J=6.9 Hz, 3H).

Example 2: Experiment on the Efficacy of Polypeptide Compounds in Relieving Colitis

Experimental animals: Wild-type AB strain zebrafishes, bred by natural pair mating. Zebrafishes aged 3 days post fertilization (3 dpf). Zebrafishes were kept in fish farming water at 28° C. (water quality: 200 mg of instant sea salt in each 1L of reverse osmosis water, with the conductivity of 450-550 μS/cm; pH of 6.5-8.5; and hardness of 50-100 mg/L CaCO₃), the experimental animal use license number is: SYXK (Zhe) 2012-0171, and the breeding management met the requirements of the international AAALAC certification (certification number: 001458).

Experimental Method

(1) Grouping: Polypeptide group: prepared into a stock solution of 20.0 mg/mL with ultrapure water and stored at −20° C.

Positive control group: prednisone, as white powder, with batch number C10016501, Shanghai Macklin Biochemical Technology Co., Ltd., stored at 4° C.; prepared into a 15.0 mg/mL stock solution with DMSO, and stored in aliquots at −20° C.

Normal control group and model control group.

(2) Experimental method: 3 dpf wild-type AB strain zebrafishes were randomly selected and placed in a 6-well plate, with 30 zebrafishes in each well (experimental group). Except for the normal control group, all other experimental groups were given TNBS in water to establish the zebrafish model of intestinal mucosal injury. After 2 days of treatment at 28° C., TNBS was removed, and polypeptide compound in water (at concentrations shown in Table 4) was given respectively, and for the positive control, prednisone was 15.0 μg/mL. A normal control group (healthy group) and a model control group (intestinal mucosal injury group) were set up at the same time. The capacity of each well (experimental group) was 3 mL. After 2 days of treatment at 28° C., 10 zebrafishes were randomly selected from each experimental group and photographed under a dissecting microscope. NIS-Elements D 3.20 advanced image processing software was used to analyze and collect data, and the intestinal lumen area of the zebrafish was analyzed. The statistical analysis results of this indicator were used to evaluate the efficacy of the samples in relieving colitis. The statistics results were expressed as mean±SE. SPSS26.0 software was used for statistical analysis, and p<0.05 indicates statistically significant difference.

Experimental results: The results of the efficacy of the polypeptide compound in relieving colitis are shown in Table 4:

TABLE 4
Results of the experimental evaluation of the efficacy
of polypeptide compounds in relieving colitis (n = 10)
		Intestinal lumen
	Concentration	area (pixels,
Group	(μg/mL)	mean ± SE)
Normal control group	—	32743 ± 1560**
Model control group	—	41868 ± 1671
Prednisone group	15.0	34929 ± 1913*
Compound 1	250	39333 ± 2095
	500	26497 ± 1245***
	1000	26174 ± 1898***
Compound 4	250	48915 ± 2720
	500	40432 ± 3736
	1000	33664 ± 3758*
Compound 5	250	42960 ± 2661
	500	45713 ± 4481
	1000	33977 ± 3524*
Compound 6	250	53093 ± 3839
	500	45831 ± 3894
	1000	28429 ± 3711**
Compound 12	250	48857 ± 5649
	500	43802 ± 3228
	1000	26727 ± 2106**
Compound 15	250	40719 ± 4647
	500	31319 ± 5274*
	1000	30268 ± 2437*
Compared with the model control group,
*p < 0.05,
**p <0.01,
***p < 0.001

According to the data in Table 4, it can be known that the polypeptide compound groups including compounds 1, 4, 5, 6, 12 and 15 showed significant statistical differences compared with the model control group (p<0.05; p<0.01; p<0.001), and the effect was better than that of the prednisone group. The experimental results show that the polypeptide compound provided in the present application has the effect of alleviating colitis, which is specifically manifested in significantly alleviating intestinal lumen dilatation.

The concentration gradient of the test substances set in this experimental system was 250 μg/mL, 500 μg/mL, and 1000 μg/mL. By counting the intestinal lumen area of the zebrafish after intervention in each group, it can be seen that most of the test substances with the effect of relieving colitis had a more obvious effect at a concentration of 1000 μg/mL (p<0.05; p<0.01; p<0.001). When the concentration of the test substance was further increased for intervention, the death phenomenon of zebrafishes was found in the group; therefore, in the subsequent rounds of activity evaluation, each test polypeptide compound was uniformly administered at 1000 μg/mL for intervention. The results are summarized in Table 5.

TABLE 5
Summary of the activity of polypeptide compounds in alleviating
intestinal lumen dilatation of colitis in zebrafishes
         Activity in
         relieving
         intestinal
Compound lumen
No.      dilatation
1        ***
2        ND
3        ND
4        *
5        *
6        **
7        +
8        +
9        **
10       **
11       +
12       **
13       −
14       +
15       *
16       +
17       +
18       −
19       +
20       &
21       +
22       +
23       +
24       +
25       **
26       *
27       +
28       +
29       *
30       +
31       *
32       +
33       +
34       *
35       −
36       +
37       +
38       *
39       +
40       +
41       +
42       +
43       ND
44       −
45       #
46       +
47       +
48       **
49       *
50       *
51       *
52       +
53       *
54       ***
55       *
56       ND
57       **
58       +
59       +
60       −
61       ND
62       *
63       ***
64       +
65       *
66       *
67       *
68       **
69       +
70       *
71       +
72       **
73       ND
74       +
75       *
76       +
77       −
78       +
79       +
80       +
81       +
82       +
83       *
84       +
85       *
86       *
87       +
88       *
89       **
90       *
91       +
92       **
93       *
94       ***
95       **
96       ***
97       ***
98       **
99       *
100      ***
101      ND
102      +
103      *
104      ***
105      **
106      **
107      ND
108      ND
Note:
The activity of each compound to relieve intestinal lumen dilatation of colitis in zebrafishes was completed in several batches of trials, and for comparison purposes, its activity against intestinal lumen dilatation was compared with that of the control group of an equivalent number of batches of the experimental model:
* p < 0.05,
** p < 0.01,
*** p < 0.001;
ND indicates not detected,
“−“ indicates absence of activity,
“+” indicates some relief of intestinal lumen dilatation,
“#” indicates that all the zebrafishes died in the experiment, and
“&” indicates that 13 zebrafishes died in the experiment.

According to the data in Table 4 and Table 5, there was a significant statistical difference between the polypeptide groups and the model control group (p<0.05, p<0.010r p<0.001), and the effect was better than that of the prednisone group. Under the experimental conditions, compounds 1, 4-6, 9, 10, 12, 15, 25, 26, 29, 31, 34, 38, 48-51, 53-55, 57, 62, 63, 65-68, 70, 72, 75, 83, 85, 86, 88-90, 92-100, and 103-106 all had a significant effect of alleviating colitis, as manifested by relieving intestinal lumen dilatation (p<0.05); and compounds 7, 8, 11, 14, 16, 17, 19, 21-24, 27, 28, 30, 32, 33, 36, 37, 39-42, 46, 47, 52, 58, 59, 64, 69, 71, 74, 76, 78-82, 84, 87, 91 and 102 had a certain effect of alleviating intestinal lumen dilatation.

Example 3: Evaluation of the Therapeutic Effects of Polypeptide Compounds on TNBS-Induced Model of Acute Inflammatory Bowel Disease (UC) in SD Rat

Objective: To evaluation the therapeutic effects of polypeptide compounds on TNBS-induced model of acute inflammatory bowel disease in SD rat

Materials and Methods

In this experiment, a rat model of ulcerative colitis was established by administering trinitrobenzene sulfonic acid (TNBS) to laboratory animal male SD rats for a single enema intervention. Acute colitis in rats induced by trinitrobenzene sulfonic acid (TNBS) is an immune response induced by cytokines secreted by Th1 type cells. The colon of animals in the model control group shows the reactivity of obvious atrophy and intestinal wall thickening, and the ratio of colon weight to length increases significantly. Fissure-like ulcer foci are observed on the surface of the intestinal mucosa, and typical granulomas are observed in the submucosal layer and muscular layer, internally accompanied by infiltration of inflammatory cells mainly composed of lymphocytes and plasma cells. At the same time, there is obvious hyperplasia of small blood vessels and connective tissue (fibroblasts), and crypt structure destruction and bleeding are observed around the ulcer foci. This model is simple to establish and has good reproducibility. It is an experimental animal model widely used in evaluating drugs for the treatment of inflammatory bowel disease. The experimental animals (male SD rats) were randomly divided into 6 groups according to body weight parameters on the first day of the experiment, namely normal control group, model control group, positive drug mesalazine treatment group, compound 1 low-dose treatment group, compound 1 high-dose treatment group, compound 6 low-dose treatment group, compound 6 high-dose treatment group and compound 12 treatment group, with 10 rats in each group. On the day of grouping (DO), except for the normal control group which was given the vehicle, the animals in the remaining experimental groups were given TNBS in ethanol by enema to induce the model; the test article and positive control drug treatments were started on the second day of model induction, with the treatment dose being respectively 3.0 mg/kg and 6.0 mg/kg for compound 1, respectively 1.4 mg/kg and 2.8 mg/kg for compound 6, 0.8 mg/kg for compound 12, and 30.0 mg/kg for positive control drug mesalazine, all of which were administered by enema at a frequency of once a day for 14 consecutive days. During the experimental treatment period (D1-D14), the body weight and general clinical observation indicators (including but not limited to food intake, water intake, activity level and defecation, etc.) of the animals in each experimental group were dynamically collected. At the same time, based on the relevant scoring standards for the disease activity index of ulcerative colitis, the reactivity such as the weight loss degree, stool morphology and trait, and bloody stool of the animals in each experimental group after TNBS induction were scored, and the disease activity index (DAI) of ulcerative colitis was calculated, once a day for 14 consecutive days. At the end point of the experiment, colon tissues of animals in each experimental group were collected, and the length and weight of the colon were measured and then the non-autopsy images were collected. Then the colon was cut open along the intestinal wall longitudinally and autopsy images were collected. Based on the “Criteria for Scoring Gross Morphological Manifestations of the Colon”, the gross damage with respect to colon adhesions, colon ulcers and inflammation of animals in each experimental group was observed and scored. Ulcer images were collected under a stereomicroscope and the area of colon ulcer foci was calculated, followed by routine fixation. According to the statistical analysis results of various pharmacodynamic test indicators, the therapeutic effect of the test polypeptide compound on the ulcerative colitis disease model under the set treatment regimen was evaluated.

Results and Conclusions

In this experimental research system, the animals in the model control group showed obvious disease characteristics of ulcerative colitis, including weight gain inhibition, soft and loose stools, significantly increased ulcerative colitis disease activity index (DAI) score, and macroscopically observed colon atrophy and typical ulcer foci and colon fusion ulcer foci. The test compound 1 had a significant effect of improving the weight gain inhibition of the model animals under the set treatment regimen, and the degree of improvement was statistically significant compared with the weight change degree of the animals in the model control group in the same period (P<0.05), while the test compounds 6 and 12 had no obvious improved therapeutic effect on the weight gain inhibition of the model animals.

TABLE 6
Effects of the test polypeptide compounds on changes in the body weight of model animals
		Experimental	Experimental	Weight change
	Grouping day	day 5	endpoint	range
Group	(D 0, g)	(D 5, g)	(D 14, g)	(D 0-D 14, %)
Normal control	273.86 ± 7.48	281.46 ± 12.97	310.67 ± 22.39	13.38 ± 6.25
group
Model control	278.66 ± 9.87	236.52 ± 14.56***	267.73 ± 28.89**	***−3.83 ± 10.82
group
Mesalazine	276.64 ± 7.47	234.86 ± 8.07	264.43 ± 17.65	−4.29 ± 7.79
treatment group
Compound 1 low	274.40 ± 9.10	251.65 ± 18.30#	296.07 ± 19.58#	7.96 ± 7.32#
dose group
Compound 1	279.99 ± 10.57	263.90 ± 15.38##	299.37 ± 14.64##	6.97 ± 4.73##
high dose group
Compound 6 low	276.61 ± 9.81	243.72 ± 22.18	277.96 ± 29.18	0.48 ± 9.87
dose group
Compound 6	275.55 ± 7.92	246.74 ± 22.76	279.67 ± 30.93	1.50 ± 10.78
high dose group
Compound 12	276.36 ± 7.47	244.90 ± 21.75	272.00 ± 33.21	−1.52 ± 12.20
treatment group
Note:
All data were statistically analyzed using mean ± standard deviation (SD).
*P < 0.05,
**P < 0.01,
***P < 0.001,
****P < 0.0001 represent the statistical analysis results of the model control group and the normal control group.
#P < 0.05,
##P < 0.01, represent the statistical analysis results of the test polypeptide compound treatment group and the model control group.

The DAI score results of the experimental period show that the test compounds 1, 6 and 12 had a significant improvement effect on the disease progression of ulcerative colitis in the model animals under the set treatment regimen. The fecal trait pathological characteristics and weight loss reactivity of the animals in the corresponding treatment groups were significantly alleviated, and the mean DAI scores showed a decrease, which was significantly statistically different from the model control group in the same period (P<0.05). The improvement in treatment effect of compound 1 was the most significant, and the treatment effects of the compounds 1 and 6 were significantly dose-dependent.

TABLE 7
Effects of the test polypeptide compounds on the DAI scores of model animals
	Experimental day 1	Experimental day 3	Experimental endpoint
Group	(D 1, point)	(D 3, point)	(D 14, point)	AUC(0-14 d) (D 0-D 14)
Normal control	0.3 ± 0.5	0.2 ± 0.4	0	1.10 ± 0.65
group
Model control	3.8 ± 1.0	6.1 ± 1.0	2.2 ± 1.3	57.00 ± 2.97****
group
Mesalazine	4.2 ± 0.4	6.2 ± 0.6	2.1 ± 1.6	58.75 ± 2.93
treatment group
Compound 1 low	3.5 ± 1.3	4.9 ± 1.6	0.5 ± 0.7	37.65 ± 3.60####
dose group
Compound 1	3.9 ± 0.6	4.3 ± 1.8	0.1 ± 0.3	30.65 ± 2.93####+++
high dose group
Compound 6 low	3.9 ± 0.9	5.0 ± 1.7	1.3 ± 1.2	49.65 ± 3.95####
dose group
Compound 6	4.2 ± 0.8	4.8 ± 1.0	0.7 ± 1.2	39.55 ± 3.99####++++
high dose group
Compound 12	4.1 ± 0.6	4.9 ± 1.0	1.4 ± 1.8	46.40 ± 3.68####
treatment group
Note:
All data were statistically analyzed using mean ± standard deviation (SD).
*P < 0.05,
**P < 0.01,
***P < 0.001, and
****P < 0.0001 represent the statistical analysis results of the model control group and the normal control group.
#P < 0.05,
##P < 0.01,
###P < 0.001, and
####P < 0.0001 represent the statistical analysis results of the animals in the test polypeptide compound treatment group and the model control group.
+P < 0.05,
++P < 0.01,
+++P < 0.001, and
++++P < 0.0001 represent the statistical analysis results between the compound 1 or 6 dose groups.

The results of gross anatomy and colon tissue injury scores at the experimental endpoint show that the test compounds 1, 6 and 12 had obvious therapeutic effects on TNBS-induced gross colon injury status (colonic adhesion, ulcer and inflammation), colon ulcer focus area and abnormal increase in colon weight/length ratio. The degree of improvement was statistically significant compared with the model control group in the same period (P<0.05). The therapeutic effect of the compound 1 was the most significant, and its therapeutic effect was significantly dose-dependent.

TABLE 8
Effects of the test polypeptide compounds on the gross
damage and ulcer area of the colon in model animals
	Colonic adhesion	Colon ulcer and	Colon
	score	inflammation score	ulcer area
Group	(point)	(point)	(cm2)
Normal control	0	0	0
group
Model control	2.80 ± 0.42****	4.40 ± 0.70****	7.72 ± 4.02****
group
Mesalazine	2.60 ± 0.52	4.30 ± 0.95	7.50 ± 3.51
treatment group
Compound 1 low	1.10 ± 0.57####	2.50 ± 0.85####	3.77 ± 1.91#
dose group
Compound 1 high	0.60 ± 0.52####	1.40 ± 0.84####++	2.15 ± 0.74###+
dose group
Compound 6 low	1.70 ± 0.67###	3.00 ± 0.94##	3.46 ± 2.06##
dose group
Compound 6 high	1.30 ± 0.82####	2.50 ± 1.43##	3.66 ± 2.36#
dose group
Compound 12	1.20 ± 0.63####	2.30 ± 0.82####	3.79 ± 1.63#
treatment group
Note:
All data were statistically analyzed using mean ± standard deviation (SD).
*P < 0.05,
**P < 0.01,
***P < 0.001, and
****P < 0.0001 represent the statistical analysis results of the model control group and the normal control group.
#P < 0.05,
##P < 0.01,
###P < 0.001, and
####P < 0.0001 represent the statistical analysis results of the animals in the test polypeptide compound treatment group and the model control group.
+P < 0.05,
++P < 0.01,
+++P < 0.001, and
++++P < 0.0001 represent the statistical analysis results between the compound 1 or 6 dose groups.

TABLE 9
Effects of the test polypeptide compounds on the
colon weight/length ratio of model animals
	Colon	Colon	Colon weight/
	weight	length	length ratio
Group	(g)	(cm)	(100* g/cm)
Normal control	1.90 ± 0.16	18.14 ± 1.23	10.53 ± 1.01
group
Model control	3.26 ± 0.97***	12.76 ± 0.92****	25.37 ± 6.35****
group
Mesalazine	3.42 ± 1.15	14.76 ± 2.06	22.99 ± 5.49
treatment group
Compound 1 low	2.48 ± 0.46#	15.34 ± 1.99##	16.40 ± 3.29###
dose group
Compound 1 high	2.20 ± 0.28##	16.55 ± 1.67####	13.37 ± 1.93####+
dose group
Compound 6 low	2.23 ± 0.39##	13.37 ± 1.40	16.93 ± 3.87##
dose group
Compound 6 high	2.41 ± 0.63#	13.89 ± 1.60	17.70 ± 5.71#
dose group
Compound 12	2.10 ± 0.19##	13.74 ± 1.97	15.68 ± 3.14#
treatment group
Note:
All data were statistically analyzed using mean + standard deviation (SD).
*P < 0.05,
**P < .01,
***P < 0.001, and
****P < 0.0001 represent the statistical analysis results of the model control group and the normal control group.
#P < 0.05,
##P < 0.01,
###P < 0.001, and
####P < 0.0001 represent the statistical analysis results of the animals in the test polypeptide compound treatment group and the model control group.
+P < 0.05,
++P < 0.01,
+++P < 0.001, and
++++P < 0.0001 represent the statistical analysis results between the compound 1 or 6 dose groups.

In this trial, TNBS was used for intervention by enema in male SD rats to induce colonic lesions and establish a rat ulcerative colitis model that conforms to the clinical characteristics of the disease. The next day after model induction, the treatment with test compounds 1, 6 and 12 and positive control drug mesalazine was started. During the treatment period (D1-D14), the changes in the weight, the disease activity index (DAI) score of ulcerative colitis, the score of gross colon damage manifestation (colonic adhesion, ulcer and inflammatory response), the ulcer area of the colon tissue and the ratio of colon weight to length of the experimental animals were monitored to evaluate the therapeutic effect of the test articles on the model of TNBS-induced ulcerative colitis in SD rat. The results showed that:

1) After TNBS induction, the experimental animals showed significant manifestations of ulcerative colitis disease, including significant weight loss, significant increase in ulcerative colitis disease activity index score (DAI score), significant increase in colon adhesion and ulcer score, increase in colon tissue ulcer area and significant increase in colon weight/length ratio, indicating that the rat ulcerative colitis model suitable for the pharmacodynamic study of this experiment was successfully established.

2) The test compound 1 had a significant improvement effect on the weight loss response of the model animals under the set treatment regimen, and the degree of improvement was statistically significant compared with the model control group during the same period (P<0.05), while the test compounds 6, 12 and the positive control drug mesalazine did not show a significant weight improvement effect.

3) The test compounds 1, 6 and 12 had a significant improvement effect on the disease progression of ulcerative colitis in model animals under the set treatment regimen, and their DAI scores showed a significant decrease compared with the model control group during the same period. The therapeutic effect of the test compound 1 was the most significant. At the same time, the treatment improvement effect of the test compounds 1 and 6 was significantly dose-dependent, while the positive control drug mesalazine had no significant effect on the disease symptoms of ulcerative colitis in model animals.

4) The test compounds 1, 6 and 12 had significant therapeutic effects on the gross damage manifestation of the colon in model animals under the set treatment regimen. Compared with the model control group in the same period, their colon adhesion score, colon ulcer and inflammation score and colon tissue ulcer area all showed a significant decrease, and the degree of improvement was statistically significant (P<0.05). The therapeutic effect of the test compound 1 was the most significant, and its improved therapeutic effect was significantly dose-dependent.

5) The test compounds 1, 6 and 12 had a significant improvement effect on the colon atrophy process of model animals under the set treatment regimen. Compared with the model control group in the same period, their colon weight/length ratio was significantly decreased (P<0.05).

It can be seen that this experiment established a rat model of ulcerative colitis that conforms to the clinical characteristics of the pathogenesis, and the results of the efficacy evaluation in this model show that the test compounds 1, 6 and 12 all had significant therapeutic effects.

Example 4: Study on the Effect of Polypeptide Compounds on the Proliferation of CaCo-2 Cells In Vitro

The following cell lines were used to study in vitro proliferation of the polypeptide compounds:

TABLE 10
Cell line information
Serial	Cell		Growth
No.	line	Cancer type	characteristics	Culture medium
1	CaCo-2	Colorectal	Adherence	(MEM + 0.01 mM
		cancer		NEAA) + 20% FBS

Experimental Method

Cells will be thawed and maintained according to the culture conditions shown in Table 10.

Day 1 (cell plating): Cells in the logarithmic growth phase were collected, resuspended, counted using a cell counter and detected for activity. The cell suspension was diluted according to the required plating density and 90 μL of the cell suspension was added into each well of a 96-well plate (the plating density of cell would be adjusted based on historical data or density optimization experiments). While plating, three replicate wells were plated for each cell as TO plates. All 96-well plates were placed in a 37° C., 5% CO₂ thermostatic incubator overnight.

Day 2 (medium change): The medium with the corresponding serum concentration was replaced according to the platemap, 90 μL per well. Day 2: The TO plate was read and treated with the test compound. 10 μL of culture medium was added into each well of the TO plate to make up the total volume to 100 μL. 50 μL of CellTiter-Glo® Reagent was added to each well. The system was mixed and shaken for 5 min to fully lyse the cells. The system was incubated at room temperature for 10 min to stabilize the luminescent signal (note: temperature, cell density, and edge effects can all lead to uneven luminescent signals). Fluorescent signals were detected using EnVision Multi Label Reader. The test compound was configured according to the corresponding molecular weight, C1=91.08 μM, diluted C2=9.108 μM, and C3=0.9108 μM. Cisplatin was diluted as shown in Table 11 to prepare a 10× compound working solution. 10 μL of working solution (10×) was added to each well, so that the final volume per well of all plates was 100 μL. The cells were cultured in a 37° C., 5% CO₂ incubator.

On the 5th day, treatment with the test compound was performed for 72 h (plate reading): whether the status of the drug-treated group and the control group is normal was observed under a microscope. 50 μL of CTG reagent was added to each well. The system was mixed on a shaker for 5 min to allow cells to fully lyse. The system was incubated at room temperature for 10 min to stabilize the luminescent signal. Fluorescent signals were read using EnVision Multi Label Reader.

TABLE 11
Cisplatin concentration after dilution
	C1-1	C2-1	C3-1	C4-1	C5-1	C6-1	C7-1	C8-1	C9-1	C10-1
Concentration (μM)	1000	333.33	111.11	37.04	12.35	4.12	1.37	0.46	0.15	0
Solution volume (μL)	90	90	90	90	90	90	90	90	90	90
Broth volume (μL)	209.7	209.7	209.7	209.7	209.7	209.7	209.7	209.7	209.7	209.7

$\mathrm{Cell}\mathrm{viability}\left(\%\right)={\mathrm{Lum}}_{\mathrm{test}\mathrm{compound}}/{\mathrm{Lum}}_{\mathrm{solvent}\mathrm{control}}\times 100\%.$

Experimental results: The statistical results of the proliferation-promoting activity of the selected polypeptide compounds are shown in Table 12:

Compound No. Proliferation-promoting activity
1            Cell viability > 110%
20           /
44           /
45           /

The concentration gradient of the administered test substance set in this experimental system was set as C1=91.08 μM, diluted C2=9.108 μM, and C3=0.9108 μM, with 0.88% FBS as the reference. The experimental results show that the polypeptide compound 1 of the present application has the activity of promoting the proliferation of Caco-2 cells, which is specifically manifested as an increase in cell viability after intervention.

In summary, the above-mentioned polypeptide compound of the present invention has a short peptide chain and is absorbed faster and better. The experimental results show that the polypeptide compound provided in the present application has the activity of alleviating the intestinal lumen dilatation of colitis in zebrafishes; and has a significant therapeutic effect in the trial for rat model of acute inflammatory bowel disease model. The polypeptide compound of the present invention has a significant effect of alleviating colitis and can be used to prepare drugs for treating enteritis, especially drugs for ulcerative colitis.

Although the present invention discloses the above Examples, the embodiments of the present invention are not limited to the above Examples, and any other changes, modifications, replacements, combinations, and simplifications that do not deviate from the present invention should be considered as equivalents and are included in the scope of protection of the present invention.

Claims

1. A compound of formula (I) or a physiologically compatible salt thereof, wherein the compound of formula (I) is as follows: H—Xa—Z1—Z2—Z3—Z4—Xb—OH  (I)whereinZ1 is Pro, Ala, Gly, D-Pro or is absent;Z2 is Val, Ala, D-Val, Ile or is absent;Z3 is Pro, Ala, Gly, D-Pro or is absent;Z4 is Gln, Ala, Glu, Ile, D-Gln or is absent;provided that at most 2 of Z1, Z2, Z3 and Z4 are absent.Xa is a sequence containing 0-10 amino acid residues; andXb is a sequence containing 0-9 amino acid residues.

2. The compound according to claim 1 or a physiologically compatible salt thereof, wherein 2 of Z1, Z2, Z3 and Z4 are absent; or Z1 and Z2 are absent; or Z3 and Z4 are absent; or 1 of Z1, Z2, Z3 and Z4 is absent; or Z1 is absent; or Z4 is absent; or 0 of Z1, Z2, Z3 and Z4 is absent.

3. The compound according to claim 1 or a physiologically compatible salt thereof, wherein 0 of Z1, Z2, Z3 and Z4 is absent.

4. The compound according to claim 1 or a physiologically compatible salt thereof, wherein Z1 is Pro; Z2 is Val; Z3 is Pro; and Z4 is Gln; or Z1 is D-Pro; Z2 is Val; Z3 is Pro; and Z4 is Gln; or Z1 is Pro; Z2 is Val; Z3 is Ala; and Z4 is Gln; or Z1 is Pro; Z2 is Ile; Z3 is Pro; and Z4 is Gln; or Z1 is Pro; Z2 is Val; Z3 is Pro; and Z4 is absent; or Z1 is Pro; Z2 is Ala; Z3 is Pro; and Z4 is Gln; or Z1 is Gly; Z2 is Val; Z3 is Pro; and Z4 is Gln; or Z1 is Pro; Z2 is Val; Z3 is Gly; and Z4 is Gln; or Z1 is Ala; Z2 is Val; Z3 is Pro; and Z4 is Gln; or Z1 is Pro; Z2 is Val; Z3 is Pro; and Z4 is Glu; or Z1 is Pro; Z2 is Val; Z3 is D-Pro; and Z4 is Gln; or Z1 is Pro; Z2 is Val; Z3 is Pro; and Z4 is D-Gln.

5. The compound according to claim 1 or a physiologically compatible salt thereof, wherein Z1 is Pro; Z2 is Val; Z3 is Pro; and Z4 is Gln.

6. The compound according to claim 1 or a physiologically compatible salt thereof, wherein Xa is Xa10—Xa9—Xa8—Xa7—Xa6—Xa5—Xa4—Xa3—Xa2—Xa1—*, wherein * indicates the position linked to Z1-Z2—Z3—Z4, whereinXa10 is Gly or is absent,Xa9 is Gly, Pro, Ser or is absent,Xa8 is Pro, Glu, Ser or is absent,Xa7 is Arg, Glu, Thr, Ser or is absent,Xa6 is Lys, Thr, Ala, Asp, Glu, Arg, Ser or is absent,Xa5 is Asp, Ala, Val, Arg, Phe, Ile, Pro, Lys, Glu or is absent,Xa4 is Val, Phe, Pro, Pyro-Glu, Lys, Leu, Ile, Ala, Asp or is absent,Xa3 is Tyr, Leu, Pro, Asp, Arg, Glu, Lys, Tys, Val, Ile or is absent,Xa2 is D-Lys, Lys, Ala, Arg, Val, Glu, Tyr or is absent, andXa1 is Glu, Ala, D-Glu, Tyr, Gln, Asp, Asn or is absent.

7. The compound according to claim 6 or a physiologically compatible salt thereof, wherein Xa is Xaa—Xa2—Xa1—*, wherein * indicates the position linked to Z1-Z2—Z3—Z4, Xa2—Xa1 is Lys-Glu-*, Arg-Glu-*, Val-Tyr-*, Glu-Glu-*, Lys-Gln-*, Lys-D-Glu-* or Tyr-Glu-*, and Xaa is Xa10—Xa9—Xa8—Xa7—Xa6—Xa5—Xa4—Xa3—, wherein Xa10 is Gly or is absent, Xa9 is Gly, Pro, Ser or is absent, Xa8 is Pro, Glu, Ser or is absent, Xa7 is Arg, Glu, Thr, Ser or is absent, Xa6 is Lys, Thr, Ala, Asp, Glu, Arg, Ser or is absent, Xa5 is Asp, Ala, Val, Arg, Phe, Ile, Pro, Lys, Glu or is absent,Xa4 is Val, Phe, Pro, Pyro-Glu, Lys, Leu, Ile, Ala, Asp or is absent, and Xa3 is Tyr, Leu, Pro, Asp, Arg, Glu, Lys, Tys, Val, Ile or is absent.

8. The compound according to claim 7 or a physiologically compatible salt thereof, wherein Xaa is Arg-Lys-Asp-Val-Tyr-, Gly-Pro-Glu-Thr-Ala-Phe-Leu-, Val-Pro-Pro-, Pyro-Glu-Leu-, Arg-Lys-Asp-, Gly-Pro-Glu-Thr-Ala-Phe-Leu-Arg-, Ser-Ser-Glu-Asp-Ile-Lys-Glu-, Ser-Ser-Glu-Asp-Ile-Lys-, Val-Pro-Tys-, Pro-Ala-Tys-, Arg-Lys-Asp-Val-, Ser-Ser-Glu-Asp-Ile-, or is absent, wherein the rightmost connector—indicates linkage to —Xa2—Xa1.

9. The compound according to claim 7 or a physiologically compatible salt thereof, wherein Xa is Xaa—Xa2—Xa1—*, wherein * indicates the position linked to Z1-Z2—Z3—Z4, wherein Xa2—Xa1 is Lys-Glu-*, and Xa is as defined above.

10. The compound according to claim 6 or a physiologically compatible salt thereof, wherein Xa is Glu-*, Ala-*, D-Glu-*, Asp-*, Asn-*, Lys-Glu-*, D-Lys-Glu-*, Ala-Glu-*, Lys-Gln-*, Lys-D-Glu-*, Lys-Ala-*, Arg-Lys-Asp-Val-Tyr-Lys-Glu-*, Gly-Pro-Glu-Thr-Ala-Phe-Leu-Arg-Glu-*, Val-Pro-Pro-Lys-Glu-*, Pyro-Glu-Leu-Lys-Glu-*, Arg-Lys-Asp-Val-Tyr-*, Gly-Pro-Glu-Thr-Ala-Phe-Leu-Arg-Lys-Glu-*, Ser-Ser-Glu-Asp-Ile-Lys-Glu-LysGlu-*, Ser-Ser-Glu-Asp-Ile-Lys-Glu-Glu-*, Val-Pro-Tys-Lys-Glu-*, Pro-Ala-Tys-Lys-Glu-*, Arg-Lys-Asp-Val-Tyr-Glu-*, Ser-Ser-Glu-Asp-Ile-Lys-Glu-* or is absent, wherein * indicates the position linked to Z1-Z2—Z3—Z4.

11. The compound according to claim 1 or a physiologically compatible salt thereof, wherein Xb is **—Xb1—Xb2—Xb3—Xb4—Xb5—Xb6—Xb7—Xb8—Xb9, wherein ** indicates the position linked to Z1—Z2-Z3—Z4, whereinXb1 is Ala, D-Ala or is absent,Xb2 is Lys, Ala, D-Lys, Arg or is absent,Xb3 is Pro, Gly, D-Pro, Ser, Val, Ala or is absent,Xb4 is Arg, Ala, Ser, Pro, D-Arg or is absent,Xb5 is Lys, Ala, D-Lys, Glu, Tyr or is absent,Xb6 is Val, Asp, D-Val, Ala or is absent,Xb7 is Ala, D-Ala, Ile or is absent,Xb8 is Ala, D-Ala, Lys or is absent, andXb9 is Gln, Ala, Glu, Asn, D-Gln or is absent.

12. The compound according to claim 11 or a physiologically compatible salt thereof, wherein Xb is **—Xb1—Xb2—Xb3—Xb4—Xb5—Xb6—Xb7—Xb8—Xb9, wherein ** indicates the position linked to Z1-Z2—Z3—Z4, wherein Xb1 is Ala or D-Ala,Xb2 is Lys, Ala or D-Lys,Xb3 is Pro, Gly, or Ala,Xb4 is Arg or D-Arg,Xb5 is Lys or is absent,Xb6 is Val, D-Val, Ala or is absent,Xb7 is Ala is absent,Xb8 is Ala or is absent, andXb9 is Gln, Asn, D-Gln or is absent.

13. The compound according to claim 11 or a physiologically compatible salt thereof, wherein Xb is **—Xb1—Xb2—Xbb, wherein ** indicates the position linked to Z1-Z2—Z3—Z4, Xb1—Xb2— is **-Ala-Lys-, **-Ala-Lys-, **-Ala-D-Lys-, **-Ala-Ala- or **-D-Ala-Lys-, Xbb is —Xb3—Xb4—Xb5—Xb6—Xb7—Xb8—Xb9, wherein Xb3 is Pro, Gly, D-Pro, Ser, Val, Ala or is absent, Xb4 is Arg, Ala, Ser, Pro, D-Arg or is absent, Xb5 is Lys, Ala, D-Lys, Glu, Tyr or is absent, Xb6 is Val, Asp, D-Val, Ala or is absent, Xb7 is Ala, D-Ala, Ile or is absent, Xb5 is Ala, D-Ala, Lys or is absent, and Xb9 is Gln, Ala, Glu, Asn, D-Gln or is absent; or Xb3 is Pro, Gly, or Ala, Xb4 is Arg or D-Arg, Xb5 is Lys or is absent, Xb6 is Val, D-Val, Ala or is absent, Xb7 is Ala or is absent, Xb5 is Ala or is absent, and Xb9 is Gln, Asn, D-Gln or is absent.

14. The compound according to claim 13 or a physiologically compatible salt thereof, wherein Xbb is -Pro-Arg-Lys-Val, -Pro-Arg-Lys, -Pro-Arg, -Ala-Gln, -Ala-Ala, -Pro, -Lys-Val, -Val-Pro-Tyr, -Arg-Lys, -Val-Ala, -Pro-Arg-Lys-Val-Ala, -Lys-Val-Ala-Ala-Gln, -Pro-Arg-Lys-Val-Ala-Ala-Gln, -Pro-A rg-Lys-Val-Ala-Ala-Gln, -Pro-Ala-Lys-Val-Ala-Ala-Gln, -Pro-Arg-Ala-Val-Ala-Ala-Gln, -Pro-Arg-Lys-Val-Ala-Ala-Ala, -Gly-Arg-Lys-Val-Ala-Ala-Gln, -D-Pro-Arg-Lys-Val-Ala-Ala-Gln, -Pro-Arg-D-Lys-Val-Ala-Ala-Gln, -Pro-Arg-Lys-Val-D-Ala-Ala-Gln, -Pro-Arg-Lys-Val-Ala-D-Ala-Gln, -Ser-Ser-Glu-Asp-Ile-Lys-Glu, -Pro-Arg-Lys-Val-Ala-Ala-Asn, -Pro-Arg-Lys-Val-Ala-Ala-Gln, -Pro-Arg-Lys-D-Val-Ala-Ala-Gln, -Ala-Arg-Lys-Val-Ala-Ala-Gln, -Pro-Arg-Lys-Ala-Ala-Ala-Gln, -Pro-Arg-Lys-Val-Ala-Ala-Gln, -Pro-D-Arg-Lys-Val-Ala-Ala-Gln, -Pro-Arg-Lys-Val-Ala-Ala-D-Gln or is absent, wherein the leftmost connector—indicates linkage to Xb1—Xb2.

15. The compound according to claim 13 or a physiologically compatible salt thereof, wherein Xb is **—Xb1—Xb2—Xbb, wherein ** indicates the position linked to Z1-Z2—Z3—Z4, Xb1—Xb2— is **-Ala-Lys-, and Xbb is as defined above.

16. The compound according to claim 1 or a physiologically compatible salt thereof, wherein Xb is **-Ala-, **-Ala-Lys, **-Ala-D-Lys-, **-Ala-Ala-, **-D-Ala-Lys, **-Ala-Arg, **-Ala-Lys-Pro-Arg-Lys-Val, **-Ala-Lys-Pro-Arg-Lys, **-Ala-Lys-Pro-Arg, **-Val-Ala-Ala-Gln, **-Lys-Val-Ala-Ala, **-Ala-Lys-Pro, **-Pro-Arg-Lys-Val, **-Ala-Lys-Val-Pro-Tyr, **-Lys-Pro-Arg-Lys, **-Arg-Lys-Val-Ala, **-Ala-Lys-Pro-Arg-Lys-Val-Ala, **-Pro-Arg-Lys-Val-Ala-Ala-Gln, **-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln, **-Ala-Ala-Pro-Arg-Lys-Val-Ala-Ala-Gln, **-Ala-Lys-Pro-Ala-Lys-Val-Ala-Ala-Gln, **-Ala-Lys-Pro-Arg-Ala-Val-Ala-Ala-Gln, **-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Ala, **-Ala-Lys-Gly-Arg-Lys-Val-Ala-Ala-Gln, **-Ala-Lys-D-Pro-Arg-Lys-Val-Ala-Ala-Gln, **-Ala-Lys-Pro-Arg-D-Lys-Val-Ala-Ala-Gln, **-Ala-Lys-Pro-Arg-Lys-Val-D-Ala-Ala-Gln, **-Ala-Lys-Pro-Arg-Lys-Val-Ala-D-Ala-Gln, **-Ala-Lys-Ser-Ser-Glu-Asp-Ile-Lys-Glu, **-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Asn, **-Ala-D-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln, **-Ala-Lys-Pro-Arg-Lys-D-Val-Ala-Ala-Gln, **-Ala-Lys-Ala-Arg-Lys-Val-Ala-Ala-Gln, **-Ala-Lys-Pro-Arg-Lys-Ala-Ala-Ala-Gln, **-D-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln, **-Ala-Lys-Pro-D-Arg-Lys-Val-Ala-Ala-Gln, **-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-D-Gln, or is absent, wherein ** indicates the position linked to Z1-Z2—Z3—Z4.

17. The compound according to claim 1 or a physiologically compatible salt thereof, wherein the compound is selected from: Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 1);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys (Compound 2);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg (Compound 3);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 4);Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 5);Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 6);Lys-Glu-Pro-Val (Compound 7);Val-Ala-Ala-Gln (Compound 8);Glu-Pro-Val-Pro (Compound 9);Lys-Pro-Arg-Lys (Compound 10);Ala-Lys-Pro-Arg (Compound 11);Pro-Val-Pro-Gln (Compound 12);Val-Pro-Gln-Ala (Compound 13);Pro-Gln-Ala-Lys (Compound 14);Arg-Lys-Val-Ala (Compound 15);Lys-Val-Ala-Ala (Compound 16);Gln-Ala-Lys-Pro (Compound 17);Pro-Arg-Lys-Val (Compound 18);Ala-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 19);Lys-Ala-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 20);Lys-Glu-Ala-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 21);Lys-Glu-Pro-Val-Ala-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 22);Lys-Glu-Pro-Val-Pro-Ala-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 23);Lys-Glu-Pro-Val-Pro-Gln-Ala-Ala-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 24);Lys-Glu-Pro-Ala-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 25);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Ala-Arg-Lys-Val-Ala-Ala-Gln (Compound 26);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Ala-Lys-Val-Ala-Ala-Gln (Compound 27);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Ala-Val-Ala-Ala-Gln (Compound 28);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Ala-Ala-Ala-Gln (Compound 29);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Ala (Compound 30);Lys-Glu-Gly-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 31);Lys-Glu-Pro-Val-Gly-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 32);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Gly-Arg-Lys-Val-Ala-Ala-Gln (Compound 33);Lys-Glu-Pro-Val-Gly-Gln-Ala-Lys-Gly-Arg-Lys-Val-Ala-Ala-Gln (Compound 34);Lys-Glu-Gly-Val-Gly-Gln-Ala-Lys-Gly-Arg-Lys-Val-Ala-Ala-Gln (Compound 35);Lys-Glu-Gly-Val-Pro-Gln-Ala-Lys-Gly-Arg-Lys-Val-Ala-Ala-Gln (Compound 36);Lys-Glu-Gly-Val-Gly-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 37);Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys (Compound 38);Pro-Val-Pro-Gln-Ala (Compound 39);Pro-Val-Pro-Glu-Ala (Compound 40);Pro-Val-Pro-Ile-Ala (Compound 41);Pro-Val-Pro-Ala (Compound 42);Glu-Pro-Val-Pro-Gln-Ala (Compound 43);Pro-Val-Pro-Gln-Ala-Lys (Compound 44);Glu-Pro-Val-Pro-Gln-Ala-Arg (Compound 45);Ala-Pro-Val-Pro-Gln-Ala-Lys (Compound 46);Glu-Pro-Val-Pro-Ala-Ala-Lys (Compound 47);Glu-Pro-Val-Pro-Gln-Ala-Ala (Compound 48);Asp-Pro-Val-Pro-Gln-Ala-Lys (Compound 49);Asn-Pro-Val-Pro-Gln-Ala-Lys (Compound 50);Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala (Compound 51);Glu-Pro-Ala-Pro-Gln-Ala-Lys (Compound 52);Glu-Ala-Val-Pro-Gln-Ala-Lys (Compound 53);Glu-Pro-Val-Ala-Gln-Ala-Lys (Compound 54);Glu-Pro-Val-Pro-Glu-Ala-Lys (Compound 55);Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val (Compound 56);Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg (Compound 57);Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro (Compound 58);Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg (Compound 59);Pro-Val-Pro-Gln-Ala-Lys-Pro (Compound 60);D-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 61);Lys-D-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 62);Lys-Glu-D-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 63);Lys-Glu-Pro-D-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 64);Lys-Glu-Pro-Val-D-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 65);Lys-Glu-Pro-Val-Pro-D-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 66);Lys-Glu-Pro-Val-Pro-Gln-D-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 67);Lys-Glu-Pro-Val-Pro-Gln-Ala-D-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 68);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-D-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 69);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-D-Arg-Lys-Val-Ala-Ala-Gln (Compound 70);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-D-Lys-Val-Ala-Ala-Gln (Compound 71);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-D-Val-Ala-Ala-Gln (Compound 72);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-D-Ala-Ala-Gln (Compound 73);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-D-Ala-Gln (Compound 74);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-D-Gln (Compound 75);Glu-Gly-Val-Pro-Gln-Ala-Lys (Compound 76);Glu-Pro-Val-Gly-Gln-Ala-Lys (Compound 77);D-Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 78);Glu-D-Pro-Val-Pro-Gln-Ala-Lys (Compound 79);Glu-Pro-D-Val-Pro-Gln-Ala-Lys (Compound 80);Glu-Pro-Val-D-Pro-Gln-Ala-Lys (Compound 81);Glu-Pro-Val-Pro-D-Gln-Ala-Lys (Compound 82);Glu-Pro-Val-Pro-Gln-D-Ala-Lys (Compound 83);Glu-Pro-Val-Pro-Gln-Ala-D-Lys (Compound 84);Lys-Glu-Pro-Val-Pro (Compound 85);Glu-Pro-Val-Pro-Gln (Compound 86);Lys-Glu-Pro-Val-Pro-Gln (Compound 87);Val-Pro-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 88);Pyro-Glu-Leu-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 89);Pro-Ala-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 90);Arg-Lys-Asp-Val-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 91);Arg-Lys-Asp-Val-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 92);Arg-Lys-Asp-Val-Tyr-Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 93);Arg-Lys-Asp-Val-Tyr-Pro-Val-Pro-Gln (Compound 94);Gly-Pro-Glu-Thr-Ala-Phe-Leu-Arg-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 95);Gly-Pro-Glu-Thr-Ala-Phe-Leu-Arg-Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 96);Ser-Ser-Glu-Asp-Ile-Lys-Glu-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 97);Ser-Ser-Glu-Asp-Ile-Lys-Glu-Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 98);Ser-Ser-Glu-Asp-Ile-Lys-Glu-Pro-Val-Pro-Gln (Compound 99);Val-Pro-Pro-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 100);Glu-Pro-Val-Pro-Gln-Ala-Lys-Ser-Ser-Glu-Asp-Ile-Lys-Glu (Compound 101);Glu-Pro-Val-Pro-Gln-Ala-Lys-Val-Pro-Tyr (Compound 102);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Glu (Compound 103);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Asn (Compound 104);Lys-Gln-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 105);Lys-Glu-Pro-Ile-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 106);Val-Pro-Gln-Ala (Compound 107); orVal-Pro-Gln-Ala-Lys (Compound 108).

18. The compound according to claim 1 or a physiologically compatible salt thereof, wherein the compound is selected from: Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 1);Lys-Glu-D-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 63);Gly-Pro-Glu-Thr-Ala-Phe-Leu-Arg-Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 96);Val-Pro-Pro-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 100);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Asn (Compound 104);Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 6);Pro-Val-Pro-Gln (Compound 12);Glu-Pro-Val-Ala-Gln-Ala-Lys (Compound 54);Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg (Compound 57);Lys-Glu-Pro-Val-Pro-Gln-Ala-D-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 68);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-D-Val-Ala-Ala-Gln (Compound 72);Pyro-Glu-Leu-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 89);Arg-Lys-Asp-Val-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 92);Arg-Lys-Asp-Val-Tyr-Pro-Val-Pro-Gln (Compound 94);Gly-Pro-Glu-Thr-Ala-Phe-Leu-Arg-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 95);Ser-Ser-Glu-Asp-Ile-Lys-Glu-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 97);Ser-Ser-Glu-Asp-Ile-Lys-Glu-Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 98);Lys-Gln-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 105);Lys-Glu-Pro-Ile-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 106);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 4);Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 5);Glu-Pro-Val-Pro (Compound 9);Lys-Pro-Arg-Lys (Compound 10);Arg-Lys-Val-Ala (Compound 15);Lys-Glu-Pro-Ala-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 25);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Ala-Arg-Lys-Val-Ala-Ala-Gln (Compound 26);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Ala-Ala-Ala-Gln (Compound 29);Lys-Glu-Gly-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 31);Lys-Glu-Pro-Val-Gly-Gln-Ala-Lys-Gly-Arg-Lys-Val-Ala-Ala-Gln (Compound 34);Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys (Compound 38);Glu-Pro-Val-Pro-Gln-Ala-Ala (Compound 48);Asp-Pro-Val-Pro-Gln-Ala-Lys (Compound 49);Asn-Pro-Val-Pro-Gln-Ala-Lys (Compound 50);Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala (Compound 51);Glu-Ala-Val-Pro-Gln-Ala-Lys (Compound 53);Glu-Pro-Val-Pro-Glu-Ala-Lys (Compound 55);Lys-D-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 62);Lys-Glu-Pro-Val-D-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 65);Lys-Glu-Pro-Val-Pro-D-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 66);Lys-Glu-Pro-Val-Pro-Gln-D-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 67);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-D-Arg-Lys-Val-Ala-Ala-Gln (Compound 70);Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-D-Gln (Compound 75);Glu-Pro-Val-Pro-Gln-D-Ala-Lys (Compound 83);Lys-Glu-Pro-Val-Pro (Compound 85);Glu-Pro-Val-Pro-Gln (Compound 86);Val-Pro-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 88);Pro-Ala-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 90);Arg-Lys-Asp-Val-Tyr-Glu-Pro-Val-Pro-Gln-Ala-Lys (Compound 93);Ser-Ser-Glu-Asp-Ile-Lys-Glu-Pro-Val-Pro-Gln (Compound 99); orLys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Glu (Compound 103).

19. A method for treating enteritis, comprising administering, a therapeutically effective amount of compound according to claim 1 or a physiologically compatible salt thereof to a subject.

20. (canceled)

21. A pharmaceutical composition comprising the compound according to claim 1, or a physiologically compatible salt thereof, and a pharmaceutically acceptable excipient.